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Abstract 
The aim of this thesis is to examine the effect of anti-donor antibodies in the clinical 
management and outcomes of antibody incompatible kidney transplantation. Initial 
studies were conducted to improve measurement of anti-ABO specific blood group 
antibodies. The specificity of antibody binding to blood group antigens depended upon 
the assay platform and the nature of the core structure to which the blood group antigen 
was bound. A standardised haemagglutination assay was shown to produce excellent 
reproducibility, which was then applied to the analysis of samples derived from the 
ABOUT-K study. In this study of ABO incompatible kidney transplantation (ABOiKTx) in 
the UK, good clinical outcomes were achieved but there was wide variation in the 
method and result reported in local assays quantifying blood group antigen specific 
antibodies. This did not seem to alter graft survival within the limitations of a study of 
100 patients however may have altered the exposure to treatment. 
In a highly sensitised HLA incompatible kidney transplant recipients (HLAiKTx), I 
demonstrated long term outcomes were poor compared to a compatible cohort. In 
particular outcomes were worse with pre-formed donor specific anti-HLA Class II 
antibodies than with HLA class I alone. The histological injury of antibody damage 
occurred significantly earlier than with Class I antibodies. I then demonstrated that 
despite the activation of complement, anti-donor ABO specific antibodies did not display 
the same inflammatory phenotype in allograft biopsies as anti-HLA antibodies. Finally, 
the inhibition of terminal complement activation, whilst reducing early antibody-
mediated rejection did not abrogate all inflammation. This resistance to inhibition of 
terminal complement activation may be contributed to by IgM DSA which may play a 
 
 
 
 
role in cellular recruitment into the allograft but can be removed easily through plasma 
exchange.  
Reproducible and standardised assays are needed for antibody assessment in order to 
make good clinical decisions to improve patient outcomes. Further studies are needed to 
stop production or block mechanisms of ongoing cellular infiltrate to improve patient 
outcomes.  
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Chapter 1  Introduction 
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1.1 End Stage Renal Failure in the UK 
Chronic kidney disease significantly increases the mortality and morbidity in patients [1, 
2]. The incidence of end stage renal failure (ESRF) has doubled in the UK since 1995 and 
is a growing international health problem [3]. This high mortality in patients on dialysis 
is significantly reduced following kidney transplantation [4]. Kidney transplantation has 
been shown to improve quality as well as length of life for recipients and this has driven 
increasing numbers of transplants being performed each year for an expanding recipient 
population [5-7]. The time from initiating dialysis to transplantation reduces the 
longevity of the kidney allograft and reduces the benefit with respect to mortality [8, 9]. 
The ability to pre-emptively transplant patients before commencing dialysis increases 
patient and allograft survival [10]. 
1.2 Live Donor Transplantation as a treatment option for ESRF 
The first successful kidney transplantation took place in 1954, in Boston, USA [11, 12]. It 
was allowed due to the genetic identity of both recipient and donor, because they were 
identical twins. Previous attempts at renal transplantation, although technically 
surgically successful, had failed within the first fortnight due to graft rejection.  
The current major barrier to organ transplantation is the lack of adequate numbers of 
available organs to potential recipients. The development of Donation after Cardiac 
Death (DCD) criteria deceased donor organs has provided an additional source of organs 
for transplantation. The application of DCD is growing, but there are still potential 
developments to improve outcomes. While Donation after Brain Death (DBD) kidney 
donation rate is static, an increase in the donation is beginning to bridge the gap 
between supply and demand [13]. Live donor kidney transplantation is beneficial in 
many ways, but significantly improves clinical outcomes for allograft survival, timing of 
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transplantation and health of the donor kidney without the consequences of brain stem 
death, peri-operative trauma and reduced ischaemic time. In the UK, about 30% of any 
potential unrelated live kidney donor and recipient pairs are ABO blood group 
incompatible in which cases the majority of recipients are blood group “O” and blood 
group “B”. The median waiting time for deceased donor kidneys in the UK is higher in 
these blood groups compared to blood group “A” (1381 days, 1329 days and 925 days 
respectively, data according to NHSBT Dec 2013)[13].  
1.3 Immunological barriers to transplantation 
The blood group barrier to transplantation was discovered through early clinical 
experience in which incompatibility was associated with hyperacute rejection. This 
became an immediate absolute contraindication [12]. However, similar events could 
occur despite blood group compatibility and in 1960’s Terasaki and colleagues 
developed a crossmatching tool to enable reactivity of donor lymphocytes and recipient 
serum to be assessed prior to transplant surgery [14, 15]. The combination of improved 
immunosuppression and increased tissue typing technology has improved the early 
survival of kidney transplants year on year [16]. An increasing number of patients with 
failed transplants are waiting for another kidney transplant, which means that although 
historically pregnancy and transfusion were the most common pathways to allo-
sensitisation, there is increasing sensitisation through prior transplantation [17].  
As the development of assays for detecting HLA antibodies in potential kidney recipients 
have become more sensitive, the task of matching donors and recipients has become 
increasingly complex. These immunological barriers may preclude transplantation in 
otherwise anatomically possible kidney transplantation. 
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Pooled exchange live kidney donation is an alternative for avoiding immunological risk, 
though this will not be the solution to all kidney transplant donor and recipient pairs 
[18, 19]. In the pooled exchange programmes, blood group ‘O’ recipients awaiting kidney 
transplantation will accumulate, as will the highly HLA-sensitized patients.  As increased 
time on dialysis is associated with poorer allograft survival and increased mortality, 
timely transplantation is an important goal in improving patient outcomes [20].  
Desensitization is the name given to the process of removing alloantibodies and 
preventing subsequent alloantibody production to allow successful transplantation [21, 
22]. The application of different techniques for desensitization have been used to allow 
transplantation across these barriers, in order to achieve an antibody level at which the 
solid organ can be implanted without hyperacute rejection [23]. While techniques for 
desensitization vary between centres and between ABO incompatible or HLA 
incompatible transplantation, the practice in UK transplantation is growing (Figure 1.1). 
Published data have been mainly from single centres using differing techniques. The 
survival benefit of desensitization was shown in a large single centre cohort by 
Montgomery, who demonstrated that despite higher immunological risk, sensitized 
patients transplanted across immunological barriers had better patient survival than 
those who had a successful wait for a compatible transplant, or those who remained on 
dialysis [24].  
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Figure 1.1. UK Registry Data on Live Donor Kidney Transplantation.   
The considerable increase in antibody incompatible kidney transplantation activity in 
the UK over the last 5 years is demonstrated. From 2004 to 2010 there is an increase 
from <1% to ~10% of total live donor kidney transplantation [25]. 
  
 
 
30 
 
1.3.1 ABO Blood Group 
1.3.1.1 Chemistry of A/B antigen formation  
Chromosome 9 encodes for a glycosyl transferase which conjugates a terminal 
oligosaccharide onto the H antigen on cell surfaces (Figure 1.2A), following prior 
fucosyltransferase activity encoded on chromosome 19 [26]. Individuals of blood group 
‘A’ have a terminal α-N-acetylgalactosamine molecule, whilst in blood group ‘B’ the 
terminal molecule is D-galactose (Figure 1.2B).  
1.3.1.2 Development of anti-ABO specific antibodies 
Anti-ABO specific antibodies are not produced at birth and it is postulated that anti-ABO 
specific antibodies develop secondary to exposure to exogenous carbohydrate antigens. 
The presence of anti-ABO specific antibodies is explained according to Landsteiner’s 
rule. They develop against the A/B antigen that is absent in that individual [27]. The 
quantity of antibody present or titre increases with early childhood immune 
development [28]. The blood group “O” population has higher titres than blood group 
“A” or “B” populations although there is significant overlap, and the amount of antibody 
so quantified may be affected by age, gender and dietary intake [29, 30].  
The delayed development of anti-ABO specific antibodies has been used for clinical 
benefit in ABO incompatible infant heart transplantation by West and colleagues who 
demonstrated that cardiac transplantation in very young infants had good clinical 
outcomes, despite them later developing anti-ABO specific antibodies [31]. Interestingly, 
blood group “O” recipient infants develop anti-ABO specific antibodies only to the 
antigen not present on the allograft, suggesting an immunologically tolerant phenotype.  
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Figure 1.2. Biochemical pathway and structure of A/B conjugation and antigen.  
Diagrammatic process of terminal oligosaccharide conjugation and structure of the 
terminal sugar. [32]. Abbreviations: Fuc, L-fucose; Gal, D-galactose; GDP, Guanosine 
diphosphate; GlcNAc, N-acetyl-D-glucosamine; Glc, D-glucose; UDP, Uridine diphosphate; 
N-acetylgalactosamine (GalNAc) 
Figure 1.2A. Activity of H-transferase and A and B transferase for antigen production. 
 
Figure 1.2B – ABO blood group antigen and structure with terminal sugar structure. 
Arrows demonstrate difference between A and B structure with N-acetylgalactosamine.   
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1.3.1.3 Subtyping of ABO Blood Group Individuals 
ABO blood groups are divided into 4 main groups (O, A, B and AB), but these can be 
further sub-divided according to antigen density and structure. For blood group “A”, 
these are often identified as “A1” antigen or “non-A1”. The “A1” cohort can be identified 
directly by Helix pomatia lectin binding in haemagglutination assay, which is specific for 
“A1” antigen molecule N-acetyl-d-galactosamine. About 80% of blood group “A” 
individuals are “A1” which is differentiated by the concentration of the pre-dominant 
antigen which is of clinical importance. “Non-A1” individuals have fewer “A” epitope 
molecules on red cells and in the kidney [33]. The lower "A" antigen density is due to 
reduced levels of A transferase activity in “non-A1” blood groups (only 10%), compared 
to “A1”.  Also this glycosyl transferase in “non-A1” individuals does not conjugate H 
antigen on with type 3 and type 4 structures.  Blood group “AB” individuals express both 
A and B antigens, but since the action of these ‘A’ and ‘B’ transferases is competitive, 
with a fixed amount of cell surface H antigen, there is a reduction in A or B antigen 
density, relative to an individual in those who are homozygous or indeed compound 
heterozygoteswith a null allele [34]. 
1.3.1.4 ABO antigen and core structures  
While anti-ABO specific antibody measurement will be explored quantitively and 
qualitatively in the next section, it is important to note that the red cell assay on which 
haemagglutination is based depends on the expression of A/B antigen on red cells. This 
is predominantly a type 2 chain structure. The core structures of A and B antigens in the 
kidney are not only different from the red cell, but different for each antigen. Breimer’s 
laboratory demonstrated that A antigen is predominantly a type 4 structure with small 
amounts of type 2 and minimal type 1 and type 3 involvement. However, B antigen is a 
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type 2 structure with type 4 being a relatively minor structure [35]. The distribution of 
core saccharide type structures in different tissues is shown in Table 1.1.  
In ABOiKTx, clinical management is directed by the ability to monitor patients with 
serological tests following transplantation, which often demonstrate low levels of anti-
ABO specific antibodies. However, follow up in the Japanese ABOiKTx cohort has 
demonstrated that over a longer period there is reduction in A/B antigen expression on 
biopsies of the donor kidneys and a profile similar to the recipient blood group is seen 
[36]. There is also a reduction in circulating A/B glycosyl transferase [37].  
 
 
Table 1.1. Blood group core chain expression in different tissues  
The core oligosaccharide chain expression varies significantly between red blood cells, 
kidneys and other visceral organs, adapted from Rydberg [38]. 
 Core Saccharide Chain Type 
Organ Type 1 Type 2 Type 3 Type 4 
Red Blood cell + +++ ++ + 
Vascular Tissue ++ + ++ - 
Liver ++ - - - 
Kidney + + (+) +++ 
Pancreas +++ + (+)  
Stomach +++  - - 
Intestinal Epithelial Cells +++ (+) - - 
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1.3.1.5 Clinical effect ABO Blood Groups  
The majority of kidney transplant recipients are adults who have already developed 
anti-ABO specific antibodies. There are racial differences in ABO blood group 
distribution which poses additional barriers within ethnic communities where there is a 
more limited donor and recipient pairing or availability of deceased donor organs. Asian 
ethnic groups have a significantly higher blood group “B” population than European 
Caucasians and are over-represented in kidney transplant waiting lists [39]. In a small 
UK study, there was no major difference in anti-A titre in blood group “B” Asian patients 
waiting for a transplant compared to Caucasians [40]. Analysis of the UNOS database for 
“A2” donor kidneys showed that a significantly higher non-white proportion of 
recipients benefitted when “A2” kidneys were used across A to B blood group barriers, 
with similar clinical outcomes for patient or allograft survival [41]. Implementation of 
ABOiKTx in deceased donor transplantation with high anti-ABO specific titres against 
the donor is difficult due to timings after organ retrieval and the need for antibody 
removal. However, there is the possibility of low titre ABOiKTx being an effective tool in 
transplanting blood group “B” waiting recipients on a deceased donor waiting list. This 
has been modelled in paediatric kidney transplantation for potential A2-to-B 
transplantation in low titre recipients. It has also been successfully practiced in order to 
increase transplantation rate with quarterly ABO titre measurement and similar 
outcomes to ABO compatible kidney transplants in an adult population in the USA with 
an increase of 25% more “B” recipients receiving transplants [42-44]. This would allow 
an increase in the overall availability of group “B” kidneys in a national scheme, if local 
“B” recipients with low anti-A titres have all been successfully transplanted, and thus 
have increased benefit to other non-white ethnic groups in different regions. 
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1.3.2 HLA sensitization 
 MHC class I and II proteins  are cell surface glycoproteins. Class I expression is 
present on most cells, whilst Class II is restricted to predominately B lymphocytes; 
dendritic cells and some endothelial cells, but can be up-regulated in inflammatory 
responses. It is the specific role of MHC class I and class II molecules in presenting 
antigenic peptide to the T Cell receptor (TCR) that underlies their significance as 
barriers to transplantation. The consequences of TCR engagement and co-stimulation 
are proliferation and differentiation of the T cells into effector phenotypes and 
concomitant production of cytokines. The role of immunosuppression is to target 
signalling pathways responsible for T cell activation, including TCR/CD3 engagement by 
the MHC, co-stimulatory pathways such as CD28 binding by CD80/CD86  and cytokine 
signalling pathways such as IL-2 binding to the IL-2 receptor including CD25.   
Exposure to HLA alloantigen leads to the development of anti-HLA antibodies through B 
cell activation which at least for these protein antigens  requires T cell help. Anti-HLA 
antibodies are produced against both Class I and Class II antigens. The specific nature of 
the sensitizing event on antibody production has been described to affect the IgG 
subclass and isotype [45]. 
 
1.4 Antibodies and the measurement of antibodies 
1.4.1 Isotype production 
Naïve B lymphocytes are present in the germinal centres, where activated CD4+ T 
lymphocytes recognise MHC class molecule and peptide presentation and the TCR binds 
to the MHC class 2 molecule. CD40/CD40L interaction triggers cytokine release from the 
effector T lymphocyte, causing proliferation and class switching of the B lymphocytes. 
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Antibody class switching takes place in the DNA sequence with switch regions marking 
all the constant regions for each class. The human sequence of class switching after IgM 
and IgD is: IgG3; IgG1; IgA1; IgG2; IgG4; IgE and IgA2. Different isotypes can occur at the 
same time in the B cell’s progeny, during maturation and proliferation [46]. The 
structure of the constant region is important as it affects the immunological function of 
the isotype. The Fc region of the antibody is recognised by the Fc Receptors which 
initiate a response in specific effector cells (such as macrophage and neutrophils), bind 
complement and aid antibody transportation. Once the B lymphocyte has matured, 
antibody production is either short lived (plasmablasts) or long lived (plasma cells). 
Plasma cells find their niche in the bone marrow and survive through anti-apoptotic 
mechanisms, which include stimulation through CXCR4, APRIL and IL-6[47]. The 
determinant of pathways is important as long lived plasma cells continue to produce 
antibody, whilst short lived plasmablasts will have a finite life span and if there is no 
further stimulation of B cells, antibody production will be halted. Understanding of the 
longevity of these cells plays a crucial role in understanding persistent alloantibody 
production and guides appropriate therapeutic interventions [48, 49]. IgG is the 
predominant form of affinity matured antibody population, and its presence has been 
associated with acute antibody-mediated rejection. However, the presence of non-IgG 
HLA antibodies has been detected and the role of these antibodies are debated.   
 
1.4.2. Significance of Isotype 
The isotype or subclass of anti-HLA antibody has potential to affect the clinical 
consequences of these antibodies in the circulation and on the allograft. The FcR and 
consequent complement activation varies with each class (Table 1.2). The persistence of 
alloantibody after transplantation is associated with poor outcomes, whilst the 
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elimination from the circulation of alloantibody is associated with improved outcomes 
following a positive crossmatch [50]. These data suggest that an immunological 
response to the allograft may be followed by cessation of alloantibody production, 
without specific immune-modulatory therapies. 
Recently, DSA IgG has been eluted from transplant biopsies, and correlates well with the 
specificity of the circulating DSA IgG, C4d deposition and features of antibody-mediated 
injury [51]. In a small series of highly sensitized kidney transplant recipients with a 
negative CDC crossmatch but with solid phase DSA, there was no difference in allograft 
survival up to 8 years, compared with controls with non-donor specific HLA antibodies. 
Patients with DSA had more episodes of rejection which all took place within the first 45 
days [52].  The presence of anti-HLA IgG has also been shown to be deleterious to the 
graft regardless of whether it was donor specific or non-donor specific [53].  
1.4.3. Anti-HLA IgM 
The role of IgM has previously been thought of as not clinically relevant, without 
prognostic significance and in many cases simply auto-reactive. The presence of anti-
donor IgM has been described by a positive result in CDC or FCX which became negative 
on dithiothreitol (DTT) treatment or heat treatment. Thus, positive crossmatches 
become negative in the assay with the reducing reaction. In these cases a transplant can 
proceed without immediate immunological complication [54]. Arnold et al showed that 
there was a low prevalence of IgM (17%) anti-HLA antibodies in patients waiting for 
transplantation and the distribution of IgM antibodies was more against class I than 
class II HLA specificities [55]. This has also been demonstrated by Diaz where only 3% 
of patients were described as having only an IgM isotype. However, 30% of patients had 
an antibody population which was changed by DTT treatment, suggesting the presence 
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of IgM contributing to antibody binding [56]. The detection of IgM in acute rejection 
could indicate that these antibodies have an active role in allograft dysfunction. This 
may be non-specific binding and only IgG is clinically useful according to McCalmon who 
demonstrated no clinical effect of IgM [57, 58]. However, there was strong staining for 
IgM in kidneys with hyperacute rejection that demonstrated no IgG staining, suggesting 
there may be a pathogenic role for IgM alloantibody [59]. In a different study, despite 
early IgM development, there was no longer term detrimental [60]. No conclusive data 
has been published, which in part reflects the difficulty in standardising the 
methodology for assessment of IgM anti-HLA antibodies across centres.   
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Table 1.2.  Description of proportions and properties of different isotypes and 
subclasses of immunoglobulins. 
Adapted from Schroeder. [61] 
 Serum 
(%) 
Structure Complement 
Fixation 
Opsonizing Other 
function 
Fc 
Receptor 
IgG 75 Monomer + +++ For all IgG 
subclasses: 
FcγR 
IgG1 67% IgG Monomer Yes Yes Secondary 
response 
I, II, III 
IgG2 22% IgG Monomer Yes Yes Neutralize 
toxins and 
virus 
II 
IgG3 7% IgG Monomer Yes Yes  I, II, III 
IgG4 4% IgG Monomer No No  I, II 
IgM 10 Pentamer ++++ - Primary 
response 
 
IgA 15 Monomer, 
dimer 
- - Mucosal 
response 
FcαR 
(CD89) 
IgA1  Monomer, 
dimer 
- -   
IgA2  Monomer, 
dimer 
- -   
IgD <0.5 Monomer - - Homeostasis FcδR 
IgE <0.01 Monomer - - Allergy FcεR I, II 
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1.4.4. IgG Subclasses 
The development of anti-HLA antibody and its subclass may be dependent on the 
context in which sensitisation had taken place. Lowe at al showed in all patients with 
DSA, there were highest levels of IgG1detected. If sensitization to HLA occurred through 
transfusion or transplantation, IgG2 was the second most frequently detected subclass. 
This is in contrast to sensitization secondary to pregnancy where IgG3 subclass is the 
second most frequently detected subclass [45]. Arnold el at demonstrated, patients 
waiting for a kidney transplant had 25% prevalence of IgG2 and/or IgG4, of which 88% 
had had a previous transplant as their sensitizing event [55]. The entire IgG4 antibody 
population was directed against HLA class II antigens. In a different study by Karuppan 
et al, poor-complement fixing anti-HLA antibodies (IgG2 and IgG4) were found in 
patients who had graft loss, although the subclass distribution was heterogeneous. The 
presence of only IgG2 and IgG4 in two separate patients who experienced early graft 
loss was noted [62]. Monteiro reported that IgG1 against class I HLA mirrors the total 
IgG response to the same class I antigens. The significance of higher levels of PRA against 
class I was correlated with poorer graft outcome in this patient group [63]. The effect of 
complement binding of IgG subclasses with anti-HLA antibodies is described by 
Kushihata et al. They showed the predominant subclass was IgG1, with other subclasses  
detected infrequently [64]. While there is consensus that detection of anti-HLA antibody 
IgG1 is the most common subclass, there is no consensus about the significance of the 
presence of other subclasses and associated clinical outcomes. With the development of 
complement binding assays (C1q), functional assessment of antibody subclasses may be 
tested and associated with clinical events. 
In ABOiKTx, the IgG isotype is clinically significant in predicting outcome and risk of 
rejection, however no IgG was found in allografts that experienced humoral rejection, 
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only IgM [65]. Stussi described that anti-ABO specific antibody subclass distribution of 
healthy donors was dominated by IgG2 subclass, with IgG1 and IgG3 being detected, but 
no IgG4 by flow cytometry bound to RBCs [66]. The range of subclass detected in an 
early study by Kay, using haemagglutination with subclass specific AHG, demonstrated a 
blood group distribution variability. Blood Group “A” and “B” donors produced all 4 IgG 
subclass antibodies in less than 14% of donors, whereas 48% of blood group “O” donors 
produced all 4 IgG subclasses. A large proportion of blood group “O” donors also 
produced complement binding subclasses IgG1 and IgG3, >87% and >74% respectively 
[67]. The assessment of IgG subclass antibodies has not been extensively studied in 
ABOiKTx. 
1.4.4. HLA antibody measurement 
The development of technology for measuring anti-HLA antibodies has led to an 
increase in sensitivity with newer assays. Complement Dependent Cytotoxicity (CDC) 
testing was the gold standard test for donor-recipient matching and significantly 
reduced the cases of hyperacute rejection. A positive CDC crossmatch vetoed a potential 
transplant. Assessing recipients before transplantation, to avoid lengthy CDC testing, led 
to the development of panels of lymphocytes with known common HLA phenotypes 
against which patients waiting transplantation would be tested. The degree of reactivity 
against these lymphocyte panels would then profile patients into an antibody risk 
profile: panel reactive antibody (PRA). Flow cytometry can differentiate between B and 
T lymphocytes and calculations can be made for donor-recipient reactivity based on T 
lymphocyte, predominantly Class I expressing and B lymphocytes with both Class I and 
II expression. 
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Recombinant HLA proteins were developed for solid phase assays and initially used in 
ELISAs and then flow cytometry machines. This allowed identification of potential 
recipient serum reactivity against known HLA protein profiles, without donor cells 
required. This is now used with microspheres in Luminex® technology. The detection of 
antibodies against HLA molecules allows more specific identification of anti-HLA 
antibodies. Defining these specificities for a patient leads to a calculated reaction 
frequency (CRF) which has replaced PRA in predicting the degree of sensitization of the 
patient against the potential donor pool.  
1.4.3.1 Complement Dependent Cytotoxicity (CDC) 
Complement dependent Cytotoxicity was developed in the 1960s and became a clinical 
tool following the development of the Terasaki plate [15]. Figure 1.3A demonstrates the 
assay. The incubation of recipient serum with potential donor lymphocytes, with the 
addition of complement, followed by staining to determine apoptosis of donor 
lymphocytes became the gold standard for donor-recipient compatibility.  
1.4.3.2. Flow Cytometric Crossmatch (FXM) 
The development of FXM technique has been proven to increase the sensitivity of 
detecting anti-donor antibodies. Whilst the early experience was developed in different 
single centre laboratories, a comparative study demonstrated agreement in 80% of 
cases [68]. This study, however, demonstrated a discrepancy in 20% of cases which may 
have had a positive result in one centre, and a negative in a different centre. Figure 1.3B 
demonstrates FXM which involves incubating donor lymphocytes with recipient serum. 
Following washing, secondary staining was performed with antibodies for cell 
phenotype (CD19/20 for B cells; CD3 for T cells) and for IgG. Thus, separation of cell 
types and binding of IgG antibody can be assessed. The histogram median value is the 
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channel shift, which is either subtracted or divided by the negative control crossmatch, 
thus providing an internal control for each crossmatch. Different laboratories use 
different defined points of reactivity to determine a positive result.  
1.4.3.3. Single Antigen Bead Detection (SAB) 
Luminex® technology allows multiple microspheres to be assessed simultaneously in 
the same well for the same sample (Figure 1.3C). This technology for identifying anti-
HLA antibodies is ideally suited to screening and characterising antigen specificity, as 
reactivity against different antigens can be simultaneously tested. The machine 
automatically gates the microspheres into the appropriate region, based on the 
fluorescence of the microspheres (containing different ratios of two fluorochromes). The 
binding of antibody to the antigen on the microspheres is determined by secondary 
labelling of the antibody by Phycoerythrin (PE).  
1.4.3.4. Combination of techniques 
A component of this thesis is based on the immunological assessment of antibodies in 
transplanted patients at Mayo Clinic, Rochester, MN, USA. Gloor used all these antibody 
assessment techniques in a cohort of patients, which showed the relationship between 
antibodies quantified by CDC, FCX and Luminex. These are evidently progressively more 
sensitive techniques with however significant inter-patient variation in their 
correspondence to one another (Figure 1.4A) [69]. Prior to this, Burns had compared 
different antibody measure methods with histological injury and the degree of injury 
with the different antibody levels seen in Figure 1.4B [70].    
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Figure 1.3. A comparison of different techniques in clinical use for analysing anti-
HLA antibodies in transplantation 
There are different techniques using cellular and solid phase assays to assess anti-HLA 
antibodies and each are demonstrated below (complement dependent cytotoxicity 
(CDC) in panel A; flow cytometric crossmatch (FXM) in panel B and Luminex®(Bead) in 
panel C) [71]. 
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Figure 1.4 Comparison of results of different anti-donor testing in +XMKTx at Mayo 
Clinic, USA. 
Figure 1.4A - Baseline comparison of 
crossmatch techniques and 
cumulative MFI in Luminex® 
assessment of DSA at Mayo Clinic. 
This demonstrates the significant 
differences in sensitivity between 
crossmatch techniques, and 
highlights that even negative 
crossmatch recipients are not without 
significant levels of DSA [69]. T-AHG = 
T cell anti-human globulin CDC; 
FXMCS = flow cytometric crossmatch; 
-XM = negative crossmatch 
Figure 1.4B – Comparison of 
different antibody detection 
techniques with histological 
assessment with BFXM (A); Luminex 
® SAB (B) and TFXM (C) levels in 
patients. Higher levels of antibody 
were associated with the 
development of more severe 
antibody-mediated tissue injury [70].   
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1.4.5. Anti-ABO specific antibody measurement 
While anti-HLA measurement has progressed in the last 50 years, the measurement for 
anti-ABO specific antibodies is still largely based on techniques from Landsteiner’s 
report from over 100 years ago. This haemagglutination technique is a serial doubling 
dilutions of patient plasma until no reactivity is found. Antibody reduction in ABOiKTx is 
seen as the key to improving outcomes, in particular the high risk of hyperacute 
rejection. Target titre levels of equal or less than 1:8 on the day of transplant have been 
shown to have improved outcomes [65]. The importance of lowering antibody titres to 
less than 1:8 to prevent negative outcomes with higher anti-graft antibodies is logical as 
early clinical outcomes in Japan showed that higher pre-operative IgG levels were 
associated with worse clinical outcomes both in graft survival and humoral rejection 
[65].  
Despite good outcome data, the need to improve the delivery of care with accurate titre 
levels continues to be a goal that has not yet been achieved. The number of antibody 
removal therapies are based on accurate measurement, and this has an impact on 
patients; staffing and ultimately the cost of the process of transplantation [72, 73].  
Early rejection of transplanted kidneys is most likely to be humoral rejection, involving 
antibody binding to renal vascular endothelium. This antibody-mediated process may 
not initially be accompanied by elevated antibody levels as adsorption of antibodies in 
the kidney may  keep levels constant, until saturation of the binding sites leads to 
antibody titre levels rising [74]. Antibody titres of greater than 1:128 have been 
successfully transplanted with post-transplantation titres of <1:16 being maintained, 
without antibody-mediated rejection occurring [75]. 
In assessing transplantation across blood groups, analysis of antibody titres is crucially 
important. The assay used defines the titre of antibody present with a margin of error 
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usually of one titre either side of the median. IgM and IgG are often both individually 
measured. Chapter 2 outlines in more detail assays to describe anti-ABO specific 
antibody.  
1.4.6. Other anti-donor antibodies 
Major-histocompatibility-complex (MHC) class I–related chain A (MICA) antibodies were 
first shown to have a detrimental effect on kidney allograft by Zou et al [76]. A 
subsequent study showed that the effect of MICA positive antibody recipients did not 
have inferior outcomes to MICA negative recipients which supported data from Terasaki 
et al [77, 78]. 
Anti-endothelial cell antibodies (AECA) found in one study were predominantly IgM 
rather than IgG (66% vs 14%). Other non-HLA antibodies measured include vimentin, 
glomerular basement membrane protein agrin [79]. The presence of anti-idiotypic 
antibodies, directed against the idiotype of an HLA antibody, has been associated with a 
reduction of chronic rejection, despite the presence of donor allo-antibody although its 
role is still controversial [80]. More recently, angiotensin II type-1 receptor antibodies 
have been measured and associated with worse outcomes. Larger studies are needed to 
determine the clinical effectiveness for monitoring and the longer term outcomes [81, 
82]. 
Anti-galili antibodies, the immunological barrier to xenotransplantation, are produced 
by natural antibody producing B cells. Anti-galili antibodies are about 1% of circulating 
IgG and 4% of IgM. Large amounts of IgM are deposited in xenografts in rejection. The 
presence of anti- galili IgM and IgG can increase with exposure to antigen, though there 
is a class switch at day 21 with a decline in IgM and replaced by IgG in circulation [83]. 
In the context of allotransplantation, not xenotransplantation, anti-gal antibody does not 
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affect allograft outcomes. There is a suggestion that anti-Gal binding may overlap with 
that of other blood group antibodies (A or B), as the epitopes are similar structures, 
though the clinical relevance of this has not been demonstrated [84]. 
1.5 Preformed antibodies as a barrier to transplantation. 
1.5.1 ABO incompatible kidney transplantation 
Despite Starzl and colleagues publishing a series of ABO incompatible and ABO 
compatible donor-recipient pairs with comparable results, early experience led to blood 
group incompatibility being considered an absolute barrier to transplantation. USA 
Transplant registry data from 1967 demonstrated a very significant poor outcome of 
ABOiKTx, with 45.8% (11/24) never functioning and only 7.7% (1/13) functioning more 
than 1 year post-transplant [85-87]. However, an “inadvertent” breach of the blood 
group compatibility in 1980 in Portsmouth, UK demonstrated successful reversal of 
antibody-mediated damage with anti-A antibodies with 65% reduction in antibody 
levels measured, and this led to more centres developing treatment regimens to 
overcome this barrier [88]. Alexandre et al in Belgium expanded practice in ABOiKTx, 
initially with “A2” donor kidneys with reasonable clinical outcomes [89] . As previously 
described, “A2” donors have fewer "A" antigens present on cell surface and thus pose 
less of an immunological risk and were initially used, before progression to “A1” donor 
kidneys. Breimer and colleagues demonstrated this by comparing “A antigen” 
expression on kidney transplant biopsies, demonstrating less expression in “A2” kidneys 
compared to “A1” kidneys [90]. 
There has been greater use of ABOiKTx in Japan where the largest cohorts have been 
carried out due to cultural reasons preventing a large deceased donor pool and so live 
donation has been the main source of organs for kidney transplantation [91]. This was 
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initially treated with regime that included heavy burden of immunosuppression, which 
has become less intensive. The first regime published had five pharmacological agents 
and splenectomy and this was comprised of methylprednisolone, cyclosporine, 
azathioprine, antilymphocyte globulin and deoxyspergualin [92]. The earliest protocols 
also included total irradiation of the allograft prior to implantation.  The patient survival 
of these ABOiKTx compared to the ABOcKTx cohort in historic controls was not 
significantly different. There was significant early graft loss up to 3 years in the 
ABOiKTx, but no significant difference after this time period (Figure 1.5, [93]). The 
emphasis of therapies since then has been on the reduction in burden of 
immunosuppression. 
 
Figure 1.5. Early graft loss is significantly higher in ABOiKTx compared to 
ABOcKTx cohorts.  
Despite increased early allograft losses in the ABOiKTx cohort, medium to longer term 
graft survival outcomes were not significantly different in Japanese data [93].  
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1.5.2 HLA incompatible kidney transplantation 
The presence of anti-HLA antibodies is associated with poor allograft outcome and this 
is worse with anti-HLA antibodies against donor HLA [53]. However, re-transplantation 
is increasing, leading to an increased number of patients with HLA sensitization at the 
time of transplant. The amount and specificity of the antibody are defined by different 
techniques. The methods of anti-HLA antibody testing have been described in this 
chapter. The result of these methods has an impact on both the treatment of these 
patients and on the transplant outcomes. The level of antibody against donor HLA (often 
defined by the test used for detection) and its specificity will significantly impact the 
allograft survival [94].  
Early experience used pre-transplantation conditioning similar to that used for 
treatment of vasculitis in patients with high PRA antibody levels. The use of 
cyclophosphamide and plasma exchange demonstrated satisfactory antibody reduction 
[21, 95]. After treatment of a CDC positive crossmatch could be changed to negative, a 
cohort study demonstrated early allograft survival benefit using immunoadsorption 
rather than plasma exchange for antibody removal, although this conclusion remains 
controversial [96].  
Experience with T-Cell CDC negative transplants, but B-cell positive crossmatches 
demonstrated some degree of transplantation success at 1 year post transplant, 
however there were still allografts lost due to CDC negative but flow cytometric 
lymphocyte positive reactivity against donor T-cells [97, 98]. Seven patients (7/10) in 
whom anti-B lymphocyte antibodies were detected had chronic rejection or early severe 
rejection. This resulted in recommendations to avoid transplanting patients with anti-
donor positive flow crossmatches, despite negative T-cell CDC crossmatches due to the 
high rates of antibody-mediated vasculitis [99]. Kidney transplantation with historic 
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positive crossmatches, but negative at the time of transplant, also demonstrated early 
humoral rejection and poor clinical outcomes.   
Many series of antibody incompatible kidney transplantation have now been reported 
from different centres across the world; however comparison is difficult due to 
heterogeneous techniques, both in desensitization and in particular, measuring and 
defining anti-HLA antibodies.  
1.5.3 Limitations of pooled exchange programme  
The clinical implementation of paired exchange, multiple exchanges and domino chains 
benefit patients who have an incompatible live donor in order to overcome antibody and 
other barriers. However, the application of pooled exchange will not be successful in 
every donor/recipient pair and there remains a limitation in transplanting the highly 
sensitised (>95% PRA) and in accumulating blood group “O” recipients. A combination 
of exchange transplantation with desensitisation is another option [100]. Further to this, 
exchange to avoid DSA but with acceptable ABOi combinations has been demonstrated 
to have good outcomes [101]. 
1.6 Desensitization 
Desensitization can be can be categorised as reducing antibody production, removing 
antibody and preventing the action of antibody on the allograft after transplantation. 
There are no large scale randomised controlled studies demonstrating comparative 
efficacy in the different techniques used in current practice. The numbers from single 
centre experience are small and there is much heterogeneity within these cohorts. 
1.6.1 Antibody Production 
Cyclophosphamide was initially used in early protocols to halt antibody production. 
Intravenous immunoglobulin (IVIg) can modulate the levels of HLA antibodies prior to 
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transplantation. The use of regular high dose IVIg (2g/kg) reduced the levels of antibody 
in potential live donor recipients to a negative crossmatch (CDC) in 92.3% (24/26), and 
allowed successful deceased donor transplantation in 94.1% (16/17) of patients with 
high PRAs ( >50%) [102]. Low doses of IVIg have been used after antibody removal. Its 
mechanistic role is not understood. 
Splenectomy has also been used as a therapy to reduce antibody production, but has 
now largely been replaced by the use of rituximab therapy, a monoclonal antibody 
directed against CD20 expressing B lymphocytes, which has demonstrated equivalent 
outcomes  in ABOiKTx [103-106].  The current role of splenectomy in order to salvage 
allografts is in accelerated early antibody-mediated rejection which has been 
demonstrated in case series [107, 108]. 
Using rituximab can have an effect on reducing anti-HLA antibodies after 
transplantation, but the beneficial effect on anti-HLA antibody production has not been 
clearly demonstrated pre-transplantation [109]. Its efficacy on depleting circulating B 
cells and in removing B cells from sensitised patients’ lymphoid tissue is well described 
in the ABOiKTx cohort by Genberg [110-112]. However, in some centres current 
protocols have abandoned the routine use of anti-CD20, rituximab [104]. 
In HLAiKTx, there is less agreement on regimes for reducing antibody levels. The role of 
bortezomib, a proteasome inhibitor, to reduce plasma cell production has yet to 
demonstrate a significant reduction in circulating antibodies in large cohort studies, 
despite encouraging in vitro results demonstrating reduced plasma cells producing 
antibodies [113-115]. Newer proteasome inhibitors are under development which may 
have improved efficacy. 
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1.6.2 Extracorporeal Antibody Removal Treatment 
The use of protein-A columns to remove antibody has been replaced with plasma 
exchange which is widely available in most nephrology and transplant centres. The use 
of plasma exchange to remove antibodies to a level acceptable to the transplantation 
team is widely published and is often used routinely post transplantation [88, 116-118].  
Plasma exchange removes a volume of circulating plasma and replaces it with the same 
volume of fluids, which usually consist of a combination of crystalloid, human albumin 
and plasma [119, 120]. The protocol developed by Tyden and colleagues, introduced 
A/B antigen specific antibody removal, Glycosorb® ABO (Glycorex, Sweden) with 
rituximab therapy [121, 122]. This technology conjugates A/B trisaccharides to 
Sepharose beads, and plasma is filtered through these antigens, thus avoiding removal of 
important clotting proteins, complement, other immunoglobulins and albumin [123]. 
While Glycosorb® columns reduce the use of infusion products and reduce removal of 
clotting agents, there is still a reduction in anti-carbohydrate antibodies, namely 
pneumococcal and haemophilus, while protein-based immunity is unaffected [124]. 
Early data comparing ABOi and ABO compatible (ABOcKTx) using this technique 
demonstrated equivalent clinical outcomes between the groups [125]. More recently, a 
pan-immunoglobulin technique has been introduced into this expanding area of 
transplantation and demonstrated similarly good clinical outcomes in transplantation 
and removal of anti-ABO specific antibodies and anti-HLA antibodies [126-129].  This 
uses sheep anti-human antibodies to remove human immunoglobulin, and can be eluted 
and re-used unlike Glycosorb® columns. 
Whichever technique is used, an intervention to reduce antibody before transplantation 
is currently considered a pre-requisite in order to achieve successful transplantation. In 
ABOiKTx, an antibody haemagglutination titre of 1:8 dilution is a target that is used 
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widely, however there is a range that different centres find acceptable up to 1:16 and 
1:32 dilution of titre [130, 131]. It is difficult to compare centre to centre final ABO titre 
cut-off values, as different assays are used. The maximum titre pre-treatment is yet to be 
defined, as this is dependent on the titre assay used for measuring anti-ABO specific 
antibody. Reproducible and thus comparative titre results will direct successful 
antibody reduction and ultimately a good allograft and patient outcomes at 
transplantation. In the study by Lawrence et al, a titre of 1:256 was considered the 
maximum titre that could be successfully reduced to enable transplant surgery [132].  In 
HLAiKTx, Extracorporeal Antibody Removal Treatment (EART) is often targeted at 
making a crossmatch negative before transplantation; this can either be CDC or FXM 
depending on the transplant unit’s protocol. 
Post-transplant surgery, antibody removal is based either on an individual unit’s set 
protocol, a rise in titre to pre-determined level (often 1:16-1:32) or only in response to 
antibody-mediated rejection [121, 133-135]. Antibody-mediated rejection is treated 
with EART, along with pharmacological intervention, after transplantation until 
resolution of the acute clinical deterioration. 
1.6.3 Prevention of allograft damage 
Post-operative therapies to prevent allograft damage have been based on a combination 
of techniques above. In addition, C5 inhibition with eculizumab has been used for trials 
and for ‘rescue therapy’ in cases of aggressive AMR successfully [136, 137]. The drug 
works by blocking terminal complement activation and thus membrane attack complex 
formation associated with cell apoptosis. In addition, splenectomy has been effective in 
reducing early AMR in transplanted patients and in response to aggressive early AMR, 
without significant side-effect profile [138, 139].   
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Early experience in Japan for ABOiKTx used anti-coagulation to prevent early allograft 
thrombosis which demonstrated an increased allograft survival benefit of 13% at 5 
years, though this has not become standard practice in the majority of centres 
performing ABOiKTx at present [91]. 
1.7 Rejection 
The presence of anti-donor antibody is strongly correlated with early antibody-
mediated rejection, which in turn is associated with reduced long term allograft survival. 
In addition to early antibody-mediated rejection, Figure 1.6 details the processes 
occurring in the allograft loss over time and demonstrates antibody-mediated injury as 
the predominant process involved after 1 year in a cohort of indication transplant 
biopsies [140]. Thus, after surviving the early transplant period, antibody-mediated 
injury becomes the major contributor; indeed 64% of allografts that failed after biopsy 
were AMR related. On further analysis of the cohort, Sellares et al describe the same 
phenotype in allografts regardless of C4d presence or absence, with the same molecular 
phenotype of antibody-mediated rejection, endothelial and NK transcript expression 
[141]. The Banff criteria for transplant histology have evolved over the past 8 years to 
reflect the role of antibody on histological samples and correlate with clinical outcomes 
[142, 143]. More recent studies demonstrate that whilst allograft function can be within 
normal or acceptable range, there can be histological injury associated with alloantibody 
which is only detected on surveillance or protocol biopsies [144]. Thus understanding 
the processes involved in humoral damage to the allograft may guide future therapies. 
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Figure 1.6. Distribution of histopathology diagnoses in biopsies expressed as 
probability plots conditional on the time of biopsy post-transplantation.  
Sellares’ diagram demonstrates the profile of mechanisms impacting allograft injury 
over time [140]. The probability of antibody-mediated injury increases after 6 months at 
a faster rate than other pathological processes. 
 
 
1.7.1. Defining Antibody-Mediated Rejection 
The diagnostic criteria of early antibody-mediated rejection are the presence of donor 
specific alloantibody, tissue injury in keeping with AMR and the presence of C4d [145].  
Each of these elements will be discussed in the following sections. Histological findings 
consistent with antibody-mediated injury are shown in Table 1.3.  Risk factors for 
humoral rejection include a previous transplant, female gender, pregnancy, historical 
positive cross-match, and increased PRA [146]. 
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1.7.2 Peritubular capillaritis (PTCitis) 
A study by Liptak et al of ultrastructural changes in early AMR describes peritubular 
capillary infiltration comprised of 59% monocytes; 14% neutrophils and 12% 
lymphocytes, with the rest as unspecified mononuclear cells. In the acute biopsies, there 
was evidence of lytic injury with excessive swelling and disorganization of endothelial 
cells with fibrin fibre attachments and denudation of basement membrane; pericapillary 
endothelial cell apoptosis was increased in frequency with no direct contact with 
inflammatory cells and lastly fragmentation of the endothelial layer and formation of 
apical blebs with detachment of fragments from the basement membrane. The follow up 
biopsies for 2 patients (2 of 25) showed signs of transplant glomerulopathy at 26 and 27 
days respectively, but ultimately all allografts failed. There was evidence of 
subendothelial space widening and multiplication of the basement membrane. The rapid 
progression to TG within 1 month following allograft implantation shows that this 
process is a spectrum following antibody-mediated injury [147].  Infiltration of the 
allograft with scoring for peritubular capillaritis was recommended by the Banff 2007 
meeting [142].  The scoring system is based on presence of inflammation and the extent 
of inflammatory cells in the lumen. The type of cell and the minority/majority of 
population of these cells should be noted as well as the association of C4d deposition 
with PTCitis. The technique for C4d staining should be noted, as immunofluorescence is 
more sensitive and correlated with clinical data better than immunohistochemistry. 
1.7.3 Glomerulitis 
Glomerulitis (Table 1.3) is defined by the percentage of glomeruli with inflammation and 
the extent of involvement of each glomerulus. The inflammation of the glomeruli is 
defined by the degree of mononuclear cell infiltration and endothelial cell enlargement 
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[148]. Glomerulitis can be present in both cellular and antibody-mediated rejection. In 
the context of AMR, glomerulitis is associated with staining for CD68, macrophage 
lineage cells, but these are absent in the context of cellular rejection [149]. The impact of 
the presence of glomerulitis and its severity is associated with worse allograft outcomes 
and other lesions associated with chronic antibody-mediated rejection [150]. 
1.7.4 Microcirculation injury scores  
In order to identify allografts with increased risk of failure, combined scores using both 
glomerulitis and peritubular capillaritis have been used to assess risk of allograft failure 
and prediction of outcome [151]. The presence of late (>1 year) microcirculation 
inflammation is highly predictive of the presence of donor specific antibody and 
allograft failure, whilst C4d positivity was not predictive (p=0.581). Furthermore, 
receiver operating characteristic analysis demonstrates that in patients with de novo 
analysis, the severity of the microcirculatory score is more sensitive for allograft failure 
than the presence of C4d deposition alone in the allograft biopsy, which supported 
earlier work demonstrating equally poor allograft survival in patients with 
microcirculation injury as with acute antibody-mediated rejection [152, 153].  
  
 
 
59 
 
Table 1.3. Banff criteria for antibody-mediated rejection and the histological 
scoring of microcirculation inflammation.  
Antibody-Mediated Rejection is defined by having histological injury (Criteria 1) with 
evidence of C4d deposition (Criteria 2) and evidence of anti-donor antibodies (Criteria 
3). The Banff classification for inflammation associated with antibody-mediated 
rejection are shown below. 
Antibody-Mediated Rejection[142] 
Grading Criteria 1 Criteria 2 Criteria 3 
Grade 1 ATN-like minimal inflammation 
C4d 
deposition 
Circulating 
anti-donor 
antibodies 
Grade 2 Capillary and or glomerular 
inflammation (g/ptc>0) and/or 
thomboses 
Grade 3 Arterial involvement - v=3 
Histological Scoring [148] [142] 
Glomerulitis 
0 No glomerulitis 
1 Glomerulitis in less than 25% of glomeruli 
2 Segmental or global glomerulitis in 25-75% of glomeruli 
3 Glomerulitis (mostly global) in more than 75% of glomeruli 
Peritubular 
capillaritis 
0 No significant cortical ptc, or <10% of PTCs with inflammation 
1 ≥10% of cortical peritubular capillaries with capillaritis, with max 3 
to 4 luminal inflammatory cells 
2 ≥10% of cortical peritubular capillaries with capillaritis, with max 5 
to 10 luminal inflammatory cells 
3 ≥10% of cortical peritubular capillaries with capillaritis, with >10 
luminal inflammatory cells 
 
 
 
60 
 
1.7.5 Complement and Antibodies 
1.7.5.1 Complement Activation 
The deposition of C4d in the allograft reflects the biological process of antibody binding 
to antigen and activating the complement cascade causing tissue injury via the classical 
complement pathway (Figure 1.7). C4d is a breakdown product of activated C4, when 
C4b is cleaved. This occurs in the classical pathway of complement activation after C1q 
binding to antibody-antigen complexes. C4d deposition in the allograft is due the 
covalent binding to tissue, whilst other C4 and C3 breakdown products do not remain in 
the allograft on biopsies. C4d (thought to be inactive) is bound and thus detectable in 
biopsies and correlates well with antibody-mediated damage [154]. C4 can also bind to 
mannose binding protein (lectin pathway) and follow the same activation pathway. 
 
Figure 1.7. Activation of complement pathways.  
There are 3 different pathways for complement activation which are shown in the 
diagram below. (MBL, mannose binding lectin; CRP, C-reactive protein; MASP, 
MBL‑associated serine protease; SAP, serum amyloid P;CR, complement receptor; C3aR, 
C3a receptor; C5aR, C5a receptor and CRIg, Complement Receptor of the 
Immunoglobulin superfamily) 
Taken from Sacks and Zhou [155].  
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1.7.5.2 Complement Activation and Chronic Injury 
The further evidence for rejection with C1q-mediated classical pathway activation with 
presence of DSA IgG was shown by C1q binding to DSA IgG on single antigen beads 
(SAB) correlating with the development of transplant glomerulopathy and graft loss. 
C1q positive DSA IgG was associated with the presence of C4d in graft histology, but also 
with a higher incidence of acute rejection [156, 157]. Anti-HLA antibodies that fix C4d in 
vitro assay are also strongly associated with early AMR, and if C4d was not activated on  
the SAB, there was no early AMR [158]. Furthermore, increased deposition of C4d in the 
allograft is associated with significantly worse allograft outcomes [159]. Whilst the 
presence of C4d in the biopsy is associated with the detection of circulating antibody, the 
absence of C4d does not signify the absence of anti-donor antibodies. C4d negative 
biopsies with circulating DSA still display microcirculation injury and the new Banff 
criteria of AMR reflect this change in viewpoint [151, 160-164]. This also reflects the 
temporal nature of biopsies, sampling and intensity of binding. Loupy and colleagues 
have recently demonstrated in a large cohort that despite significant DSA levels, if C1q 
binding was negative, the allografts survival was not inferior to patients without DSA, in 
contrast to the poor outcomes in the combined DSA/C1q+ patients [165]. 
C4d staining has been correlated with multi-layering of the peritubular capillary 
basement membrane by Regele. The presence of C4d in the graft at biopsy without 
transplant glomerulopathy was associated with progression to transplant 
glomerulopathy at follow up biopsy greater than 9 months in 82% allografts [166]. 
Acute antibody-mediated rejection is a risk factor for the development of transplant 
glomerulopathy as is the presence of anti-HLA antibodies, particularly with anti-class II 
antibodies [167-169]. The deposition of C4d with the presence of anti-HLA antibodies is 
associated with microcirculation injury, an indicator of antibody-mediated injury. 
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1.7.5.3 Antibody damage without Complement 
Early humoral rejection in allografts that have a positive B lymphocyte flow crossmatch 
with DSA can be prevented by C5 inhibition (eculizumab). C5 inhibition blocks the final 
complement pathway step prior to terminal membrane attack complex (MAC) 
formation. The presence of C4d in the allograft biopsy demonstrated complement 
activation was initiated, but no endothelial or tubular damage occurred early which is 
associated with antibody associated mechanisms. There was significant reduction in the 
incidence of early AMR, which in the control cohort was 41.2%, and only 7.7% in 
treatment group in high titre HLA incompatible kidney allografts [136]. In atypical HUS 
(aHUS), the use of eculizumab post-transplant has shown a dramatic reduction in 
activated terminal complement complex. However, in the presence of anti-donor 
antibody without AMR, transplant glomerulopathy develops despite C5 inhibition, 
suggesting that the classical complement pathway for what is called chronic antibody-
mediated damage may not be the only process involved in allograft damage [170-172].  
Acute rejection with anti-donor antibodies does not always need the antibody-C1q 
complex. A murine model demonstrated that if C1q donor neg/recipient neg 
transplantation does not protect from early acute rejection, with presence of high anti-
donor IgG and low IgM [173]. This was associated with higher levels of graft infiltration 
of macrophages and neutrophils, the hallmark of antibody-mediated rejection. The roles 
of non-classical complement activation pathways in the presence of antibody are 
postulated in this paper. In a different paper, the absence of circulating C4 in murine 
models does not improve allograft outcome when donor or recipient was depleted of C4 
[174]. Furthermore, non-classical pathways of complement activation are a different 
mode for graft injury and complement deposition. The development of features 
consistent with chronic AMR can take place in the presence of anti-donor antibodies but 
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in the absence of C3 component. This was true with different immunoglobulin isotypes 
producing tissue injury with similar features of neointimal thickening and cellular 
infiltrates as expected in antibody-mediated rejection [175]. 
1.7.6 Chronic Antibody-Mediated Rejection  
Transplant glomerulopathy is defined as the characteristic duplication of the glomerular 
basement membrane (GBM) observed by light microscopy with degree of severity 
determined by the percentage of glomeruli capillary loops affected (Table 1.4) [148].  
Chronic damage associated with allograft loss was broadly classified as chronic allograft 
nephropathy without attempting to define the pathological processes that cause 
allograft loss. More recently, an attempt to increase the specificity by which the 
mechanism of injury is defined in these cases has been developed. This however 
represents a consensus of expert opinion using often limited data. Consequently these 
classifications have changed with each iteration of Banff consensus definitions. 
Increasingly, microarray molecular phenotyping is used in research to define 
immunological processes in allograft biopsies [176]. Chronic glomerulopathy describes 
a process that has significant impact on allograft survival and is associated with 
alloantibody, in the absence of other diseases that may cause the same phenotype of 
endothelial injury and is irreversible. With antibody-mediated injury occurring before 
allograft failure, it can be used as an endpoint which will allow the evaluation of both: 
types of anti-donor antibody and effective interventions to prevent chronic antibody-
mediated damage. 
1.7.7 Accommodation 
 The presence of alloantibody is associated with tissue injury but not all allografts 
display a phenotype of allograft injury, despite the presence of alloantibody. This has 
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been called “accommodation”. The phenomenon of accommodation was described in 
animal models of xenotransplantation when there was no xenograft loss despite the 
presence of anti-donor antibody [177]. More recently it is commonly seen in ABOiKTx, 
but the term accommodation has not been widely used in HLAiKTx [178-180]. The 
precise definition of accommodation is important because initially it was defined as the 
presence of alloantibody without allograft dysfunction [181]. However, histological 
assessment allows a more detailed analysis of allografts, prior to deterioration in renal 
function. Further to this, molecular markers of immunological injury/activation are now 
being used, which demonstrate activation of the immune system, despite good allograft 
function and no chronic histological injury in light microscopy. Thus accommodation 
may simply be “slow” rejection, as true accommodation should reflect no allograft injury 
in the presence of alloantibody [182].  
 
 
Table 1.4. Criteria for Chronic Antibody-Mediated Renal Allograft Rejection.  
Adapted from Colvin, R.B. [142, 183]. 
Diagnostic criteria for chronic antibody-mediated rejection 
Histological evidence of  
chronic injury 
1. Arterial intimal fibrosis without elastosis 
2. Duplication of glomerular basement membrane 
3. Multilaminated peritubular capillary basement 
membrane 
4. Interstitial fibrosis and tubular atrophy 
Evidence of antibody 
action/deposition in tissue 
1. C4d deposition 
Serological evidence of  
DSA 
1. Anti-HLA antibodies 
2. Other anti-donor antibody 
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1.8 What happens after an antibody incompatible transplant  
1.8.1 Clinical Outcomes in HLAiKTx 
The outcomes of HLAiKTx have been described in single-centre case series. There are 
few studies which report longer term outcomes (more than 2 years follow up, Table 1.5). 
As previously described, the level of the antibody is key to defining the degree of 
HLAiKTx. The current three main methods of stratifying HLAi are by complement 
dependent cytotoxicity (CDC) assay; lymphocyte flow crossmatch (FXM) (either B or T 
lymphocytes) and using solid phase assay beads (SAB) coated with HLA proteins. A 
comparison of data between these methods in a single centre demonstrates the 
relationship between each of these testing methods and clinical outcomes; namely that 
across a population there is an association between levels of anti-HLA antibody and 
tissue injury [70].  
Allograft outcomes are difficult to compare directly between centres due to lack of 
standardisation of the anti-HLA antibody assays, different antibody targets and the 
different therapies used. The results suggest higher antibody levels associated with 
increased rates of AMR and worse allograft outcomes [184]. The outcomes of centres 
report allograft survival and creatinine, however the histological analysis of HLAiKTx 
are not widely published [185]. More recently, the development of C1q binding assays, 
detecting the activation of complement for a particular DSA will further impact the 
interpretation of these results, as patients with high DSA levels, but without C1q binding 
have significantly better clinical outcomes [165].  
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Table 1.5. A comparison of outcomes in early period HLAiKTx for patient and allograft survival in different centres and with 
registry data. 
The rate of AMR across different centres is wide, with centres using more sensitive methods of DSA detection having lower rates of AMR, 
suggesting lower antibody levels. Similarly, the 1 year allograft survival rate ranges from 78% to 100%. 
Centre Year Published 
Patient 
Number 
DSA technique 
Patient Survival Allograft Survival 
AMR 
rate 1yr 3yr 5yr 1yr 3yr 5yr 
Hopkins [22] 2000 4 CDC/ELISA 100% n/a n/a 100% n/a n/a 100% 
Mayo Clinic [186] 2003 14 CDC/ELISA 86% n/a n/ a 78% n/a n/ a 43% 
UCLA  [102] 2003 42 CDC 98% n/a n/a 90% n/a n/a 31% 
Paris [187] 2007 32 CDC n/a n/a n/a 84% 78% 78% 41% 
Maryland [185] 2009 41 
CDC/ELISA/L
uminex 
n/a n/a 78% 90% 74% 70% 12% 
Chicago [188] 2005 12 Flow 100% n/a n/a 100% n/a n/a 25% 
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1.8.2 Clinical Outcomes in ABOiKTx 
Whilst single centres report good outcomes, equivalent to ABO compatible cohorts 
within centre, there is data suggesting a significant difference between ABOi and ABOc 
across registry data [25, 189]. This is in contrast to Futagawa’s study with earlier data 
from UNOS which showed equivalent outcomes in ABOi to ABOc between 1995 and 
2003 [190]. This study was smaller than Montgomery et al (n=392 vs. n=738) and 
compared both deceased donor and live donor together, but this was in the early 
experience of ABOiKTx. There are many factors that could explain the differences in 
outcomes in these cohorts. Table 1.6A shows data from some centres performing 
ABOiKTx, reflecting the differences in outcomes. 
There is a higher rate of antibody-mediated rejection in the ABOiKTx group than in 
ABOcKTx (Mayo Clinic data, 46% vs. 2%)[191]; however, this was not reported in 
Tyden’s study, in which the cellular rejection rate was very low and not significantly 
different between the ABOiKTx and ABOcKTx  (Table 1.6B) [125, 192]. 
The risk factor associated with allograft loss through hyperacute antibody-mediated 
rejection and early antibody-mediated rejection is the level of the anti-donor ABO titre, 
in particular the IgG isotype [193]. It is difficult to separate the analysis of IgG and IgM 
data, as often they are both present at similar levels – insofar as high titre patients 
generally have high levels of both isotypes.   
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Table 1.6. Clinical outcomes of ABOiKTx with survival and AMR as endpoints.  
Table 1.6A - A comparison of outcomes in ABOiKTx for patient and allograft survival in 
different centres and with registry data. 
Centre Patient 
Number 
Patient Survival Allograft Survival 
1yr 3yr 5yr 1yr 3yr 5yr 
Hopkins [194] 60 96.3% 96.3% 89.4% 98.3% 92.9% 88.7% 
Mayo Clinic [73] 40 95% 89% n/a 96% 80% n/a 
Guys Hospital [195] 62 94.5% 91.9% n/a 98.4% 98.4% n/a 
Karolinska, Sweden [196] 45 100% n/a n/a 96% 91.1% n/a 
US Transplant Registry [189] 738 96.8% 93.7% 88.3% 94.1% 89.6% 82.6% 
Japanese Transplant Registry – 
early era [197] 
451 92% 89% 86% 82% 76% 70% 
Japanese Transplant Registry –
modern era [197] 
1427 98% 97% 96% 96% 93% 91% 
 
 
Table 1.6B. A comparison of rejection rates for ABOiKTx in different centres 
demonstrating wide range of clinical outcomes in each data set. 
Centre Number 
Rejection Rates 
AMR Cellular 
Montgomery [194] 60 16.7% (n=10) 18.3% (n=11) 
Mayo Clinic [191] 24 45.8%(n=11) 16.7% (n=4) 
Japan [198] 494 Combined 58% (n=256) 
Karolinska, Sweden [125] 60 0% 6.7% (n=1) 
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1.9 Summary and Scope of this thesis 
The benefit of kidney transplantation is proven, yet antibody-mediated rejection 
significantly reduces the allograft survival. For patients with antibody incompatible 
donors, it is very important to provide accurate information in order to make clinical 
decisions, both for the clinician and for the patient. 
The aim of this thesis is to: 
1) Develop an assay for reproducible measurement of anti-ABO specific antibodies 
2) Compare the anti-ABO specific antibodies between UK transplant centres 
3) Examine the clinical outcomes in ABO incompatible kidney transplantation in the 
ABOUT-K study and the effect of differences in anti-ABO specific antibody 
measurement on these outcomes. 
4) Define the long term clinical and histological outcomes of positive crossmatch 
kidney transplants with regards to their HLA class of antibody 
5) Assess the cellular infiltrate in antibody incompatible kidney transplant 
recipients and the clinical outcomes 
6) Investigate the possible cause for early antibody-mediated rejection in patients 
treated with C5 inhibition. 
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Chapter 2  Novel Assay Development for anti-ABO blood group antigen 
specific antibodies 
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2.1 Introduction 
2.1.1 ABO Titration 
The measurement of anti-ABO specific antibodies has not substantially changed in the 
last 100 years since their identification by Landsteiner. Identification of an individual’s 
blood group has been done, by testing patient red blood cells (RBC) against known 
reagents that agglutinate known red cell phenotypes or more recently genetically. 
Alternatively the blood group may be deduced from the specificity of binding from the 
individual’s plasma, referred to as reverse blood group typing (Landsteiner’s rule) [199]. 
Red cells of known blood group are incubated with plasma of the patient and if there is 
agglutination, then a positive result is recorded. The antibody reaction is determined by 
serial doubling dilution of plasma against red cells, known as ABO titration and 
quantification of anti-ABO specific antibody is determined by the number of dilutions 
necessary to abrogate the reaction. There have been different variations on this 
technique’s protocol, but all are based on the same principle of serial doubling dilutions 
until the lowest concentration of plasma that agglutinates is recorded as the titration 
value. This application has been used for assessing risk in haemolytic disease of the 
newborn and for determining transfusion from donors with high or low anti-ABO 
specific antibody titres [200].  
Measuring the amount of antibody is considered a pre-requisite for ABOiKTx. The 
reduction of anti-ABO specific antibody to acceptable levels and monitoring for early 
complications is routinely performed in clinical practice. The method of quantification of 
anti-ABO specific antibody was transferred from transfusion practice into 
transplantation practice.  
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2.1.2 Immunoglobulin Isotypes 
ABO titration has been adapted for isotypes; in that measurements can be taken for total 
isohaemagglutination; treated with DTT for measurement of non-IgM isotype 
(presumed IgG) and total agglutination using different ionic strength diluents to 
measure predominantly IgM [201-203]. The addition of anti-human globulin (AHG) to 
increase agglutination and measurements at different temperatures have also been used 
to differentiate plasma antibody reactions attributable to IgG and IgM [204, 205]. The 
significance of isotypes in transfusion reactions is important. Greenbury and colleagues 
inferred that only 25 anti-A1 IgM molecules per RBC are required for direct 
agglutination of A1 red blood cells, but 20,000 IgG molecules were necessary [206]. In 
order to initiate complement binding, it has been estimated that 7000 molecules of anti-
A IgG per RBC are required to bind complement using an anti-C3c reagent, although data 
for IgM is not available [207]. The proportion of anti-A IgG of total IgG was found by 
Buchs to be 1/104-1/106 [208]. Furthermore, the temperature at which agglutination 
takes place helps to identify isotype, for example at 4ºC IgM anti-ABO specific antibodies 
agglutinate better while IgG have increased agglutination at 37ºC.  
The agglutination of RBC by different IgG subclasses demonstrates high levels of IgG2 
binding – but interestingly a quarter of patients had all 4 subclasses found, although 
these were not quantified [209]. While IgG2 binding is high, maternal anti-ABO specific 
antibodies causing haemolytic disease of the new-born are predominantly IgG1 and IgG3 
in distribution, because IgG2 does not cross the placenta. 
2.1.3 Poor reproducibility of ABO titration  
Data from Japan and Sweden was the first to demonstrate significant variation in results 
from different centres and users performing the ABO titration [210, 211]. There was up 
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to an 8 log2 dilution difference between the lowest and highest readings in Ishida’s 
study. Kumlien and colleagues demonstrated that using a defined protocol significantly 
reduced the variation in assay; however this did not eliminate variation within an intra-
laboratory standard of ±1 dilution from the median titre. The American Pathology 
Society coordinated an international study in laboratory variation and if a set protocol 
was followed using a gel card technique at a set temperatures using a defined endpoint, 
this produced more reproducible results [205]. This study demonstrated that at 37ºC 
there was less variation than at 4ºC. The use of pooled red cells or donor cells is still 
debated; however this study also demonstrated that using the same cells reduced 
variation between laboratories. However, pooled RBCs have the possibility of true 
standardisation of antigenicity and may be “normalised” through an adequate quality 
assurance process. National pooled RBCs will reflect the genetic distribution with each 
region, but will not be applicable to different international regions.  
The assumption that donor A/B antigen RBC expression reflects the kidney A/B antigen 
expression remains unproven. Indeed, A/B antigen expression will also vary, as 
transferase activity will also depend on the expression of core chains, the variation of 
which remains ill described. Thus, ultimately testing anti-ABO specific antibodies against 
RBCs may not be testing the appropriate antigen-antibody interactions in 
transplantation [212].  The primary function of haemagglutination is to assess the 
agglutination function of the antibody, rather than the quantity of antibody. There are 
also qualitative differences in antibody binding that cannot be assessed by 
haemagglutination. 
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2.1.4 Alternative techniques for anti-ABO antibody assessment 
Flow cytometry is a different technique for analysing antibody binding to RBCs 
demonstrated by Stussi et al to be sensitive and specific for both isotype and subclass of 
anti-ABO specific antibodies [66]. Krishnan and colleagues assessed flow cytometric 
analysis with correlation to haemagglutination titre in clinical cases and demonstrated 
the ability to correlate anti-ABO specific antibody changes over time with both 
haemagglutination and flow cytometry and in response to clinical therapies [213].  
Further analysis of clinical assessment of antibodies using ELISA assays demonstrated 
that different isotypes and subclasses of anti-ABO specific antibodies may play an 
important role. Ishida et al demonstrated a difference between rejecters and non-
rejecters during the first month post ABOiKTx. Whilst at 1 week both groups had an 
initial rise in IgM, IgG1 and IgG2, at 1 month there was a further rise of IgM; IgG1 and 
IgG2 in rejecters but falling levels of IgM and IgG2 in non-rejecters [214]. This paper 
does acknowledge that at 1 month all rejecters had returned to dialysis. This data has 
yet to be reproduced by other groups. Importantly, the assessment of antibody after a 
clinical event has very little benefit to clinical management. To be able to predict risk 
and to guide subsequent management, an assay to determine higher risk patients is 
required [212, 215]. Clinical data shows that despite the return of anti-ABO specific 
antibodies, there is seldom rejection or allograft dysfunction and while there is an 
increased risk of having antibody-mediated rejection if the starting titres are higher; 
there are still a large proportion of patients who have very good clinical courses who 
had initial high titres [216].  
Anti-ABO specific antibody binding to A/B antigens was shown using surface plasmon 
resonance [217, 218]. Surface plasmon resonance is a platform that allows molecular 
interaction to be assessed, as association and dissociation of molecules are displayed 
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and data can be extrapolated for the binding affinities of binding molecules [219]. 
Different binding properties of anti-ABO specific antibodies may explain the differences 
in outcome between the same agglutination titre of antibody.  
The aim of these studies was to explore the development of reliable and reproducible 
assays to measure anti-ABO specific antibodies. Improved anti-ABO specific antibody 
quantification, specifically improved precision and reproducibility is an important step 
towards:  
1) Prospective multicentre studies of intervention, including EART and 
immunosuppression 
2) Risk stratification based upon antibody quantification, with a view to identifying 
patients likely to develop early allograft loss or antibody-mediated rejection who may be 
offered alternative treatment strategies such as paired exchange. 
It may also be possible to differentiate antibodies on the basis of antigen specificity, 
isotype or other characteristics that specifically identify those more or less likely to 
contribute to organ damage (rather than just haemagglutination)    
2.2 Anti-ABO specific antibody assay development 
2.2.1 Haemagglutination 
2.2.1.1 Introduction 
The measurement of anti-ABO specific antibody by agglutination is the current best 
practice in red cell immunohaematology. I aimed to produce a robust, reproducible 
assay for haemagglutination and differentiate IgG binding from IgM. In order to 
differentiate isotypes, DTT was used in the methodology to determine isotype 
distribution and thereby the effects of different isotypes on the allograft outcomes, 
specifically rejection and allograft survival [220].  
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2.2.1.2 Methods 
Using protocols based on NHSBT Red Cell Immunohaematology laboratory practice and 
UK NEQAS (National External Quality Assessment Service), day to day variability; 
different red cell batches and with freeze/thaw samples were investigated. Plasma was 
obtained by centrifuging human blood in EDTA for 10 minutes at 5000rpm. A DiaMed 
gelcard was used according to manufacturer’s protocol and both direct and indirect 
agglutination were measured. 
2.2.1.2.1. Preparation of Red Blood Cell Test Blood Group Sample.  
This is same for both Haemagglutination (HG) techniques. Red Blood Cells (RBC) 
were obtained from NHSBT Supplies (NHSBT Liverpool); A1rr (product code PR014); 
Brr (product code PR035) and OR1r (product code PR041), in a Cell Stat suspension, 0.8 
±0.2% concentration/ml used for all assays requiring red cells. 
A 0.8% red cell suspension was prepared in ID-Diluent 2 using red blood cell blood 
group according to specificity of binding required. The ID-Diluent-2 solution was 
allowed to reach room temperature before use and 1ml of ID-Diluent-2 was dispensed 
into a clean tube. Ten microL of packed red cells was added and gently mixed. The cell 
suspension could be used immediately, or stored at 2-8°C for 48hours.  
One aliquot of plasma was treated with 0.1M DTT (Sigma, Poole Dorset, UK). Three 
hundred microL of plasma was diluted with 300 microL of 0.1M DTT for 30minutes at 
37ºC. ID Diluent 2 was used for serial dilutions of plasma using a doubling dilution 
method.  
Direct agglutination at room temperature (DRT) was performed using neutral 
DiaMed cards (005015, NaCl, Enzyme Test and cold Agglutinins, BioRad, UK) with 50 
microL of RBCs suspended in ID Diluent 2 to each microtube. Fifty microL of each 
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plasma dilution was added to the corresponding microtube and incubated at room 
temperature for 15 minutes. The microtubes gel cards were centrifuged (85g) for 10 
minutes in DiaMed (I-Centrifuge 12S-II, BioRad, UK). The gel cards were analysed over a 
bench lamp and the last well giving a positive result of agglutination was recorded as the 
titre result for that sample. The indirect agglutination using antiglobulin technique (IAT) 
used 50microL of red cells suspended in ID Diluent 2 to each microtube and then 
25microL of the DTT treated plasma serially diluted from 1:1 with ID Diluent 2. Gelcards 
already had anti-IgG in the columns (004025, Coombs Anti-IgG, BioRad, UK). This was 
incubated at 37ºC for 15 minutes and then centrifuged (85g) and read as per previous 
assay. A single user performed multiple haemagglutination assays for historic controls 
to attain laboratory competencies. 
Different batches of RBCs were used to assess variability between HG results. 
Two different batches were obtained and HG was performed on the same sample by the 
same operator. The same sample was tested on 2 sequential days with the same batch of 
RBC to determine day to day variation. The effect of freeze/thaw was determined by 
testing samples on arrival to the laboratory. Samples were frozen at -40°C for a 
minimum of 1 week and then thawing took place in a water bath at 25°C for 30minutes.  
2.2.1.3 Assay variability 
Pooled red blood cells were obtained from NHSBT processing laboratory in Liverpool 
for ABO blood groups. Haemagglutination was tested with different RBC batches and 
intra-sample variability assessed. The results were analysed using a weighted kappa 
quadric analysis, which tests the agreement between two different tests and gave a 
result of 0.867 (0.799 to 0.936, n=16) demonstrating very good agreement of the two 
tests. The calculation is based on the difference between how much agreement is 
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actually present (“observed” agreement) compared to how much agreement would be 
expected to be present by chance alone[221]. The effect of freeze/thaw on samples was 
tested using stored samples which had been tested on day of arrival for ABO titration 
and then re-tested after thawing and the results of both titrations were within 1 dilution 
of each other. 
Finally, HG assays were performed on different days and there was good reproducibility 
(Figure 2.1). Bland-Altman plots show the difference between test 1 and test 2 for 
reproducibility. The weighted kappa quadric assessment for different day agreement of 
IgG was 0.945 (CI 95% 0.901-0.989) and IgM 0.979 (CI 95% 0.971-0.988) demonstrating 
excellent agreement between the two tests (Figure 2.2). The statistical methods are 
explained in more detail in section 2.2.5 on page 125.  
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Figure 2.1. Reproducibility of HG assay on different days by same operator.  
This figure demonstrates the reproducibility of the HG assay on inter day variability 
testing for anti-A1 IgG (A) and IgM (B) reproducibility.  HG data is log10 transformed 
from log2 dilution titre result. There is good reproducibility of the assay on the same 
sample tests on different days by the same operator. The reproducibility for anti-B IgG 
(C) and IgM (D) is also very good. The Bivariate Plot with Linear Fit is plotted with r2 
regression coefficient. n=number of samples  
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Figure 2.2. Intra-test agreement between HG assays for IgG and IgM.   
These Bland-Altman plots demonstrate agreement between test 1 and test 2 for each 
isotype by HG, with a single user for both IgG and IgM against both blood group A 
(graphs A and B respectively) and both IgG and IgM against blood group B RBCs (graphs 
C and D respectively). The data is plotted as a continuous variable, however is 
categorical in nature and thus there is overlap of data points. The plots demonstrate 
very good correlation and mean difference between the 2 haemagglutination (HG) tests 
as low in all 4 tests.  
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2.2.1.4. Conclusions 
A single user with a single methodology for ABO titration can produce results that are 
within the limits of the units of measurement of the test itself. Intra-laboratory quality 
control accepts a difference of 1 titre dilution. The use of doubling dilution in these 
assays reflects the limits of the assay performance. These reproducibility experiments 
demonstrate a mean difference between tests of one titre step (± half titre step), which 
is the limit of assay performance as defined by the size of the (minimum) increment.  
A reliable and reproducible assay is important in the comparison of clinical data 
and to assess clinical variables between different centres performing ABOiKTx. In order 
to compare antibody levels during transplant assessment and treatment, a reproducible 
method is required. Freeze/thaw had no significant effect on these results. Different red 
cell pooled batches validation has been performed so that there was very high level of 
agreement over time.  
This assay will be used to the clinical study in Chapter 3 describing the clinical 
outcomes in a multicentre observational study in ABOiKTx.  
 
2.2.2 Flow Cytometry Assay 
An alternative approach to measuring anti-ABO specific antibodies uses flow cytometry 
and I adapted this technique from a previously published method for identifying IgG and 
IgM [213]. Flow cytometry has the potential advantage of allowing identification and 
quantification of antigen specific isotype and subclass.  Furthermore, the identification 
of complement binding IgG subclasses would allow risk stratification in the assessment 
of anti-ABO specific antibody. The protocol for running samples in both isotype and 
subclass experiment was similar with different secondary labelled antibodies. 
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2.2.2.1 Methods 
A suspension of RBCs from NHSBT (as used in haemagglutination assays) was measured 
using a haemocytometer to a required concentration of 107 cells/ml in flow cytometry 
diluent. This concentration was determined by Krishnan et al to reduce the effect of 
agglutination on the assay when setting flow cytometry gating [213]. The RBC 
suspension for both blood group “A1” and blood group “B” were vortexed for 10 seconds 
to ensure adequate suspension. Twenty five microL of RBC suspension was added to the 
appropriate tube, and a further 20microL of FACS diluent was added. Five microL of the 
plasma to be tested was added to the appropriate tube. Each tube was vortexed for 10 
seconds and incubated at room temperature for 30minutes. The cells were washed with 
PBS (pH 7.4) 3 times using a Cellwash centrifuge (5 minutes at 1000g, DiaCent-CW, 
BioRad, UK) and the supernatant discarded, to leave a RBC pellet. One hundred microL 
of secondary antibody (according to isotype/subclass to be identified) was added 
according to dilution of each secondary antibody, and then incubated at 4°C in the dark 
for 15 minutes.  
Following incubation, 300microL of flow cytometry diluent was added to each tube and 
vortexed for 10 seconds. The tube was then put on the flow cytometer (BD FACSCanto™ 
II, BD Biosciences). Gating of the flow cytometer was based on the red cell population 
size using forward and size scatter. Counts of 5,000 cells were acquired per tube in the 
gated area. Data was analysed using the BD FACSCanto™ software (BD Biosciences, 
California, USA). In order to report the binding of each antibody, the relative median 
fluorescence intensity (RMFI) was calculated from the sample median fluorescence 
intensity (MFI) of sample binding divided by the MFI in the presence of  “AB” serum. 
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2.2.2.1.1 Isotypes 
The concentration of each secondary antibody for each isotype was determined using 
standard curves for each of the following antibodies: 1:800 Goat Anti-Human IgG (γ-
chain specific), F(ab′)2 fragment–FITC antibody (F1641-2ML, Sigma, UK); 1:200 mouse 
anti-human IgM (µ chain specific) R-phycoerythrin (R-PE) conjugate (9022-09. Southern 
Biotech, Birmingham, USA) and 1:100 anti-human IgA APC (130-093-113, Miltenyi 
Biotec, UK). 
2.2.2.1.2 Subclasses 
In order to perform multicolour flow cytometry on the IgG subclasses, it was necessary 
to conjugate a fluorochrome to an isotype. This comprised of incubating the mouse anti-
human IgG4 purified (9190-01, Southern Biotech, Birmingham USA) with Lynx Rapid 
PerCP conjugation kit (LNK073PERCP, AbD Serotec, UK). Conjugation was achieved by 
adding 1 microL of the Modifier reagent for every 10 microL of antibody and mixing 
gently. This sample was added directly to the LYNX lyophilized mix and mixed by gently 
pipetting in order to re-suspend. This mixture was incubated in the dark for 3 hours at 
room temperature. One microL of Quencher reagent was added for every 10 microL of 
antibody used, following incubation and left for a further 30 minutes before use. The 
other antibodies used were mouse anti-human IgG2 FITC (9080-02, Southern Biotech, 
Birmingham, USA); Mouse anti-human IgG3 R-PE (9210-09, Southern Biotech, 
Birmingham, USA) and anti-human IgG1 APC (130-093-189, Miltenyi Biotec, UK). 
2.2.2.1.3 Purification of antibody 
For positive controls in both flow cytometry and surface plasmon resonance, 
purification of both murine monoclonal and human polyclonal antibody against both A 
and B antigens was carried out. A 50ml syringe was connected to a Glycorex™ sephadex 
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column which was connected in series with a Pharmaxia LKB P1 pump and Pharmacia 
Single Path Monitor. The circuit was washed with 150ml of PBS (pH 7.4) using rate of 
8ml/min. The solution of protein for purification was added to the 50ml syringe and 
pump speed of 2ml/min. Monitoring of the protein concentration determined the 
protein adsorption to the column. Glycine elution buffer (40ml, pH 2.8 100mM) was 
added to the syringe and the pump speed reduced to 1ml/min. Eluate was collected in 
15ml Falcon Tube containing 0.5ml Tris solution( 1M, pH 8.3) for neutralisation of the 
acid. Continue with elution until the protein peak returns to baseline. The eluate was 
concentrated using Vivaspin 20 columns. The columns were initially blocked with 20ml 
of 0.1% BSA (Sigma, UK) by incubating for 30minutes at room temperature on a roller. 
The column was washed with de-ionised water and shaken in order to dry. Using 20ml 
of eluate in column, this was centrifuged at 4000g until concentrated. The volume was 
checked volume at 30minute intervals and repeat centrifuge process was performed if 
necessary to reduce volume to 5ml. The flow through was discarded. 
This protocol was used for both murine monoclonal and human polyclonal 
antibodies. The blood group typing agents against A or B antigen were used as murine 
monoclonal antibodies (clone Birma-1 or clone LB-2, Millipore, UK). The human 
polyclonal antibody was eluted from waste Glycosorb™ columns after clinical discard.  
2.2.2.2 Results 
2.2.2.2.1 Isotypes 
The assessment of blood group antibodies represented a normal distribution for both 
IgG and IgM isotypes relative to the background binding against AB serum (RMFI) which 
is shown in Figure 2.3. The relationship of the log2 transformed MFI strongly correlated 
with the HG titre data plotted on a transformed scale (log2) shown in Figure 2.4A. The 
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relationship of IgM to both IgA and IgG as measured by flow cytometry also correlate 
with each other in Figure 2.4B 
 
 
Figure 2.3. Histograms demonstrating the distribution of anti-A specific antibodies 
in flow cytometry and HG.  
Figure 2.3A. The distribution of the log2 transformed central haemagglutinin titre (anti-
A IgG) measured prior to antibody removal is normally distributed with a mean of 4.5 
and standard deviation of 2.7. (In this and subsequent figures a HG titre of 0 is neat and -
1 no reactivity) 
Figure 2.3B. The distribution of the log2 transformed RMFI (anti-A IgG) measured prior 
to antibody removal is normally distributed with a mean of 2.3 and standard deviation 
of 1.4.  
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Figure 2.4. The relationship of HG titre and flow cytometric analysis of anti ABO 
specific antibodies. 
Figure 2.4A. The log10 haemagglutination titre (log HG - x axis) and flow cytometry data 
represented by the log2 relative median fluorescence intensity (Flow RMFI log2- y axis) 
for both IgG and IgM isotypes against both A and B blood group antigens. The Bivariate 
Plots with Linear Fit (red lines) demonstrate the strongest correlation for IgG binding to 
A antigen (graph A) as demonstrated by the regression coefficient (r2). n= number 
tested.  
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Figure 2.4B. The assessment of anti blood group antibody isotypes by flow cytometry 
(FC) for IgG, IgM and IgA.  
The relationships of the log base2 transformed relative median fluorescence intensity of 
each isotype to the other isotypes are shown below.  There is the greatest correlation 
with IgG and IgM (r2=0.64) relative to the other isotypes. The data are plotted as a 
Bivariate Plot with Linear Fit (red lines) with a regression coefficient. n= number tested; 
r2=coefficient.  
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2.2.2.2.2 Subclasses 
Optimisation of the concentration of the individual subclass secondary antibodies and 
then combined in performing 4-colour flow cytometry demonstrated strong binding to 
the positive control with minimal background binding (Figure 2.5).  In a small cohort of 
patients (n=4) with antibody-mediated rejection collected from clinical practice, there 
was binding for the different subclasses which demonstrated different distributions of 
IgG subclasses over early post-transplant time points (Figure 2.6). These experiments 
require further exploration and refinement. 
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Figure 2.5. Flow cytometry histograms for subclass analysis of IgG  
These flow cytometry subclass assay histograms demonstrating the human positive 
control and negative control (human AB serum). The median fluorescence shift for each 
subclass against blood group A red cells in the positive control is shown (a concentrated 
eluted human polyclonal antibody from Glycosorb™ columns, method described in 
2.2.2.1.3). The red and green histograms represent different gated areas on the flow 
cytometer. The table shows the median fluorescence intensity (MFI) binding and the 
relative MFI (RMFI, calculated by divided the test MFI by the negative control MFI) for 
each subclass. 
 
N=1 
IgG1 
MFI 
IgG1 
RMFI 
IgG2  
MFI 
IgG2 
RMFI 
IgG3  
MFI 
IgG3 
RMFI 
IgG4  
MFI 
IgG4 
RMFI 
Negative Control 174 - 49 - 31 - 137 - 
Positive Control 5381 30.9 9905 202.1 5577 179.9 608 4.4 
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Figure 2.6. Preliminary Data for IgG subclass analysis of patient with ABOiKTx  
These data demonstrate changes in the IgG subclasses in patients with antibody-
mediated rejection compared to no rejection in the patient represented in graph A. IgG2 
is the most prevalent subclass across all patients, however no rejection was found in the 
patient represented in graph A despite high IgG2 levels. High levels of IgG4 above 
baseline were found in 1 patient (D) prior to transplantation and IgG3 was present at 
higher levels than baseline  in (C), which had a high (relative to background) response at 
the time of rejection. Time of rejection is annotated in the graphs for the patients, which 
occurred at day 10 (Graph B), Day 6 (Graph C) and Day 6(Graph D). Two of these 
patients (represented in graph A and  D) were collected as part of the ABOUT-K study 
(Chapter 3), and 2 further patients not enrolled in the ABOUT-K study with AMR were 
analysed from another centre, thus these sample times (shown in Graph B and C) 
differed from the ABOUT-K study protocol defined in Chapter 3. 
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2.2.2.3 Conclusions 
Binding to RBC with antibodies was able to be quantitatively assessed using flow 
cytometry and there was a significant correlation of the flow cytometry assay and the 
HG assay. While the two assays correlated, there was significant scatter across different 
samples (different individuals). This degree of variation was greater than expected 
based solely on the performance of the assays: primarily inter-assay variation in HG.  For 
example: in Figure 2.4A which documents HG and flow cytometric binding to rbc 
attributed to IgG, in one sample the Log2 RMFI was greater than 4 but HG was only 
detected when the sample was used neat (log10 HG = 0). Conversely, a sample with a HG 
titre of 1/512 (log10 HG = 2.75) was associated with a much lower RMFI (Log2 RMFI = 
1).1(Graph A). Importantly this may be reflect differences in the nature of antibody 
detected by the two techniques, which correlate at a population level but are not 
necessarily wholly congruent in an individual as illustrated schematically in Fig 2.7. 
These comments might equally apply to blood group antigen specific antibody binding 
to vascular endothelium, given the different pattern of core saccharide chains from 
which blood group antigens arise. This is however beyond the scope of these studies.  
IgG subclass assessment was performed in a cohort of 4 patients, but 
demonstrated in most patients an IgG2 predominance in keeping with published 
literature [66]. The association with IgG subclass and clinical outcomes is planned in 
future work developing from these results. One patient who had antibody-mediated 
rejection had increasing levels of blood group antigen specific antibody measurement 
tested highly positive for anti-A specific IgG4, however this was not seen in the others 
tested (n=4).  
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Figure 2.7. Venn diagram to represent the potential different antibody 
populations in the two different assays. 
Schematic illustration of potential relationship of antibody populations and assay 
measurements. (RMFI, relative median fluorescence intensity) 
 
 
2.2.3 Solid Phase Assay 
2.2.3.1 Microsphere Assay 
2.2.3.1.1 Introduction 
The development of assays to measure anti-A/anti-B binding, instead of using 
haemagglutination has been a goal over decades. The use of biological antigen in 
enzyme-linked immunosorbent assay (ELISA) has previously been investigated and 
whilst there was an appropriate sensitivity of antibody detection, there was background 
non-specific binding. [208]. Use of a synthetic assay will reduce the biological variability 
of different batches of red cells and allow a standardised assay. The development of 
synthetic ELISAs for measuring anti-ABO specific antibodies has demonstrated a 
correlation between the optical density measurement and the haemagglutination titre 
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for IgG and IgM isotypes. However, the correlation is variable for different isotypes with 
each blood group antigen [222].  
The use of microspheres with synthetic blood group A antigen was reported by 
Holgersson. This report demonstrated a good correlation of anti-A antibody binding to 
the microspheres with reference to the haemagglutination titre. This paper did not 
however report the specificity of binding of anti-A antibody to A antigen alone, or 
crossreactivity of anti-B antibody binding to A-antigen beads [223]. In general these 
solid phase techniques have been developed using purified anti-ABO specific antibodies 
as test samples. I set out to repeat these investigations with a view to further 
development and study of the specificity of binding of anti-ABO specific antibodies in 
plasma. 
 
2.2.3.2 Methods and Results 
2.2.3.2.1 Coupling carbohydrate antigen to microsphere beads 
Carbohydrate antigens were coupled to microspheres using a carboxyl substitution 
reaction. Carboxyl coated microspheres (BioRad; Seromap; Qiagen) were selected for 
different bead regions, according to their ratio of internal fluorescence using Luminex® 
technology. Oligosaccharides for A trisaccharide (L305, Dextra, Reading, UK) and B 
trisaccharide (G32, Dextra, Reading, UK) with terminal amine groups were a kind 
donation from Dextra Laboratories (Reading, UK). 
The microspheres were brought to room temperature and vortexed for 30 seconds and 
then sonicaided for a further 60 seconds. A suspension of 500µL microspheres were 
pipetted into a microcentrifuge tube. This tube was centrifuged at 13,400g for 4 minutes 
to achieve a microsphere pellet. The supernatant was removed and 100microL of bead 
wash buffer (BioRad, UK) was added. This was vortexed for 10 seconds and sonicaided 
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for a further 10 seconds and centrifuged again with the same settings. The supernatant 
was removed and 80microL of bead activation buffer (BioRad, UK) was added. This was 
vortexed for 30 seconds and sonicaided for a further 90 seconds and centrifuged again 
with the same settings. Fresh N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC, Sigma, UK) and N-Hydroxysulfosuccinimide sodium (S-NHS, Sigma, 
UK) were both diluted in bead activation buffer at 50mg/ml in separate microcentrifuge 
tubes. Ten microL of EDC solution and then 10microL of S-NHS solution were added to 
the bead suspension. The reaction of EDC created an unstable reactive ester replacing 
the carboxyl group, which was replace by a semi-stable amine-reactive NHS-ester after 
the addition of S-NHS. This solution was vortexed for 30 seconds and agitated at room 
temperature in the dark for 20 minutes.  
One hundred and fifty microL of PBS (pH 7.4) was added to the solution at the end of 
incubation and centrifuged at 13,400g for 4 minutes to achieve a microsphere pellet. The 
supernatant was removed and 100microL of PBS (pH 7.4) added. This was vortexed for 
30 seconds and sonicaided for a further 15 seconds and centrifuged again with the same 
settings. 
Five hundred microL of PBS (pH 7.4) containing the following masses (concentration) of 
oligosaccharide used in conjugation: 200microg (400microg/ml); 400 
microg(800microg/ml); 600 microg(1200microg/ml); 800 microg(1600microg/ml); 
1000microg(2000microg/ml) and 1200 microg(2400microg/ml) respectively were 
added to the activated bead pellet. The mass of oligosaccharide in the conjugation 
process will be used to describe the different concentrations. The oligosaccharides all 
had amine terminal conjugations, but varied depending on the conjugation structure 
(simple amine or 8 carbon linker) for each experiment and the blood group antigen 
required. Terminal A-antigen, B-antigen and H-antigen were used, as well as 
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unconjugated beads as controls. The trisaccharides were either with a terminal amine 
group directly conjugated onto the trisaccharides, or had an 8 carbon chain structure 
(Linker). These were donated by Dextra Ltd, Reading, UK. This solution was agitated at 
room temperature in the dark for 2 hours. This tube was centrifuged at 13,400g for 4 
minutes to achieve a microsphere pellet, following 2 hour incubation. Supernatant was 
removed and 500microL of PBS (pH 7.4) was used to wash the beads and this was 
centrifuged at 13,400*G for 4 minutes. The microspheres were resuspended in 
250microL blocking buffer (BioRad, UK) by vortexing for 15 seconds. The 
microcentrifuge tube was agitated for 30 minutes in the dark and then centrifuged at 
13,400g for 4 minutes and the supernatant removed. The microspheres were washed by 
500microL storage buffer (BioRad, UK) and centrifuged at 13,400*G for 6 minutes. The 
supernatant was removed and the beads re-suspended in 200microL of storage buffer 
(Figure 2.8). Centrifuge tubes with conjugated beads are stable for 1 year stored at 4ºC 
in the dark according to manufacturing instructions. 
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Figure 2.8. Coupling of carbohydrate antigens to microspheres was achieved using 
a carboxyl substitution reaction. 
 Adapted from Thermoscientific.com 
(http://www.piercenet.com/instructions/2160650.pdf) 
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Figure 2.9. Diagram of Luminex protocol for analysis of antibody binding  
   
2.2.3.2.2 Microsphere assay protocol 
A 96 well filter bottom plate (Millipore, UK) was covered with well cover, and the 
required number of wells exposed. Each required well was washed twice with 200 
microL Luminex Wash Buffer (LWB, One Lambda, CA, USA) and buffer removed using a 
Millipore Vacuum suction apparatus (Millipore, UK). Following 10 seconds of vortexing, 
the required microsphere suspensions were sonicaided for 5 minutes, to resuspend the 
microspheres. 
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Into each well 20µl of LWB was added, then 1.5µl of microsphere suspension. 8µl of 
sample was added to each well, as per experiment protocol, and then incubated with 
agitation for 30 minutes at room temperature in the dark. Two wash cycles were 
performed following incubation and 80µl of PE-conjugated secondary antibody was 
added to each well, according to protocol. For positive controls for A/B carbohydrates, 
murine monoclonals against A or B antigen were used (clone Birma-1 or clone LB-2, 
Millipore, UK), and a rat anti-mouse IgM (µ chain specific) PE conjugate (Clone 1B4B1, 
Southern Biotech, Birmingham, USA) was used as a secondary antibody. When human 
samples were used, a mouse anti-human IgG (γ chain specific, Clone H2) R-
phycoerythrin (R-PE) conjugate and mouse anti-human IgM (µ chain specific, Clone 
UHB) R-phycoerythrin (R-PE) conjugate were used at 1:100 dilution (Southern Biotech, 
Birmingham, USA). Following a further incubation with agitation for 30 minutes at room 
temperature in the dark, two more wash cycles were performed, but re-suspending the 
beads in 80µl of LWB (Figure 2.9). 
The plate was then inserted into the Luminex machine and the fluorescence of each 
microsphere determined the region, and the median fluorescence intensity of PE for 
each region determined the amount of binding of the tagged primary antibody. 
 
2.2.3.2.3 Microsphere assay development strategies 
The presence of conjugated A/B antigen on microspheres was determined by murine 
monoclonal typing agents as described above and the MFI response to different 
concentrations of antigen was used to determine the amount of antigen bound to 
microspheres. 
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In order to optimise the concentration of trisaccharides for conjugation to the 
microspheres, different concentrations of antigen were incubated with microspheres to 
enable saturation of binding. The concentrations of A and B amine trisaccharides were 
titrated up from 400microg (800microg/ml) in conjugation solution to 1200microg 
(2400microg/ml) in solution for each trisaccharides. The effect of increase in 
conjugation trisaccharides was measured by the binding of the murine monoclonal MFI. 
There was a continued increase in B trisaccharides MFI with increasing concentrations, 
which did not reach saturation (Figure 2.10).  
 
Figure 2.10. Increasing concentrations of trisaccharide incubation increase 
binding fluorescence.  
These graphs demonstrate the binding of blood group specific murine monoclonal IgM 
against each antigen dependant on the different concentrations of trisaccharide used in 
conjugation. There was a rise in antibody binding between 400 and 1200micrograms 
microspheres and a dose response to dilution of antibody at neat; 1:10 and 1:100. The B 
amine, on the other hand, did not reach a saturation plateau and the MFI binding of the 
murine monoclonal antibody was lower than that of the A amine binding MFI data. 
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2.2.3.2.4 Protocols used for Reducing Non-specific Binding 
Throughout all the experiments, binding specificities of the plasma samples and 
the microbeads did not distinguish between blood group A samples (anti-B antibody 
alone) or blood group B samples (anti-A antibody alone) due to binding to self-antigen. 
That is to say, antibodies in blood group A samples bound to A trisaccharide and 
antibodies in blood group B samples bound to B trisaccharide. This section describes 
processes that were undertaken unsuccessfully to develop specificity and reduce non-
specific binding from the microbead assay. The binding of antibody to beads 
represented a hook effect representative of serial dilutions of true antibody binding 
(Figure 2.11) 
2.2.3.2.4.1 Beads from Different Manufacturers 
Different manufacturers of microsphere beads were used to demonstrate if there 
was a reduction in background binding between manufacturers. Qiagen and BioRad 
microspheres were used. A further bead product, SeroMap has been produced 
specifically to reduce non-specific binding [224]. While all of these products had 
conjugation of oligosaccharides, there was no improvement in non-specific binding. 
Protocols for conjugation and for testing were the same between these different 
manufacturers’ microspheres.   
2.2.3.2.4.1 Conjugation Testing 
The non-specific binding of antibodies in plasma could be due to structures either 
present, or formed during the conjugation process. To determine if the conjugation 
process was increasing non-specific binding, a sample of 20microL of beads were 
removed after each process in the conjugation protocol. These were stored and then 
tested against LWB, blood group “A” plasma and blood group “B” plasma. No 
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oligosaccharides were conjugated in this protocol. These time points were pre-
treatment, after initial washing, after carboxyl activation, after EDC-NHS reaction, after 
blocking and after final wash (Figure 2.12). There was an increase in binding 
fluorescence during the conjugation process with anti-A binding higher than anti-B 
binding. 
Using trisaccharides with terminal amine or terminal 8 carbon-linker 
trisaccharides, microbeads were conjugated using the same conjugation protocol. The 
effect of binding between these two differently linked trisaccharides is shown in Figure 
2.13. The reactivity to the trisaccharides linker did not improve specificity of binding. 
Similarly, a hook effect is seen in dilutions of AB plasma. 
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Figure 2.11. Non-specific binding of human antibodies to conjugated blood group 
trisaccharides. 
These graphs demonstrate the non-specific binding of IgM antibodies of blood group “A” 
plasma (samples A1 and A2) and IgM antibodies of blood group “AB” plasma against the 
A and B amine (both 1200mg conjugated) microspheres with serial dilution of each 
plasma sample. The hook effect is demonstrated for each of these samples for both 
amine antigens. Binding against both A and B antigens occurred for both “A” plasma 
samples and “AB” plasma and MFI readings were greater against A trisaccharides than B 
trisaccharides. (n=3) 
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2.2.3.2.4.3 Pre-incubation protocols 
Twenty microL 1:10 dilution in LWB of Rabbit Serum (DAKO X0902) was used in 
the initial incubation with plasma and microspheres and incubated for 30minutes. The 
plates were washed twice with LWB and then the 20microL of LWB was added to 
resuspend the microspheres before the addition of the 8microL of plasma sample to test. 
The rest of Luminex protocol was then followed (Figure 2.14A). Super Chemiblock 
(10.5mg/ml, Millipore) was used to block non-specific binding after Waterboer et al 
using 2.5% concentration. Following the initial double washing of the wells, the Luminex 
protocol was adapted to include an additional first incubation period of 20microL of 
LWB, 1.5microL of beads and 10microL of Super Chemiblock in each well. This was 
incubated and agitated at room temperature for 60minutes. I used 10microL of serial 
dilutions of Super Chemiblock, starting with neat (10.5%); 1:2 (5.25%), 1:4 (2.625%), 
1:8 (1.313%) and 1:16 (0.656%) at the incubation stage. Eight microL of plasma was 
added to the well before completing the rest of the Luminex protocol (Figure 2.14B). 
0.5% Polyvinyl alcohol (PVA) and 0.8% Polyvinylpyrrolidone (PVP) can be used 
to reduce non-specific binding. Neither of these agents had a significant effect on 
increasing specificity when used in the protocol. They were added to microspheres just 
before adding plasma to the Luminex protocol. Waterboer et al also used a combination 
of PVA and PVP (called PVX). A 1:1 mixture of solutions was made. PVX at 1:10 ratio of 
PVX to neat plasma and incubated at 4°C for 1hour with agitation. The PVX plasma was 
then centrifuged 4 minutes at 13,400g. The supernatant was diluted to 1:10 dilution 
with LWB and added to the microbeads according to Luminex protocol and the rest of 
the protocol was carried out unchanged. This did not demonstrate a reduction in non-
specific binding (Figure 2.14A).  
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Marvel was prepared at 5% using distilled water. Twenty microL of serial dilutions of 
5%, 2.5% and 1.25% Marvel were used in the initial incubation with the microbeads and 
incubated for 60minutes with agitation at room temperature before addition of plasma 
and following the routine Luminex protocol. These concentrations of Marvel did not 
reduce non-specific binding (Figure 2.14C). Human Serum Albumin (HSA) was used at 
0.5% (Sigma, UK) for microbead blocking without a beneficial effect to reduction in non-
specific binding. Twenty microL of 0.5% HAS was added to 20microL of LWB and 
1.5microL of microbeads and incubated for 30minutes in an agitator at room 
temperature. The wells were washed with 200microL of LWB as per standard protocol 
and then 20microL of 0.5% LWB resuspended the microbeads and 8microL of plasma 
was added to each well. The remaining part of the experiment followed the standard 
Luminex protocol (Figure 2.14D).  
 
  
 
 
105 
 
Figure 2.12. Background binding to microspheres increased during the 
conjugation protocol. 
 There was non-specific binding to microspheres regardless of the manufacturer of the 
microspheres and the non-specific binding increased through the conjugation process. 
These used BioRad beads (left) and Qiagen (right) beads with no reduction in non-
specific binding. There was greater reactivity to blood group “B” plasma, than blood 
group “A” plasma. 
EDC-NHS is chemical used to activate the carboxyl group on the microsphere. Final – 
represents the unconjugated bead, following buffer washing to remove the blocking 
agent 
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Figure 2.13. Comparison of non-specific binding between Amine and Linker 
trisaccharides 
For serial dilutions AB serum, the hook effect was demonstrated for anti-
trisaccharide IgM binding but there was no reduction in non-specific binding between 
the amine-derived or the carbon-linker derived trisaccharides. 
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Figure 2.14. Incubation with blocking antibodies.  
Figure 2.14A .The use of Rabbit serum to reduce non-specific binding did not affect the 
MFI between samples tested. There was no different if PVX was used in this assay with 
or without Rabbit serum.  
 
Figure 2.14B. The increase in Super Chemiblock reduces the non-specific binding of AB 
serum to both A (blue) and B (green) conjugated microspheres as well as unconjugated 
control beads (red) shown in graph A. However, the effect of Super Chemiblock at higher 
concentrations significantly reduces the binding of the anti-A murine monoclonal 
antibody, shown in graph B. 
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Figure 2.14C. The addition of Marvel at different concentrations (5%, 2.5% and 1.25%) 
did not reduce non-specific binding of human AB serum to both A (grey) and B (dark) 
conjugated microspheres as well as unconjugated control beads (white spotted). This 
was true for both IgM and IgG isotypes (graph A and B respectively) 
 
Figure 2.14D. Addition of Human Serum Albumin (HSA) to block microbeads and as a 
suspension fluid for the microbeads did not change the non-specific binding compared 
to Luminex Wash Buffer (LWB). This was true for both IgM and IgG isotypes.  
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2.2.3.2.4.4 Different Wash Regimes  
The number of washes performed at each time point was varied after incubation 
was changed from 2, 4, 6 or 8 without any reduction in non-specific binding. 
2.2.3.2.4.5 Plasma testing 
Using samples from haemagglutination assays, the Luminex beads were tested for 
correlation of antibody titre and MFI of bead reading. There was an increase in MFI with 
higher titres, and the titres produced higher MFIs in the anti-A blood group antibodies 
than in anti-B antibodies (Figure 2.15).  
Figure 2.15. The relationship of HG titre and MFI of conjugated trisaccharide to 
microspheres. 
Using the microspheres conjugated with (1600microg/ml beads); there was high 
background binding, and lack of specificity. There was however, a quantitative increase 
in binding (MFI, y-axis) relative to the haemagglutination titre (x-axis) for anti-A titres 
and for anti-B titres (n=80). The HG titres are higher against A antigen and this reflected 
in MFI in the Luminex assay. 
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2.2.3.3 Conclusions 
In these experiments for anti-ABO specific antibody binding, I demonstrated successful 
conjugation of A and B trisaccharides to microspheres, with an increase in monoclonal 
binding suggesting that there is increased antigen conjugation with increased 
concentrations of A/B trisaccharides used.  
Although the concentration of the trisaccharides used in conjugation was the same for 
both A and B antigens, B trisaccharide conjugation did not yield the same MFI as with A 
trisaccharide when tested using the murine monoclonal typing antibody and using the 
same 2nd PE-labelled anti-murine antibody. The explanation for this could be that B 
trisaccharide does not as effectively conjugate to the microspheres or possibly that the 
anti-B murine monoclonal or second stage antibody binding kinetics differ in this 
setting, such that there are lower amounts of second stage antibody bound even in the 
event of identical bead surface density of blood group trisaccharide  
Despite using different reagents, I was not able to reduce background MFI binding to 
beads. Whilst binding to beads was consistent to increased haemagglutination titres, 
there was no specificity. Whilst this assay would not allow specificity of binding for 
blood group identification, it may allow a more sensitive assay to demonstrate changes 
in quantity in anti-ABO specific antibody during desensitization protocols. This, 
however, would need further validation. 
2.2.4 Surface Plasmon Resonance 
2.2.4.1 Introduction 
The binding affinity of antibody is determined by the relationship between association 
and dissociation of the antibody/antigen complex. The effect of affinity of antibodies is 
represented by the binding avidity. Thus IgM is usually a low affinity antibody, however, 
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its pentameric structure significantly increases binding avidity. IgG, through germinal 
centre selection, is a higher affinity antibody.  
Surface plasmon resonance (SPR), as detailed in the Figure 2.16A, is a tool that can 
measure the association and dissociation of molecular interaction in real time (Figure 
2.16B). In brief, the gold layer fixes a molecule (ligand); we used an A/B trisaccharide, 
via a carboxylation reaction. Buffer is then used to normalise the chip and equilibrate 
the machine. The effect of mass, caused by running the samples (analyte) over the gold 
chip causes a change in diffraction of light through the prism to be detected by the light 
detector. 
Previous work using this technique for antigen specific purified anti-ABO specific 
antibody, describe the antibody binding related to this purified antibody [217, 218]. 
Given my interest in these studies in assessing the individual variation of anti-ABO 
specific antibody and correlating this with the clinical outcome requiring a functional 
test deemed that it was necessary to assess whole plasma. The protocol from Kimura et 
al was adapted using a different machine Proteon XPR36 (BioRad, UK) [217]. The aim 
was to demonstrate antibody-antigen binding to determine specificity to antigen and to 
determine the binding characteristics. This work was done in collaboration with 
biomathematical engineers at University of Warwick. 
 The change in mass of the gold chip due to antibody binding alters the refractive index 
and the sensogram demonstrates this in schematic format. Stopping the analyte, and 
allowing buffer to flow, demonstrates the dissociation curve. Finally, a regeneration fluid 
is required to remove all bound analyte and then the reading is back to baseline. 
SPR, in particular the Proteon XPR36, is a tool used to analyse high numbers of analytes 
and their interaction with determined ligands. This machine can demonstrate the 
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binding of 6 analytes with 6 different ligands in one experiment, thus 36 interactions can 
take place in each experiment. 
Figure 2.16. Schematic diagrams of SPR technology. 
Figure 2.16A 
This diagram demonstrates the interaction between immobilised ligand on the gold 
layer and the analyte in fluidics passing the ligand. The light is refracted at a different 
angle and detected and a refractive unit (RU) is calculated. The plotting of the RU against 
time demonstrates the association and dissociation rate in the second diagram and then 
removal of the analyte during regeneration to return to ligand without analyte before 
next experiment [225]. 
Figure 2.16B 
Although the association stage (Ka) continues to 
increase, there is ongoing dissociation (Kd) 
throughout, until a steady state is reached [226]. 
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2.2.4.2 Methods 
2.2.4.2.1 Antigen coupling 
Antigen coupling to the SPR chip was performed according to the manufacturer’s 
recommendations. A maintenance chip was inserted and running buffer used to 
calibrate the machine. A cleaning chip was inserted to ensure a clean system, and then a 
new GLH (amine coupling) chip was inserted and labelled on machine specific software. 
Normalisation of the new chip took place using software manager. Activation of carboxyl 
groups on chip was achieved by combined mixture of N-Ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC, Sigma, UK) and N-
Hydroxysulfosuccinimide sodium (S-NHS, Sigma, UK) were both diluted in borate (pH 
8.5) buffer at 50mg/ml. The volume of each solution was 125microL to give a combined 
volume of 250microL. The SPR machine was then run on an activation setting to activate 
the chip. The injection of ligand (250microL at 1mg/ml concentration of 
oligosaccharides) in each channel was automated by the protocol and then deactivation 
of chip using 1M ethanolamine (100microL) was performed, using 250microL per 
channel. Running buffer then stabilised the chip before experiments were performed. 
Regeneration after each experiment was performed with Glycine 0.1mM (pH 2.5) with 
two regeneration steps. 
2.1.4.2.2 Buffering dilution 
The mass effect of buffer solution interfered with the reading for this assay. Thus 
adjusting the buffer solution to be as physiological as possible for plasma would reduce 
the difference between plasma sample and running buffer mass effect. We performed a 
series of experiments with different concentrations of Tween 20 (Sigma, UK) to 
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minimise the delta mass effect between sample and buffer and optimised the Tween 20 
concentration at 0.5%. 
2.2.4.2.3 Control testing 
Antigen attachment through EDC and S-NHS carboxylation was demonstrated by the 
mass effect on the Proteon chip as demonstrated by the increase in response units (RU). 
The mass effect increased with increased concentration of A/B antigen, and the 
increased mass of the A antigen had a greater RU value than the same concentration of B 
antigen. 
Murine IgM monoclonal anti-A and anti-B with high affinity antibodies were used as 
positive controls for assessing the binding specificity in this platform. The results of 
these correlated with the microspheres assays with high RU values, which demonstrated 
very good association and the dissociation was slow, demonstrating very high avidity. 
The response of the murine monoclonals was dependent on the concentration of 
antibody and ligand (Figure 2.17). Anti-A1 Lectin (100405, BioRad, UK) was used for A1 
specificity, to demonstrate that the antigen reflected the A1 antigen that I wanted to 
study. There was excellent binding association and dissociation with this and again very 
good specificity (Figure 2.18).  
2.2.4.2.4 Binding  
Having optimised the buffer for running human plasma, it was important to 
demonstrate that the binding would be specific for anti-A and anti-B and plasma from 
“A”, “B” and “AB” donors was used. There was non-specific binding to the trisaccharide 
with amine terminal chain; however the 8 carbon chain linker demonstrated antigen 
specific antibody binding - in keeping with Landsteiner’s rule (Figure 2.19A and Figure 
2.19B and Figure 2.19C). 
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The murine monoclonal IgM was purified using a Glycosorb® column as described 
above and dialysed into running buffer in order to quantify a monoclonal antibody. 
Quantification was performed using a Rad Diffusion assay as described below. 
The Rad Diffusion (The Binding Site, Birmingham, UK) plate was left open for 10minutes 
at room temperature to allow condensation to evaporate. The supplied lyophilised 
calibrators were reconstituted with distilled water. The calibrator were made for final 
concentrations of 100%, 60% and 10% using distilled water. The calibrator and samples 
were micro-pipetted into the wells on the plate (20microL) and the lids were replaced 
and incubated at room temperature (20-24°C). The plates were left for 120 hours to allow 
complete diffusion to occur. The ring diameters were then measured to the nearest 0.1mm 
using backlighting. The 3 calibrators were plots to produce a linear calibration curve with 
protein concentration on horizontal axis and ring diameter on vertical axis. The test 
concentration was read off the calibration curve. 
Using a constant concentration of both anti-A and anti-B monoclonal, inhibition assays 
were performed with incubation of respective trisaccharides in antibody solution prior 
to injection on the SPR machine. This demonstrated serial binding inhibition with 
increasing concentration of trisaccharides for both anti-A and anti-B (Figure 2.20A). A 
similar experiment was performed using purified human antibody, eluted from a 
Glycosorb® column (method in 2.2.2.1.3).  At a known quantity of antibody in solution, 
there was reduction in binding when diluted. At a defined concentration of purified 
human anti-blood group antibody, there was inhibition of anti-A antibody binding with 
increased concentrations of A trisaccharides in solution (Figure 2.20B). 
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Figure 2.17. Concentration dependant binding of murine monoclonal antibody.  
With different concentration of ligand (antigen) applied to each lane of the chip, there 
were different response units for antibody binding. With serial dilutions of a pre-
determined concentration of murine monoclonal IgM, there was a reduction in 
association response units; however the dissociation rate of the antibody was similar 
across each concentration. Using either anti-A monoclonal (left graphs) or anti-B 
monoclonal (right graphs) there was better differentiation of binding characteristics at 
lower ligand concentration for the A-trisaccharide, but no difference for the B-
trisaccharide. Antibody (analyte) concentrations are shown in the legend on the right of 
each pair of graphs. 
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Figure 2.18. Binding specificity of lectin to A-linker antigen on SPR.  
Anti-A1 lectin (pink) binding to A-trisaccharide ligand(antigen) in lanes 1-3 (left) 
demonstrated good association, but rapid dissociation and there was no binding to B-
trisaccharide in lanes 4-6, compared to running buffer (orange) as control. 
 
  
Lane 2 
Lane 4 
Lane 6 
Lane 1 
Lane 3 
Lane 5 
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Figure 2.19 Binding specificity of plasma to Linker Blood group Antigens, 
compared to amine derived antigens. 
Figure 2.19A (Binding of A Plasma) 
Binding specificity between the amine and 8 carbon linker trisaccharides is 
demonstrated in the following diagrams for blood group “A” plasma. In the upper two 
graphs, bloods group “A” plasma binds to both A and B trisaccharide amines (A and B 
respectively). However, there is no binding of blood group “A” plasma to A trisaccharide 
with 8 carbon linker, but still good binding to B trisaccharide, in the lower two graphs (C 
and D). 
Each differently coloured line demonstrates different concentrations of plasma used 
(1:5; 1:10; 1:20; 1:50 and 1:100). There is a reduction in response units as the dilution of 
the plasma increases. 
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Figure 2.19B (Binding of B plasma) 
As demonstrated with blood group “A” plasma in figure 2.19A, a similar pattern is 
displayed with blood group “B” plasma. Binding specificity between the amine and 8 
carbon linker trisaccharides is demonstrated with non-specific binding to both A and B 
trisaccharide amines in the upper two graphs (A and B respectively). While there was 
still binding to A trisaccharide 8 carbon linker, there was no binding to B trisaccharide in 
the lower two graphs (C and D respectively). 
Each graph demonstrates different concentrations of plasma used (1:5; 1:10; 1:20; 1:50 
and 1:100). There is a reduction in response units as the dilution of the plasma 
increases. 
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Figure 2.19C – This figure demonstrates control AB serum binding to the A and B 
trisaccharides amine structures in both upper graphs (A and B respectively) but no 
binding to the A and B 8 carbon liner trisaccharides in the lower graphs (C and D 
respectively). 
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Figure 2.20. Inhibition studies of murine monoclonal antibodies and purified 
human antibody. 
Figure 2.20A - I performed inhibition studies with increasing concentrations of A or B 
trisaccharides with each purified murine IgM monoclonal typing agent. There was a 
serial reduction in RU values with the increased concentration of A or B trisaccharides.  
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Figure 2.20B. Purified human anti-A IgG was quantified and serially diluted, and 
inhibited with soluble A-trisaccharide, both demonstrating a dose dependent reduction 
in binding. 
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2.2.4.2.5 Modelling 
Work undertaken in collaboration by N. Evans and M.J. Chappell, University of Warwick, 
demonstrated that simple models for prediction of antibody binding did not predict the 
pattern of binding (Figure 2.21A), however, this was refined and was very predictive of 
the binding (Figure 2.21B). The paper is attached at the end of this thesis.  
 
Figure 2.21. Modelling of antibody binding characteristics. 
Figure 2.21A – These graphs demonstrate the true SPR output data in light grey and the 
heavier black line of the Langmuir Model. Initial association and dissociation rates are 
similar, however the final on/off rates around the time of analyte stopping are not well 
modelled. Work undertaken by N. Evans   
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Figure 2.21B – These graphs demonstrate the true SPR output data in blue line and the 
new modelling in red demonstrating that the more variables included in the model, 
whether real data or assumed data increased the predictability of the model of anti-ABO 
specific binding. 
 
 
2.2.4.5 Conclusions 
Binding of anti-A and anti-B specific human polyclonal antibodies were demonstrated to 
be specific for A/B antigen with an 8 carbon linker structure, but not with amine alone 
terminal group.  These data support the observation by Bovin and colleagues suggesting 
that the presentation of the terminal A/B antigen determines the specificity of binding 
[227]. It may be that a cryptic epitope is “hidden” by the carbon linker and this may be 
revealed on the microsphere platform, but not on SPR platform with the 8 carbon linker, 
or that the proximity of antigen conjugation on the microspheres allows binding to 
different antigens to occur. There may also be other antibodies which are binding to 
these structures, as there was no cross reactivity with commercial monoclonal 
antibodies to suggest that A/B antigen conformation is changed but that a different 
epitope is revealed in the conjugation process to allow binding to take place.  
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In these experiments, the SPR platform demonstrated that in fluidics system binding of 
human plasma samples enabled specific binding. SPR showed that using an 8 carbon 
linker it was possible to achieve binding specificity; functional assessment of antibody 
binding; application of plasma samples to this assay. The application of techniques from 
laboratory to clinical to practice using clinical samples is a technical challenge which 
was not achieved in these sets of experiments. Further work to correlate the binding 
characteristics of plasma samples on SPR with the effective removal of antibody in EART 
and episodes of rejection needs to be performed.  
2.2.5. Statistical Analysis 
Descriptive statistics were used to assess the data from this study. Titres are 
reported as doubling dilutions and the log2 transformation is used for titres in order to 
normalise the data. Data are presented as mean and standard deviation (Mean± StDev) if 
found to be normally distributed by the Shapiro-Wilk test, and data are represented as 
median and first and third quartiles (Median, Q1-Q3) if there is a non-parametric 
distribution, unless otherwise specified. The Wilcoxon rank-sum test was use for 
comparison of non-parametric data, which is equivalent to a Mann-Whitney U test.  
Correlation between test data was performed using bivariate plots with linear fit, 
assessed with regression coefficient.   
Weighted kappa quadric assessment was used for agreement of data between 
two tests (treating haemagglutination titre data as continuous variables) following 
discussion with a statistician. The value of Kappa signifies the strength of the agreement 
between 2 tests, with excellent agreement value being 1. 
Comparison of reproducibility of haemagglutination titres between tests was 
performed using weighted kappa inter agreement analysis. For the Bland-Altman plots, 
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the data was treated as continuous data to assess the differences of each method from 
the mean of both tests and is plotted as the difference between test 1 and 2 on the y-axis 
against the average of test 1 and 2 on the x-axis. 
Probability of values (p) of less than 0.05 was considered significant for these 
studies. All statistics were performed using JMP 10 (SAS Institute Inc., Cary, NC, USA), 
except the haemagglutination analysis performed using MedCalc (Ostend, Belgium).  
2.3 Anti-ABO specific Antibody Conclusions 
In this chapter I have demonstrated that a single user, using a standard technique 
can produce haemagglutination assay results that approach the theoretical limits of a 
dilution assay with respect to reproducibility, that is to say a mean inter-assay variation 
equivalent to a single titre step (bearing in mind that the choice of doubling dilution in 
HG is reflects the underlying performance of the assay). The application of these results 
is important for Chapter 3, the ABOUT-K study, examining the differences in local and 
central titres in assessing risk of ABOiKTx. 
 The development of ABO synthetic assays remains a question unanswered. While 
Luminex® technology has been used for the development of different antibody 
measurements in other disease process, such as pneumococcal antibodies and HLA 
antibodies, the specificity in ABO antibodies was not achieved [228, 229]. This was due 
to a constant lack of specific binding to A or B blood group antigens. 
The absorption of anti-A or anti-B antibody in O serum has been demonstrated which 
reduces the titre against both A and B antigens and is labelled anti-A,B antibody. The 
proportion that is pure anti-A, pure anti-B and combined anti-A,B has not been 
quantified [230].   
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The lack of specificity demonstrated using amines in the Luminex® assay and in SPR 
suggests cross reactivity of antibody. This could be explained by the anti-ABO specific 
antibodies reacting with a core structure with the two glycolipid structures. 
Holgersson’s group have demonstrated this phenomenon in ELISA and microsphere 
assays. They have extended the structure from a trisaccharide to a tetrasaccharide and 
show better specific binding with the tetrasaccharide structure [231]. This work 
extended their previous data from 2007 which demonstrated good binding to synthetic 
antigen, however via a personal communication, similar difficulties were found with 
cross reactivity [223] (Holgersson - personal communication). These data suggest that 
some anti-ABO specific antibodies are type chain specific, and thus the configuration of 
the antigen changes binding; data support by Huflejt and colleagues who demonstrated 
that antibody binding differed between trisaccharide and tetrasaccharide structures 
between individuals and between A and B antigens [227]. The clinical significance of this 
is yet to be determined, with regards to antigen specific antibody removal. The data in 
my experiments on SPR support different antigen structures affecting antibody binding 
characteristics. . Cross reactivity was demonstrated by Galili, explaining the common 
epitopes as targets for anti-Gal antibodies and anti-A/B antibodies see Figure 2.22, 
binding to the terminal structure of the 1-3α gal terminal oligosaccharide [84]. 
The assessment of anti-ABO specific antibody using different assay platforms 
demonstrates different characteristics of antibody-antigen interaction. As Buchs et al 
conclude in their paper “it is difficult to compare agglutination…..with binding to A or B 
substance since the agglutination assay depends not only on antigen binding but also on 
agglutinating capacity of the antibodies” [208].  
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Figure 2.22. Similarities in antibody binding epitopes between anti-carbohydrate 
antibodies. 
This schematically shows that antibodies binding to the Gal antigen can also bind to the 
terminal molecule on A or B antigen, but not H-antigen, due to the α1,3 galactose 
molecule [84]. 
 
Synthetic trisaccharides B antigen conjugated to either microspheres or the SPR 
platform had lower measurements than the corresponding A antigen, but antigen was 
present as evidenced by the high affinity murine monoclonal binding against both 
antigens. Thus higher concentrations of B antigen on beads were required to increase 
MFI in the Luminex® platform and the binding RU values of anti-B antibodies, whether 
murine monoclonal IgM or human plasma samples did not generate high RU values. This 
may reflect many different variables. The density of the trisaccharides or the 
conjugation process may be less efficient in the B-trisaccharide compared to the A-
trisaccharide. The underlying chemistry for this is not clear, as the terminal chain of the 
two structures should be similar. The joining of the either the amine or the carbon linker 
may have bound to a different structure (part of the N-acetyl-glucosamine structure) or 
the configuration of this terminal structure with the amine prevents effective carboxyl 
substitution.  
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Binding of antibody to microsphere synthetic trisaccharides was shown by Pochechueva 
to give higher MFI in trisaccharides, rather than tetrasaccharides for A/B antigen [232]. 
This is in contrast to work done by Lindberg who demonstrated that tetrasaccharides 
removed anti-ABO specific antibodies better than trisaccharides [233]. 
Binding to synthetic antigens is described as being variable by Lindberg et al, and the 
use of IgG subclass analysis demonstrates that there are higher levels of complement 
fixing IgG1 and IgG3 subclasses in blood group “O” serum, whereas the blood group “A” 
and “B” had higher levels of IgG2, although blood group “O” serum still had high levels of 
this IgG subclass [231]. 
 In summary, the conformation of the synthetic antigen, both in the assay platform 
and the structure of the linker to the platform seem to be important to developing 
improved specificity. While synthetic assays are yet to deliver reproducible results, HG 
is still key to assessing antibody. The use of flow cytometry, however, would allow 
identification of isotypes of binding which may give more information for clinical 
decisions regarding antibody profile risk. This needs to be evaluated in a larger cohort. 
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Chapter 3  The ABOUT-K study 
A prospective, multi-centre, observational study evaluating an 
antigen-specific antibody removal protocol for ABO-incompatible 
renal transplantation in the UK 
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3.1 Introduction 
At the time of study design, there were 6 centres undertaking planned ABOiKTx 
in the UK, however this number has increased significantly over the last few years. This 
increase has been based on the outcomes from single centres performing ABOiKTx who 
reported similar clinical outcomes to their ABO compatible cohort (ABOcKTx) as 
described in Chapter 1.  No multi-centre national data had been collected on ABOiKTx 
that examined clinical outcomes, complications, antibody removal and antibody titres. 
Furthermore, no assessment had been undertaken centrally to compare local and 
central titres measurements by haemagglutination. This is a pre-requisite to compare 
clinical outcomes between centres with a standardised assay. A prospective 
observational study of practice and outcome would describe clinical outcomes and unify 
the measurement of anti-ABO blood group specific antibody titres. 
The ABOUT-K study aims to describe the prevalence of acute rejection in the first 
12 months post-transplantation, patient survival, graft survival and renal function at 1 
year. In addition, the local result of anti-A and/or anti-B titres was collated and 
compared to a centralised assay which was undertaken using a standardised technique 
in order to assess the impact of differences in titration technique on clinical practice. 
3.2 Methods 
Fourteen centres were recruited to participate in the ABOUT-K study group. Six other 
centres were approached but did not participate in the study. One hundred and eight 
patients were recruited to the ABOUT-K study from 9 different transplant centres 
between 13th January 2009 and 4th July 2012. Eight patients were withdrawn for reasons 
described in Figure 3.1.  
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This study protocol was approved by the South Birmingham Research and Ethics 
committee (08 H1207 293) and study sponsor University Hospitals Birmingham NHS 
Foundation Trust (RXK3468) and was a NIHR portfolio study (6878). The study design 
was an observational, prospective, cohort study of patients accepted into an ABO 
incompatible kidney transplant programme and due desensitization prior to 
transplantation. 
 
Figure 3.1. Total Patients recruited and exclusion with reasons 
This diagram demonstrates all patients that were recruited into the study, but 
withdrawn with reasons for these exclusions. 
 
 
3.2.1 Study Aims 
The design of this study was based upon the hypothesis that differences in clinical 
practice, specifically in the quantification of blood group-antigen specific antibody, in the 
method of EART and in immunosuppressive regime affect the outcomes and 
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complications in ABOi kidney transplantation. The degree of variation in practice 
observed and the number of centres recruiting 100 patients means that the study 
effectively stands as a pilot;, identifying the need for greater uniformity in practice if any 
definitive conclusions are to be made with respect to the optimisation of ABOiKTx.  
The primary endpoint was acute rejection in the first year following ABOiKTx. This was 
determined by the local transplant team and the centres were required to classify 
rejection as antibody-mediated rejection; biopsy-proven or non-biopsy proven. 
Treatment regimens were collected for each rejection episode. The secondary endpoints 
were patient survival and allograft survival; renal function in the first 12 months post-
transplantation; safety and efficacy of ABOiKTx including the EART pre and post-
transplant; anti-ABO antibody titres pre- and post-transplantation; the presence of non-
ABO blood group antibodies post-ABOiKTx; severity of rejection in patients; the 
occurrence of opportunistic infections and bleeding complications. 
3.2.2 Treatment Protocols  
Patients were treated according to local protocol in each transplant centre. This 
comprised of induction therapy as part of desensitization or at time of transplantation. 
Induction regime consisted of rituximab in most patients with basiliximab, with a few 
patients receiving alemtuzumab. Maintenance therapy for immunosuppression at 
initiation was tacrolimus; mycophenolate and prednisolone at intention treat analysis. 
This therapy was adjusted according to local practice and clinical indications during 
follow up. 
Extracorporeal antibody removal therapy (EART) was used to reduce anti-donor ABO 
titres to acceptable levels in keeping with the local transplant centre policy on 
acceptable titres using local laboratory titres. The level of acceptable titre against donor 
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ABO blood group was 1:8 dilution or less in the majority of centres, with others using 
1:4 dilution as a target titre according to local titration assessment (n=2). EART was 
performed using a variety of techniques, plasma exchange; double filtration plasma 
exchange and immunoadsorption. Immunoadsorption was performed using either 
Glycosorb™(Glycorex, Sweden) columns which are blood group A/B antigen specific 
columns or Therasorb™ (Miltenyi Biotec Ltd, UK) [123]. Both immunoadsorption 
techniques require plasma separation before immunoadsorption from plasma filtrate 
can occur. 
3.2.3 Study Selection and Clinical Assessment 
The patients were recruited into the study according to local clinical practice and within 
the framework of the Antibody Incompatible British Transplantation Society Guidelines 
[234].  Participants identified by local centres for ABOiKTx were approached by the local 
investigator and invited to participate in the study. Once recruited, the co-ordinating 
centre registered the patient and entered the participant’s data on the NIHR portfolio.  
Patients were included in this study who were able to given written consent and who 
met the guidelines for live donor kidney transplantation as set out in the British 
Transplantation Society – Renal Association guidelines [235]. Inclusion criteria for this 
study were: 
 Patients  who were 18 years of age or over 
 Undergoing a planned ABO incompatible kidney transplantation 
 Able to give valid consent 
Exclusion criteria for the study were: 
 Patients  who were  less than 18 years of age  
 Pregnancy confirmed by positive β-HCG pregnancy test 
 
 
135 
 
  The need for removal of anti-HLA antibodies pre-transplantation 
Subjects could withdraw at any time if they wished, without requirement for 
explanation, and with the explicit understanding that their subsequent clinical care was 
not affected by their decision to discontinue with the study.  If patients withdrew from 
the study, they continued to undergo routine clinical follow up with appropriate 
monitoring and were included in any analysis on intent to treat basis.  Patients were 
assigned a study number in the order which they are recruited for this study, labelled 
according to the local transplant centre. Patient data were stored at the local transplant 
centre and patient assigned number. The study number was recorded at study co-
ordinating centre. Data was entered onto an electronic web-based database, run by 
Eclinso, an electronic database company. Serious adverse event were treated according 
to standard clinical care and recorded in the electronic database. 
The central laboratory processed samples following central registration, and stored 
samples under the study number. This was not an interventional study and the 
management of the patient was entirely dictated by the local transplant centre.  There 
was prospective collection of relevant demographic, laboratory and outcome data.  
Parameters relating to antibody removal; induction and antibody levels prior to 
transplant were used as comparative factors between patients in this cohort. The aim of 
this study was to recruit a minimum of 100 patients across the UK from study start date 
and to follow them directly for 1 year after transplantation, with consent for 5 year 
follow up via NHSBT datasets for patient and allograft survival and allograft function. 
The primary outcomes were defined at 1 year post-transplantation, however secondary 
outcomes beyond one year have been collated using data reported to NHSBT. The date 
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of censoring for this study when the latest data was retrieved from NHSBT for this thesis 
was 9th Dec 2013. 
3.2.3.1 Informed consent 
The notes of patients who met inclusion criteria were reviewed by one of the local 
investigators who arranged to see the patient in order to specifically address inclusion 
and exclusion criteria.  Patients were given the information sheet and had the 
opportunity to return for a second consultation to give informed consent.  
3.2.4 Data Collection 
3.2.4.1 Baseline 
All patients had a full medical history taken and a clinical examination. The following 
were recorded at consent: 
a) Demographic information including date of birth, gender and race 
b) Medical history including aetiology of renal disease 
c) Dialysis history – pre-dialysis, current dialysis modality and length of time on 
dialysis 
d) Transplantation history – number of previous transplants  
e) HLA sensitization using peak and current calculated reaction frequency (CRF) 
f) Donor/recipient HLA types and HLA matching (A,B,DR) 
g) Blood group of donor/recipient (ABO) 
h) Physical examination, including weight; height and blood pressure 
i) Haematology: full blood count (FBC) including differential count and platelets 
j) Blood chemistry: urea and creatinine, albumin, lipid profile and glucose 
k) CMV status – donor/recipient 
l) Anti- A/Anti-B antibody titres – locally (and the method used for ) 
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Donor patient information was collected for: 
a) Demographic information including age, height, weight, gender and race 
b) Donor GFR uncorrected for body surface area (BSA) if performed according to local protocol 
c) Donor split renal function (right compared with left) if performed according to 
local protocol 
3.2.4.2 Study Assessments 
Participants were assessed at time points shown in Figure 3.2. Clinical assessment was 
made according to local protocol and managed according to local policy. Study 
assessment was at routine clinical appointments that correlated with the clinical study 
time points. Haematological, biochemical and immunological monitoring took place 
routinely and data was entered into the electronic database. ABO titres were measured 
prior to immunosuppressive drug therapy and prior to EART which was guided by the 
titre as well as the subsequent time points shown in Figure 3.2. The patient proceeded to 
transplantation according to local policy. Any complications from surgery were 
recorded. The number of EARTs undertaken prior to and following transplantation were 
recorded. The incidence of delayed graft function was recorded (defined as the 
requirement for dialysis in the first week post-transplantation). Following discharge 
from hospital, routine out-patient assessment continued for patients with assessment of 
graft function, immuno-suppressive medication and intercurrent complications were 
made at each visit and these were entered into the study database at the pre-specified 
time-points.  
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Figure 3.2. Time points for clinical; serological and immunological assessment 
over 1 year. 
 
 
At each time point patient and allograft survival and allograft rejection was recorded. 
Weight and blood pressure, immunosuppressive drug regime, haematology and 
biochemistry results and drug levels were also recorded. Evidence of infections, 
malignancy, opportunistic infections and other complications were recorded at each 
assessment. Proteinuria was measured according to local protocol. ABO titres were 
measured at each time point locally and a sample sent to the central laboratory. 
3.2.5 Anti-ABO specific antibody assessment 
All treatment was directed by using antibody titres measured in the local laboratory to 
the transplant centre. Anti-ABO specific antibodies were measured at 3 timepoints pre-
transplantation and 7 time points following transplantation (Figure 3.2) to assess 
antibody changes over time post-transplant and to correlate these with clinical events. 
The local technique for ABO titration measurement was recorded.  
For the purposes of comparing technique performance the samples from Guys Hospital 
were excluded from analysis since this centre used a technique in which there was no 
attempted distinction between IgG and IgM haemagglutinin. In the analysis of EART and 
its relationship to locally reported assays (compared to the central quantification of 
haemagglutinin), the results of the HG assay used by Guys were incorporated into the 
analysis of IgG, since this was the measurement on which decisions to treat with EART 
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and to proceed to transplantation was made in the other centres.   This is also referred 
to as the decision point assay below.  
The method for measurement of central anti-ABO specific antibody is described in 
Chapter 2.2.1  
 
3.2.6 Statistical Analysis 
Descriptive statistics were used to assess the data from this study. Within the 
study cohort, analysis was made between different EART treatment groups; local and 
central titre methods and titre groups according to median titre of each method. Data are 
presented as mean and standard deviation (Mean± StDev) if tested as normally 
distributed by the Shapiro-Wilk test, and data are represented as median and first and 
third quartiles (Median, Q1-Q3) if there is a non-parametric distribution, unless 
otherwise specified.  
Comparison of reproducibility of haemagglutination titres between tests was 
performed using weighted kappa inter agreement analysis. For the Bland-Altman plots, 
the data was treated as continuous data to assess the differences of each method from 
the mean of both tests. 
Kaplan-Meier survival plots for survival analysis outcomes with the log-rank test 
were used to test differences. Comparison of data between cohorts was done using t-test 
and Wilcoxon rank-sum test depending on the distribution of the data in each cohort. 
Chi squared tests were performed on categorical data. Probability of values (p) of less 
than 0.05 was considered significant for this study. All statistics were performed using 
JMP 10 (SAS Institute Inc., Cary, NC, USA), except the haemagglutination analysis 
performed using MedCalc (Ostend, Belgium).  
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3.3 Results 
3.3.1 Patient and Donor characteristics 
One hundred patients were recruited and received an ABOiKTx in this study. Seventy 
patients were blood group ‘O’ of which 51 received an ‘A’ donor; 3 ‘AB’ donor and 16 
received a ‘B’ donor. Nine ‘B’ recipients received an ‘A’ donor and 14 ‘A’ recipients were 
donated ‘B’ kidneys. The remaining 7 recipients were ‘AB’ donors into ‘A’ (n= 4) or ‘B’ 
(n=3) recipients.  The mean age of the recipients was 46.8 ± 13.2 years. There were more 
males (n=59) and the majority of recipients were Caucasian (n=86). Overall 
demographics are shown in Table 3.1.  The main causes of ESRF were 
glomerulonephritis (n=26); hypertension/ischaemic (n=14); reflux/pyelonephritis 
(n=14) and cystic kidney disease (n=14), shown in Figure 3.3. Eighty six patients 
received a first transplant. Twelve patients received their second transplant, with the 
other two patients having had 2 and 3 previous transplants. The median dialysis time 
was 32 (13-46) months, with about two thirds receiving haemodialysis as mode of renal 
replacement therapy (41/63).  The mean recipient body mass index (BMI) was 26.6 ± 
4.6kg/m2 and the median weight loss in the 12 months following transplantation was 
2.2kg (-4.8 to 2.4). The overall cohort were not sensitized to HLA antigen with a median 
calculated reaction frequency (CRF) of 0 with 3rd quartile CRF still being 0, despite 14 
patients with failed allograft being re-transplanted with an ABOiKTx. Only 2 patients 
had a CRF >50%. The donor characteristics reflected the ethnicity and age of the 
recipients. The majority (n=70) had hand assisted laparoscopy as the technique for 
nephrectomy (Table 3.2). 
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3.3.2 CMV status and prophylaxis 
There were a similar number of patients in all groups of CMV status (Table 3.3). 
Prophylaxis was used in most D+/R- and 25.8% of D+/R+ had prophylaxis. CMV 
prophylaxis was valganciclovir adjusted to renal function. This was started according to 
local clinician if treated for rejection episodes in the other CMV status cohorts. 
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Table 3.1. Demographics and baseline clinical data of ABOi kidney transplant 
recipients in the ABOUT-K study 
DEMOGRAPHICS TABLE 
Age (Mean ±  StDev) (years) 46.8 ± 13.2 
Gender (Males) (n) 59 
Ethnicity (Caucasian) (n) 86 
Pre-emptive transplantation (n) 36 
First Transplants (n) 86 
Renal Replacement Time (months) 32 (13-52) 
Dialysis time (months) 32 (13-46) 
Haemodialysis (n) 41 
Peritoneal Dialysis (n) 15 
Failing Transplant (n) 8 
Recipient Blood group(n) 
O 70 
A 18 
B 12 
Donor Blood group(n)   
A1 59 
A2 1 
B 30 
AB 10 
HLA mismatch [Median(Q1-Q3)] 
A 1 (1-1) 
B 1 (1-2) 
DR 1 (1-1) 
ABDR 3 (2-4) 
HLA sensitization 
Current CRF Median 0 (range 0-59) 
Peak CRF Median 0 (range 0-82) 
 
CRF - calculated reaction frequency  
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Figure 3.3. The underlying cause of end stage kidney disease in patients in the 
ABOUT-K study 
 
Table 3.2. Demographics and baseline clinical data of ABOiKTx donors in the 
ABOUT-K study 
Donor details 
Age (Mean ±  StDev) (years) 47.7 ± 12.1 
Gender (Male) (n) 41 
Ethnicity (Caucasian) (n) 77 
BMI (Mean ±  StDev) (kg/m2) 26.5 ± 4.8 
GFR (Mean ±  StDev) (ml/min) 97.9 ± 20.7 
Surgical technique for nephrectomy  
Hand-assisted laparoscopic (n) 70 
Laparoscopic (n) 18 
Other (n) 12 
 
Table 3.3. Table of Donor/Recipient CMV status and the use of CMV prophylaxis in 
ABOUT-K patients determined by the donor/recipient 
  
CMV prophylaxis 
CMV status (n) Day 7 Day 28 Month 3 
D+/R+ 31 25.8% (8/31) 22.6% (7/31) 16.1% (5/31) 
D+/R- 21 85.7% (18/21) 81.0%(17/21) 61.9% (13/21) 
D-/R+ 31 12.9% (4/31) 9.4% (3/31) 12.9% (4/31) 
D-/R- 17 11.8% (2/17) 29.4% (5/17) 0.0% (0/17) 
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3.3.3 Blood Pressure Control 
Blood pressure was well controlled before and after transplant with mean blood 
pressure control in target limits, except for a transient rise at day 28 (Table 3.4). 
Patients were on median 1 (IQR 1-2) anti-hypertensive agents prior to transplantation, 
which did not change within the study period at either 3 months or 12 months.  
 
Table 3.4. Blood pressure measurement in study cohort 
Blood pressure compared at recruitment and through study timepoints during 12 month 
follow up demonstrates no improvement in blood pressure control over the 1 year 
follow up.  
  
Consent Day28 Month3 Month12 
BP systolic 
(SBP) 
Mean ± 
StDev 
137 ± 21 143 ± 14 139 ± 24 137 ± 26 
BP diastolic 
(DBP) 
Mean ± 
StDev 
81 ± 11 83 ± 10 81 ± 11 79 ± 14 
BP medications 
Median 
(Q1-Q3)  
 
1 (1-2) 
 
1 (1-2) 
 
1 (1-2) 
 
1 (1-2) 
 
3.3.4 Induction and Antibody removal techniques 
Eighty patients had rituximab as an induction agent. Median time of rituximab 
administration was 27 days prior to transplant (Q1-Q3= 12-30days). Four patients had 
alemtuzumab as a single induction agent. Basiliximab was used on the day of 
transplantation in 56 patients, of which 38 patients received rituximab as well. 
Intravenous Immunoglobulins (IVIg) were administered in 4 patients prior to 
transplantation. The majority of patients had immunoadsorption (n=55), and 14 
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patients did not have any EART. A summary of immunological characteristics and 
desensitisation therapies are shown in Table 3.5.  
Discussion of titre differences are further described in a later section; however 
analysis of titre reduction in EARTs was performed on local titres, as these directed the 
number of therapies. Median reduction of local IgG log2 dilution titre per EART therapy 
was similar in IA than PEx (0.75, Q1-Q3 0.25-1 vs. 0.54, Q1-Q3 0.17-0.75, p=0.099).  The 
number of sessions of EART was significantly higher in the PEx group than IA group 
(median 6[3-8] vs. 4[2-5], p=0.006). Importantly the IgG titres (or other decision point 
assay) in the local assay were also significantly higher in PEx group (Median log2 
dilution 6[5-7] vs. 4[3-7], p=0.007, Figure 3.4A and 3.4B). This may explain the higher 
number of EART episodes. There was, however, no difference in median IgG log2 dilution 
titre between the PEx and IA groups when analysed using the central assay (Median log2 
dilution 4.5[2-6] vs. 3[2-6], p=0.487, Figure 3.9C). Differences in assay technique may 
affect the result reported, which may account for the higher number of treatments given 
in the plasma exchange cohort, where the local titre was reported as significantly higher 
than the central titre. It is not however possible to definitively attribute causation in a 
study of this design. 
Median (Q1-Q3) local IgG log2 titre reduction was 3 (1-4) vs. central IgG log2 titre 
2 (1-4) (Wilcoxon rank-sum test, p=0.676) and the median (Q1-Q3) local IgM log2 titre 
reduction was 3(2-4) vs. central IgM 3(1-4) (Wilcoxon rank-sum test, p=0.878). When 
the reductions were analysed by EART, there was no difference at either local or central 
IgG assay [median (Q1-Q3) IgG log2 titre reduction (local IgG titre IA 3(1-5) vs. PEx 3 (2-
5) titre reduction, p=0.721; central IgG log2 titre IA 2(1-4) vs. PEx 3(2-5) reduction, 
p=0.223)]. There was a higher median (Q1-Q3) IgM log2 titre reduction in the PEx cohort 
than the IA cohort in the central IgM log2 titre IA 3(2-4) vs. PEx 4 (3-5) titre reduction, 
 
 
146 
 
p=0.006, but this was not significantly different with local IgM (local IgM log2 titre IA 
3(2-3) vs. PEx 3 (2-5) titre reduction, p=0.346). 
3.3.4.1 Albumin concentrations in the recipients 
There was no significant change in serum albumin in those who received IA, PEx or no 
EART at each timepoints before transplantation or in the early follow up period (less 
than 28 days). After EART, there was no difference between the groups with mean 
albumin on the day of transplant (IA 36.2±5.5; PEx 33.5±7.3 and No EART 36.4±5.2, 
p=0.404) 
3.3.5 Acute Rejection post ABOiKTx 
There were 29 patients who experienced episodes of acute rejection during follow up. 
Only four of these were diagnosed with antibody-mediated rejection (Figure 3.5). All 
AMR took place in blood group “O” recipients with kidneys with blood group “A” as 
donor antigen (either as A [n=3] alone or as AB [n=1]), which was not statistically 
significant compared to the other non-“O” recipients (5.9% vs 0%, p=0.17). There was 
an increased risk of rejection in blood group “B” recipients compared to other blood 
groups (58% [n=7] p=0.017) with an odds ratio (OR 4.2, 1.22-15.5). Three (16%) blood 
group “A” recipients (16%, n=3) and 19 (27%) blood group “O” recipients had rejection. 
 Renal biopsies were performed in 44 patients over the 1 year follow up period. 
Seventeen patients had biopsies in the first week after transplant. Twenty two patients 
had biopsies after 1 week before 1 month. Twenty one patients had biopsies between 
month 1 and month 3. There were 17 biopsies performed between 3 months and 1 year. 
In total, 77 biopsies were performed for all patients in 1 year follow up. 
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Table 3.5. Antibody data and desensitisation techniques for the ABOUT-K study  
The predominant method for local ABO titration technique was by test tube. The titres 
measured locally and centrally had similar distribution; however, the central IgG titre 
was 1 dilution lower than local assays overall. Guy’s titre values are presented 
separately as the isotype was not distinguished in this assay. 
 
Immunological Details TABLE 
Local HG method 
Test Tube 63 
Gel Card 37 
    
Starting Titre*# 
Local measurement IgG 5 (3-7) 
Local measurement IgM 5 (3-7) 
Central measurement IgG 4 (2-6) 
Central measurement IgM 5 (4-6) 
  
Guy’s local titre measurement 5 (4-7) 
Guy’s central measurement IgG 1 (1-5) 
Guy’s central measurement IgM 4 (2-6) 
 
Induction Agent  
Rituximab  80 
Alemtuzumab 4 
Basiliximab 56 
EART – pre transplantation 
Immunoadsorption  55 
Plasma Exchange  31 
No EART  14 
 
* Titres are pre-induction, or pre-EART if this data was not available and expressed as 
log2 dilution. # Titres are expressed as Median (1st Quartile -3rd Quartile) 
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Figure 3.4 Comparison of titres between local and central assays.  
Figure 3.4A. Comparison of anti-ABO specific donor titre IgG (log2)  before antibody 
removal using HG assay by local and central assay assessment reveals non standardized 
assays given clinically significant different titre results, but not on the central assay. 
 
Figure 3.4B. Comparison of anti-ABO specific donor titre IgG (log2) by EART therapy 
group demonstrates local titres were higher in the PEx group and this is reflected in 
significantly higher number of EART therapies (p<0.01). 
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Figure 3.5. The rejection rates of patients after ABOiKTx.  
Antibody-mediated rejection occurred in 4 (13.8%) of the patients who had rejection. 
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Analysing rejection by antibody titre, all rejection episodes were grouped together into a 
rejection group as the number of antibody-mediated rejection episodes was too low for 
statistical analysis in this cohort.  Acute rejection episodes occurred in the early post-
transplant period and this was at a significantly higher rate in blood groups “B” and “O” 
recipients compared to “A” (p=0.035, Figure 3.6). The majority of rejection occurred 
within 30 days. After 120 days post-transplant there were few episodes of rejection 
(n=3). 
 
Figure 3.6. Rejection free survival in allograft following ABOiKTx 
Blood group “A” recipients (red) has significantly less rejection than blood group B, not 
O in follow up in the first year following transplantation (“A” vs. “B” 17.6% [3/17] vs 
53.8% [7/13], p=0.035, “A” vs. “O” 17.6% [3/17] vs. 27.1% [19/70], p=0.419, Pearson 
Chi squared). Blood group “B” recipients (green) had more rejection than other blood 
group recipients (“B” 53.8% [7/13] vs. “non-B” vs. 25.3% [22/87], p=0.034, Pearson Chi 
squared). 
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3.3.6 Patient and Allograft Survival 
One patient died secondary to sepsis at 97 days after transplantation, giving a 1 year 
survival of 99%. Allograft failure occurred in 6 patients by 1 year. Two grafts were lost 
early secondary to antibody mediated rejection refractory to intervention by antibody 
removal and immunosuppressive agents. One graft was lost on day 1 from acute renal 
artery thrombosis, attributed to surgical complication in the absence of a rise in ABO 
titre and the kidney was pale and ischaemic. Histological examination demonstrated 
severe acute tubular injury with no inflammation or tubulitis; the C4d stain was negative 
and there was no peritubular capillaritis, which would support an acute AMR episode. 
One graft was lost on day 79 due to recurrence of FSGS.  One graft loss was attributed to 
BK nephropathy at 146 days post-transplant and another was attributed to mixed 
cellular humoral rejection at 177 days. A latter graft loss at 483 days was attributed to 
non-compliance.  There was no allograft survival difference correlated with blood group 
of recipients.  There was no statistical difference in 2 year allograft survival between 
different antibody removal techniques (IA 94.6% vs. 81.6%, p=0.406). The Kaplan-Meier 
plots in Figures 3.6A, B and C demonstrate allograft loss over time in relation to overall 
allograft survival; blood group and EART. 
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Figure 3.7 Allograft survival divided into overall survival; survival by recipient 
blood group and by antibody removal technique 
 
Figure 3.7A.  All allograft Kaplan-Meier death censored survival (median follow up 700 
day (IQR 355-1057)  
 
 
Figure 3.7B. Allograft Kaplan-Meier death censored allograft survival by recipient blood 
group. Death censored allograft survival by blood group type. Both “A” and “B” recipient 
cohorts did not lose any allografts and the lines overlap. All transplants that failed were 
in blood group “O” recipients; this did not reach statistical significance.  
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Figure 3.7C. Death censored allograft survival by EART technique.  
Patients without EART (i.e. Low titre patients) had 100% graft survival. There was no 
statistical significant difference in allograft survival between IA, PEx or No EART 
techniques. 
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3.3.7 Renal function following transplantation 
At last follow up, serum creatinine for this cohort was median 121 micromol/L (Q1-Q3 
95.5-154.5) with median follow up 700 days (Q1-Q3 355-1057). There was no 
significant difference in creatinine at any time point within the first 12 months for the 
different EART therapies. The incidence of dialysis dependant delayed graft function 
(dDGF) was 7. Our transplant centre has published on the importance of functional 
delayed graft function (fDGF) and 16/100 patients met the criteria of less than 10% 
reduction in daily creatinine [236]. This occurred at day 3 in 11 patients and at day 5 in 
3 patients and 2 patients met criteria at day 7.  
The pre-treatment titre of patients did not distinguish between patients with delayed 
graft function needing dialysis regardless of isotype measurement or local/central 
assessment. Higher pre-desensitisation titres were associated with no fDGF regardless 
of isotype or local/central measurement (Figure 3.8). There was no association with 
allograft failure with either dDGF (p=0.40) or fDGF (p=0.96). The function of the 
allograft was no different at most recent follow up for dDGF (Median creatinine (Q1-Q3) 
147 micromol/L, (87-163) vs. 124 micromol/L, (94-150), p=0.70) however, fDGF was 
associated with poorer function at last follow up (Median creatinine(Q1-Q3) 150 
micromol/L, (120-187) vs. 121 micromol/L, (93-143), p=0.05). 
Regardless of the time of rejection experienced post-transplantation, those with 
rejection had significantly higher creatinines even at Day 3 post-transplant prior to the 
rejection episode (p=0.008). There continued to be a difference after transplant at Day 5; 
Day 7; Day 29; Month 3; Month 6 and Month 12 (Table 3.6). This was true for cellular 
rejection, but there was no difference in the few with antibody-mediated rejection. 
There was no difference in renal function at each time point stratified by recipient or 
donor blood group, or by blood group donor/recipient pairs. 
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Figure 3.8. Prediction of delayed graft function by starting titre.  
Figure 3.8A – Functional Delayed Graft Function was associated with lower starting 
anti-donor titres by either local or central assays. Patients with fDGF (red triangles) are 
displayed in both graphs, as dialysis dependent delayed graft function is a subgroup of 
fDGF. Black circles are all patients without DGF. (Wilcoxon rank-sum test) 
 
Figure 3.8B – Lower local starting anti-donor titres were associated with Delayed Graft 
Function by dialysis(dDGF). Higher starting titres by either local or central assays were 
not predictive of dDGF. fDGF (red triangles) are displayed in both graphs as dialysis 
dependent delayed graft function is a subgroup of fDGF. Black circles are all patients 
without DGF. (Differences calculated by Wilcoxon rank-sum test) 
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Table 3.6. Biochemical analysis in the patient cohort at each study time point 
 
Table 3.7. Comparison of creatinine in patients with rejection at any time point 
Rejection was defined as biopsy or non-biopsy proven rejection by local clinical team and analysis 
demonstrated regardless of time of rejection. Serum creatinine was significantly higher in those who had 
rejection in follow up data at all time points. Creatinine in micromol/L (median [Q1-Q3]). Wilcoxon rank-
sum test. 
Time point n Rejection group No Rejection group p-value 
Day 3 86 183 (121-450) 128 (92-181) 0.008 
Day 5 73 203 (115-356) 115 (88-158) 0.002 
Day 7 95 174 (120-303) 111(84-146) <0.001 
Day 28 92 151 (97-182) 115 (89-133) 0.004 
Month 3 86 155 (125-191) 116 (93.5-139) <0.001 
Month 6 73 157 (124-241) 126 (95-147) <0.001 
Month 12 88 142 (115-198) 119 (95.4-142) 0.010 
Month 24 57 158 (129-182) 115 (92-144) 0.001 
  
Consent 
Pre-
induction 
Pre-EART Pre-Txp 
Day 
3 
Day 
5 
Day 
7 
Day 
28 
Month 
3 
Month 
6 
Month 12 
Creatinine 
(µmol/L) 
Median 
(IQR) 
596 
(404-778) 
560 
(429-718) 
596 
(445-
726) 
502 
(399-
634) 
138 
(96-254) 
124 
(96-186) 
122 
(95-166) 
120 
(94-151) 
123 
(107-145) 
132 
(104-161) 
124 
(103-155) 
Urea 
(mmol/L) 
Median 
(IQR) 
20.6 
(16.7-
25.9) 
21.2 
(16.8-
25.0) 
21.2 
(15.9-
24.5) 
14.9 
(10.3-
19.1) 
9.5  
(5.8-
15.0) 
9.1  
(6.2-
14.2) 
8.5  
(6.0-
14.1) 
8.3  
(6.9- 
9.8) 
7.5  
(6.0- 
10.0) 
7.8  
(6.1- 
10.3) 
7.5  
 (6.3- 
9.3) 
Albumin 
(µmol/L) 
Median 
(IQR) 
42 
(38-46) 
41 
(37-46) 
39 
(35-42) 
36 
(32-40) 
31 
(27-34) 
32 
(29-35) 
34 
(30-34) 
40 
(36-43) 
43 
(40-46) 
43 
(40-45) 
43 
(40-46) 
Glucose 
(mmol/L) 
Median 
(IQR) 
5.3 
(4.3-6.2) 
5.2 
(4.7-6.0) 
5.7 
(4.7-6.7) 
5.4 
(4.7-6.7) 
7.0 
(5.4-8.4) 
6.7 
(5.2-8.6) 
4.3 
(3.9-5.5) 
6.4 
(5.6-7.8) 
5.2 
(4.3-6.5) 
5.5 
(4.7-6.4) 
5.7 
(4.9-6.6) 
Cholestero
l (mmol/L) 
Median 
(IQR)  
4.5 
(3.9-5.4) 
    
4.3 
(3.9-5.5) 
5.4 
(4.7-6.3) 
5.2 
(3.9-5.4) 
5.3 
(4.5-7.8) 
5.1 
(4.5-6.0) 
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3.3.8 Anti-ABO specific antibody comparison from local to central analysis and 
effect on clinical outcomes 
Inter-rater agreement was tested using kappa agreement, as there is no gold 
standard test against which both tests could be compared. The weighted kappa for anti-
donor IgG at induction was 0.613 (0.461-0.765). This decreased to 0.547 (0.389-0.705) 
before EART and down to 0.339 (0.200-0.477) on the day of transplant surgery. Thus, 
the agreement between local and central titre measurement was divergent the closer to 
the time of transplant at lower titres. Figure 3.9A demonstrates the differences between 
the central titre and the local titre and Figure 3.9B demonstrates intra-rater agreement 
for the central titration assay. 
Analysis was made at each corresponding time point prior to transplantation, 
namely pre-induction; pre-EART and at time of transplant. The antibody range before 
EART is displayed in Figure 3.10 for both local and central titres. In the 3 major 
contributing centres, there was a significant difference in IgG titres measured locally, 
however this was not  so when measured centrally as illustrated for samples quantified 
prior to EART in Figure 3.4A. 
 Table 3.8 demonstrates the number of samples at each time point collected. 
There were 86 samples collected prior to induction agent; 91 prior to antibody removal 
and 99 at time of transplantation. There were variations in local protocols, in that no 
samples were measured if no induction agent or EART was administered. The median 
local IgG titre at assessment was 1:32 (Q1-Q3 16-64). There were a significant number 
that had very low IgG titres (n=15, ≤1:4) and reasonably local high IgG titres (n=9, 
≥1:256). 
A titre of 1:8 or below is generally used as the decision point for transplantation 
to proceed, all be it that this has not been related to the sensitivity of the HG assay in use 
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at the reporting centres [65]. The number of patients on day of transplant that had a 
local titre IgG which was >1:8 was 4.1% (4/98) and 4.1% (4/97) by central titre IgG. For 
IgM, the local titre >1:8 was 11.1% (8/72) and 6.25% (6/96) by central titre IgG. There 
was no significant clinical implication of these titres being above target when correlated 
with allograft loss or allograft rejection. There was no correlation with AMR using 
central titre HG assay. 
 In this study, the analysis of local titres is complicated as one centre performs an 
isohaemagglutination test and does not identify isotype. Guy’s Hospital contributed a 
significant proportion of patients to this study (n=26), however their local laboratory 
assessment was the only laboratory to perform a single agglutination assay, 
isohaemagglutinin, not differentiating between different isotypes of anti-ABO specific 
antibody. These were treated as IgG for analysis purposes as titre that directed clinical 
therapies, as described in the methodology.    
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Figure 3.9.Comparison of local and central titres agreement plots 
Figure 3.9A -Bland-Altman plot of local to central agreement assay titres, plotted as log2 
dilutions. Titration results are ordinal, however treated as continuous, thus significant 
overlap of titre results. 
  
Figure 3.9B- Bland-Altman plot of intra-rater agreement, demonstrating excellent 
agreement on reproducibility – previously described in more detail in Chapter 2.  
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Figure 3.10. Distribution of ABO titre values at different time points and at 
different transplant centres and the variation in EART therapies based on these 
assay variations. 
Histograms of local and central assay assessment of anti-ABO specific antibodies (log2 
dilution).
 
 
Table 3.8. Number of samples at local and central collection at pre-transplant time 
points. 
The number of samples collected centrally at time point for the ABOUT-K study patients.  
 Pre-Induction Pre-EART Pre-Transplant 
Local Titre completed 100 70 100 
Central Sample sent 86 91 99 
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3.3.9 Adverse Events and Infectious Complications 
As previously described, 1 patient died from sepsis secondary to ischaemic bowel with a 
retroperitoneal haematoma. Two other patients required bowel resection in the first 
week post-transplant. One patient had ischaemic small bowel and the second had a 
perforated caecum. Both of these have had reversal bowel surgery during the study with 
no further complications (Table 3.9) 
3.3.9.1 Vascular 
There were 4 renal artery surgical complications; 2 with bleeding requiring significant 
resuscitation, 1 of which required cardiopulmonary resuscitation. These did not 
correlate with either type of antibody removal; the starting titre or degree of titre 
reduction. One renal artery dissected and needed a polytetrafluoroethylene (PTFE) 
graft. In one allograft failure, there was a primary renal artery thrombosis, which 
following thrombectomy did not improve function to the allograft. The allograft was pale 
and hypo-perfused, not necrotic nor infarcted. Biopsy revealed an ischaemic kidney with 
no evidence of AMR. One patient developed a post-transplant polyclonal 
lymphoproliferative disease 3 months post-transplant.  
Three patients had ischaemic cardiac events.  Two patients had non-ST elevation 
myocardial infarctions which occurred in the peri-operative and early post-operative 
period (<24hours). One patient had a myocardial infarction during DFPP and had 
coronary stent inserted and operation delayed. One further patient has chest pain 
following recruitment and had coronary stenting performed. This patient had a delay of 
the transplant operation by 6 months, and then proceeded to undergoing EART and 
transplantation.  One patient who had transplant renal artery stenosis was successfully 
treated with angioplasty within the first 3 months post-transplant. 
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There were 6 peri-allograft haematomas that needed intervention and 4 lymphocoeles 
that required intervention. One patient required vacuum therapy to the transplant 
wound, but had not had any of the above collections.   
3.3.9.2 Infections 
Reported infections requiring admission to hospital were: 4 chest infections and 7 urine 
infections in the 100 patients. Of the chest infections, there were 2 cases of 
pneumocystis jirovecii (PCP) in one institution. This was at the same time of an apparent 
UK national outbreak of PCP. Both recovered well with therapy. The number of recorded 
viraemias was 6 CMV viraemias, 6 BK viraemias and 3 JC viraemias. This was defined as 
a detectable PCR without clinical symptoms, blood changes or allograft dysfunction. One 
patient had varicella viral re-activation. Six patients had BK nephropathy and 4 patients 
had CMV disease, defined as kidney dysfunction with viraemia [237].  
3.3.9.3 Other Adverse Events 
Other reported serious adverse events were: 2 SVC obstructions (1 secondary to line 
insertion and 1 spontaneous); small bowel resection for strangulated hernia; 
venesection for polycythaemia; incision and drainage of scrotal abscess; severe tubulo-
interstitial nephritis drug reaction; severe duodenitis on endoscopy; calculi in 
submandibular gland; slow respiratory wean for 4 days post-bowel resection. There 
were 5 cases recorded of new onset diabetes after transplantation.  One patient had 
suicidal ideation at 6 months post-transplant and continues to have regular psychiatric 
review.  
Significant reactions to immunoadsorption were only reported in 1 patient on first 
therapy and responded to local therapy and then proceeded to transplant. Three 
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patients had their operation delayed due to complications; 1 with positive blood 
cultures for Staphlococcus aureus and 2 patients with acute cardiovascular events.  
Two patients had recurrence of focal segmental glomerulosclerosis (FSGS) in the 
allograft; of which one had early rapid recurrence by Day 3 post-transplant and re-
commenced haemodialysis early despite PEx therapy within the first year; the second 
re-occurred at 11 months post-transplant. One patient was non-compliant with his 
medication after the 1 year follow up and his allograft failed at 451 days after transplant 
with combined cellular infiltrate and chronic antibody-mediated rejection on the biopsy.  
Two patients had thrombotic microangiopathy on biopsy with elevated tacrolimus 
levels.   
3.3.9.4 Haematology 
There was an improvement over the follow up for haemoglobin and haemocrit 
following transplantation despite increase immunosuppressants (Table 3.10). At Day 7 
the haemoglobin (8.9±3.9g/L) were statistically lower than at all other time points 
(p<0.001). There was also a transient rise in leukocytes, commonly associated with 
steroid therapy at Day 7 which was higher than all other time points (12.2±4.7*109/L, 
p<0.001). At the time of transplant, there was statistically lower platelet numbers than 
at all other time points (183.2±64.5*109/L, p<0.001). 
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Table 3.9. Comparison of complications according to EART group. 
Group 
 
Renal Artery 
Complications 
Haematoma Lymphocoele 
Infections 
PCP 
Viral Disease 
IHD 
event 
Bowel 
Resection 
dDGF fDGF PTLD 
Urine Chest CMV BK 
IA  
(n=55) 
2 1 1 2 3 2 3 5 1 2 5 11 0 
PEx  
(n=31) 
2 4 2 3 1 0 0 1 1 0 1 3 0 
No EART 
(n=14) 
0 1 1 2 0 0 1 0 2 0 1 2 1 
 
Table 3.10. Haematological responses following ABOiKTx. 
These results demonstrate stable leukocytes and an improved haemoglobin following transplantation. A rise in leukocytes and 
neutrophils occurred at Day 7 in keeping with steroid immunosuppression regimes. 
  
Consent Pre-induction 
Pre-
EART 
Pre-Txp 
Day 
7 
Day 
28 
Month 
3 
Month 
6 
Month 12 
Haemaglobin 
g/L 
Mean ± StDev 10.1 ± 4.0 11.3 ± 2.4 
10.9 ± 
1.3 
10.0 ± 1.7 8.9 ± 1.6 10.4 ± 2.1 11.4 ± 2.2 12.0 ± 1.8 12.0 ± 3.2 
Haematocrit 
(%) 
Mean ± StDev 29.7 ± 13.2 34.6 ± 7.5 
33.2 ± 
4.3 
30.4 ± 5.2 26.6 ± 5.7 32.5 ± 6.5 34.9 ± 7.6 36.4 ± 8.0 35.6 ± 12.1 
Leukocytes 
x109/L 
Mean ± StDev 7.2 ± 3.0 7.3 ± 2.8 7.5 ± 3.3 7.6 ± 3.3 12.2 ± 4.7 9.8 ± 3.9 6.9 ± 3.6 7.1 ± 2.7 7.4 ± 3.5 
Neutrophils 
x109/L 
Mean ± StDev 4.8 ± 4.9 5.7 ± 5.1 5.1 ± 2.8 6.4 ± 9.8 9.4 ± 4.5 7.7 ± 3.6 4.6 ± 3.1 4.8 ± 2.3 4.9 ± 3.1 
Platelets 
x109/L 
Mean ± StDev 
210.8 ± 
101.6 
232.5 ± 89.7 
225.2 ± 
63.9 
183.2 ± 
64.5 
257.1 ± 
107.5 
273.4 ± 
105.4 
270.5 ± 
101.0 
257.6 ± 
74.7 
238.4 ± 
97.4 
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3.4 Conclusions 
ABOiKTx is an effective option for patients with end stage kidney disease in a multi-
centre study allowing pre-emptive live kidney transplantation. The overall outcomes of 
this patient cohort are in keeping with national allograft survival rates for live donor 
ABOcKTx (97%), and better than the national registry data for ABOiKTx from NHSBT, 
UK (91%). The increased survival at 1 year in the ABOUT-K study (94% vs 91%) was 
higher, although not significantly different in the number of patients in this study 
(Figure 1.1).  
 The results in ABOUT-K compared to national UK registry data suggest that the 
centres contributing to ABOUT-K study may be performing better in the early (1 year) 
period than the rest of the registry data. The ABOUT-K study had recruited about a third 
of the total UK ABOiKTx in the registry data however, the difficulty of comparing 
outcomes in the national registry data using local titre results is demonstrated well in 
the difference in titre measurement between centres in Figure 3.4A. Thus, significantly 
high titres in one centre may be associated with good outcomes, but when these results 
are assessed using a central assay, the titres are “mid-range”. In this study, it has not 
been possible to demonstrate a difference in clinical outcomes between centres or 
based on initial titres or at the time of transplant.  
In this cohort, we have not shown an adverse immunological effect with different levels 
of titre either at local or central assay titres at either pre-desensitization or at the time 
of transplantation. While the 2 early AMR allograft losses were in patients with initially 
higher pre-EART titres (greater than 1:128), this study does not answer the question at 
what level is safe to transplant patients on the day of surgery, as the study did not have 
sufficient events to be able to analyse this. The majority of patients were transplanted 
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below the threshold of ≤ 1:8 according to local and central titres.  The patients that were 
above the 1:8 titre, either locally or centrally on the day of transplant, did not have an 
obviously detrimental outcome in transplantation. This value of 1:8 is still an arbitrary 
titre value. Flint et al demonstrate using a test tube agglutination method that 1:32 is 
adequate for allowing transplantation to take place while the Tyden protocol aims for 
1:8 or less. In the Tyden paper, however, one centre transplanted patients with a pre-
transplant titre of 1:128 [130]. The authors hypothesized that this was technique 
dependent, rather than true antibody level, which is likely given the similar clinical 
outcomes between these centres [238].  
The graft survival at 1 year was 3% greater than other registry data. As registry data is 
not currently stratified according to anti-ABO specific antibody titre risk, no further 
comparisons can be made. It seems likely that assessment of clinical outcomes between 
centres would require an assay to be standardised and reproducible between centres 
and within centres to allow comparisons to be made of outcomes and for collaborative 
studies to take place. While each centre performs its own in-house quality assurance 
testing, no national programme to compare ABO titres is currently in place.   
This potentially has a significant impact on patients being initially accepted into the 
ABOiKTx programmes at local centres. As demonstrated in this cohort, when local titres 
were compared between different centres, there were significant differences between 
titre values, which at first sight suggests that different centres have local populations 
with different anti-ABO specific antibody levels. However, using titres measured 
centrally, the population in all centres was widely and normally distributed when the 
major contributing centres to this study are compared. Thus, it is possible that 
acceptance onto an ABOiKTx programme could be limited by a local assay, rather than 
true anti-ABO specific antibody levels. While this study only examines patients already 
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accepted into local ABOiKTx programmes, it does suggest that in some centres local 
ABO titres may be higher than acceptable levels in the local assay, but in a central assay 
the titre would be appropriate for antibody removal. This requires further study. This 
would increase the live donor transplantation options for donor/recipient pairs, 
especially in blood group “O” recipients. There are no published data currently in press 
that suggests the number of patients that might be prevented from ABOiKTx based on 
high local titres, only the assay variability studies [239]. It is relevant to clinical practice 
because patients who would otherwise do well may be excluded on the basis of a high 
local titre [131]. 
Secondly, while we have shown that plasma exchange has significantly higher number 
of treatments required, prior to transplantation; this was associated with a significantly 
higher titre levels reported in the local assay in the plasma exchange cohort compared 
to the immunoadsorption cohort despite similar central measurements. Clinicians were 
treating local titre value produced in their laboratory compared to those centres using 
IA. Despite there being a higher number of treatments in the PEx cohort, there was not a 
significant reduction in serum albumin levels. The number of complications from 
viraemia and the 2 patients with bowel perforations should be noted and taken into 
consideration when counselling patients who may be at higher risk for these events. 
The impact of the method and the number of EART may have an effect on complications. 
The 2 allograft losses, due to antibody mediated rejection, both occurred early and 
developed rapidly. Both patients had good functioning allografts immediately before 
AMR was clinically detected. While 2 out of 100 is a small number, these are the patients 
that need to be studied in further detail and continuation of this work will look to 
identify the markers of antibody that may distinguish them from the rest of the cohort. 
There is limited evidenced based therapy for treating these patients. The use of early 
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rescue splenectomy and eculizumab are mostly likely to salvage the allograft, although 
eculizumab as a rescue therapy does not save all allografts [240].  Both these blood 
group “O” patients had higher titres prior to EART (local highest titre ≥1:128; central 
IgG titre 1:128 and 1:256, central IgM titre 1:256 and 1:128); had B antigen donors and 
a greater degree of HLA mismatch (6 and 5 respectively) but within the cohort they had 
no other distinguishing characteristics pre-transplant. Importantly, neither had anti-
HLA DSA detected. The early allograft loss associated with ABOiKTx in registry data is 
likely to be comprised of the accelerated early antibody-mediated rejection that was 
seen in the two patients, as well as other more routine cause of early allograft loss.  
ABOiKTx patients with early accelerated AMR need to be studied in more depth to be 
able to predict the likelihood of risk prior to transplantation. There were no specific 
characteristics that denoted these as higher risk. One patient was Afro-Caribbean 
female with lupus as an underlying disease who was a 6 antigen (ABDR) mismatch and 
was both A and B blood group incompatible. The second patient had hypertensive 
nephropathy and had a B donor who was a 5 antigen (ABDR) mismatch. Both patients 
were treated with immunoadsorption prior to transplantation and had local titres of 1:8 
at the time of transplant surgery (central titres IgG 1:2 and 1:8 respectively).  
The allograft loss from BK nephropathy had rapid onset and progression of 
nephropathy. The rate of BK nephropathy (6%) in this cohort seems to be similar to 
other published literature using immunoadsorption (8%, 3/42) and lower than plasma 
exchange only regimes (17.5%, 11/62), however Flint et al published a series of 37 
ABOiKTx without any BK nephropathy [130, 237, 241]. The role of natural immunity in 
the context of transplant viral infections is yet to be fully investigated. Does antigen 
exposure of to A or B antigen reduce immune response to similar antigen, which are 
known to be expressed in BK and JC sialic receptors [242]? Both BK and JC viral 
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receptors can mediate haemagglutination of red cells and thus immunological tolerance 
to A/B incompatible antigen may down regulate immune response to both these 
viruses. However the level of immunosuppression is likely to play a significant factor in 
the higher incidence, as Flint et al demonstrated that without rituximab induction the 
rate of BK and CMV viraemia was equivalent between ABOiKTx and ABOcKTx [130] . 
The timing of onset of BK nephropathy in the paper by Sharif et al demonstrated that 
75% of cases occurred in the first 6 months following transplantation and our data 
supported this early onset (4/6 within 6 months).  
These data suggest that good outcomes in ABOiKTx can be achieved but there is 
however a strong argument for further standardisation of the assessment of blood 
group antibodies. This is a prerequisite for alignment of practice and for the initiation of 
any meaningful study of intervention, including different EART and optimal use of 
paired exchange.    
In conclusion, ABOiKTx is an effective tool for kidney transplantation for recipients 
without an ABO compatible live donor, especially in blood group “O” recipients. A 
standardised technique to measure ABO titres in order to ensure equality of access and 
comparison across centres is necessary. The survival advantage of early, pre-emptive 
transplantation is likely to outweigh the higher risks of undergoing this type of 
transplantation; however a cohort comparison study needs to be done to compare this 
and require longer term follow up.  
3.5 Further Work 
The outcomes of these patients will continue to be monitored for 5 year 
outcomes via NHSBT. The analysis of study samples will continue for the post-
transplant period to correlate outcomes with antibody changes in the early period after 
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transplantation. Assays that have been developed in this thesis will continue to be 
developed and applied to this study cohort.  
A cohort study, using NHSBT data, matched for transplant centre, year of 
transplant, age, gender and transplant waiting time could be completed to compare the 
outcomes in this cohort. A comparison of the paired exchange patients in the UK who 
were ABO incompatible could also be performed as a better control cohort, who are 
unable to undergo direct live donor kidney transplantation. This would include the time 
of entry into the paired exchange programme, and the number of “matching runs” that 
were completed before a transplant took place. The patient and allograft survival in this 
cohort would be useful comparative, but would require large numbers in a longer term 
study. 
I have also established collaborations with Prof Lori West’s laboratory in the 
University of Alberta, Edmonton, Canada who have developed an assay to measure 
isotype and IgG subclass binding to the different type chain structures of A/B antigens. 
This work is novel and may explain why certain antibody levels are high but cause no 
rejection, whilst others are more immunogenic. Other local collaborations with the 
transplant surgery department have evolved. They are investigating biomarkers in 
transplantation. Assays for endothelial injury would be a useful tool for monitoring the 
effect of anti-ABO specific antibodies on endothelium. This work is being done by Ms 
Mel Field as part of her MD thesis at University of Birmingham, UK.   
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Chapter 4  Five-Year Outcomes in Living Donor Kidney Transplants 
with a Positive Crossmatch 
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This chapter has been published in the American Journal of Transplantation [144] 
4.1 Introduction 
Antibodies against donor HLA, termed donor-specific alloantibodies (DSA), pose a 
significant barrier to successful kidney transplantation because of the increased risk of 
both early and late graft loss [53, 243].  However, since many candidates have 
antibodies which react against a broad range of HLA, finding a donor against whom they 
have no antibody can be difficult.  Over the past decade, novel “desensitization” 
protocols have been developed to enable patients with high level anti-donor antibodies 
(termed here positive crossmatch kidney transplants, +XMKTx) to receive a transplant 
with acceptable short term outcomes [22, 102, 186, 244].    Recently, paired donation 
and “acceptable mismatch” programs have provided other means for providing 
sensitized patients a donor against whom they have little or no antibody [18, 245-247].  
+XMKTx appears to have higher patient survival compared to either dialysis or waiting 
for an HLA compatible transplant [24]. However, with regards to graft survival, few 
studies have provided data beyond 1 or 2 years after transplantation and those that 
have suggest inferior graft survival in +XMKTx compared to negative crossmatch kidney 
transplantation (–XMKTx) [191].  In addition, the late outcomes of transplants in 
patients with low levels of antibody and with antibody against Class II HLA remain 
unclear.  The goal of the current study was to determine the actual 5-year graft 
outcomes in patients with antibodies against donor HLA. 
 
 
173 
 
4.2 Methods 
4.2.1 Antibody Detection  
 The presence of anti-donor alloantibody was determined using conventional 
crossmatch assays as previously described [186].  During the study period, the primary 
methods for determining the presence and level of DSA pretransplant were crossmatch 
assays including:  1) complement dependent cytotoxic (CDC) crossmatch using the T cell 
anti-human globulin enhanced technique and; 2) T and B flow cytometric crossmatch 
(FXM) for CDC- patients.  All serum was tested against donor cells for cytotoxicity using 
the T-cell anti-human globulin enhanced complement dependent cytotoxicity assay.  
However, since the T cells only express Class I (and not Class II), the only cytotoxic 
donor-specific alloantibody (DSA) identified was against Class I.   DSA positive CDC 
negative patients were those who had a positive T-cell flow cytometric crossmatch 
(TFXM) and/or a positive B-cell flow cytometric crossmatch (BFXM).  TFXM positive 
result was a channel shift of >66 and a BFXM positive result was a channel shift >99 as 
previously reported [248]. Solid phase assays were utilized in the programme beginning 
in 2006.  Therefore, in 2006 using pre-desensitization stored serum, confirmation of 
DSA and its HLA specificity generally was performed retrospectively using a solid phase, 
single antigen bead assay (LABScreen, One Lambda, Canoga Park, CA) with the amount 
reported as the mean fluorescence intensity of the highest single level against donor 
Class I and/or Class II.  Mean fluorescence intensity 1000 or greater was considered 
positive. 
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4.2.2 Study Populations.   
The study described in this chapter required Institutional Review Board (IRB) approval 
at Mayo Clinic, Rochester, USA. The outcomes were analyzed of 102 patients who 
underwent living donor +XMKTx at the Mayo Clinic in Rochester, MN, USA between 
January 2000 and December 2006  and who met all the following criteria: 1) positive 
crossmatch against their live donor prior to transplantation (prior to starting any pre-
transplant therapy); 2) retrospective verification of the presence of DSA using a solid 
phase assay and 3) achieved a negative complement-dependent cytotoxic (CDC) 
crossmatch assay on the day of transplant. Data was censored on the 1st January 2012 
and all transplant recipients had been transplanted a minimum of 5 years prior to this 
date. A comparison group included 204 –XMKTx recipients matched 2:1 for the same 
time era, age (+/-10 years) and sex for +XMKTx recipients. Data for analysis was 
censored 1st January 2012. 
In solid phase assay, a cutoff of positivity of an MFI >1000 was chosen because during 
the 5-year follow-up there were no graft losses occurred in any +XMKTx in which both 
Class  I and/or Class II DSA was <1000 at baseline (i.e 100% 5 year death-censored graft 
survival).   Of 154 +XMKTx, 102 recipients met inclusion criteria while 52 were 
excluded. These included: 8 lost to follow-up; 16 had no DSA detected by solid phase 
assay at baseline despite a positive crossmatch; 5 had DSA in which the highest MFI was 
<1000; 11 had no sera available for testing DSA retrospectively and 12 CDC+ patients 
who did not achieve a negative CDC crossmatch despite desensitization.  
The outcomes of 204 living donor kidney transplants from the same time period who 
had a negative crossmatch (-XMKTx) without antibody removal therapy against their 
donor were studied. This group was developed from a pool of 831 – XMKTx recipients 
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from the same time period by identifying 2 –XM living donors recipients of similar age 
(+/-10 years)  and sex for + XMKTx recipient.  34 –XMKTx patients who met these 
criteria were lost to follow up and were excluded from matching.  This group was not 
retrospectively tested for HLA antibodies. 
4.2.3 Desensitization and Immunosuppression 
The goal of “desensitization” was to achieve a negative CDC crossmatch on the day of 
transplant or a channel shift less than 300 in the B-cell flow cytometric assay as 
previously described by Gloor and colleagues [248].  Three general approaches to 
desensitization were utilized including: 1) plasma exchange with low-dose intravenous 
immunoglobulin (100mg/kg) plus splenectomy at the time of transplant (n=16), 2) 
plasma exchange plus immunoglobulin (2g/kg) without splenectomy (n=48), 3) high 
dose immunoglobulin alone (2g/kg, n=21) and finally no pre-transplant desensitization 
(n=17). All +XMKTx received induction with rabbit polyclonal anti-lymphocyte 
antibodies and received tacrolimus, mycophenolate mofetil and prednisolone as 
maintenance immunosuppression. –XMKTx generally also received the same oral triple 
therapy except for thirty-three (16.2%) -XMKTx who received other regimens including 
cyclosporine and sirolimus-based immunosuppression. 
4.2.4 Biopsy Scoring, Renal Function and Proteinuria 
Patients underwent surveillance allograft biopsy at 1-year and 5year time-points 
following transplantation using a percutaneous ultrasound guided 18-gauge biopsy gun 
(Bard, Murray Hill, NJ) as previously described.  Each biopsy was deemed adequate for 
interpretation by a Mayo Clinic renal pathologist and scored using the Banff 97 
classification [148].  In addition, the presence of C4d was assessed by 
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immunofluorescence in the +XMKTx by frozen sections.  Patients with both a biopsy at 
1-year and 5-year timepoints were included in a paired analysis. Paired biopsies were 
examined retrospectively for peritubular capillaritis according to Banff 2007 criteria 
[142]. 
Graft loss was defined as return to dialysis or re-transplantation.  Renal function was 
calculated from creatinine readings using the Modification of Diet in Renal Disease 
(MDRD) equation [249]. Proteinuria was assessed using 24-hour urine collection.  
4.2.5 Statistical Analysis 
 Analysis was made on JMPv9. (SAS, Cary, NC,) using Kruskal-Wallis/ Wilcoxon rank-
sum test; Pearson and paired t-tests according to the variable data comparison. 
Normality of distribution of variables was tested using Shapiro-Wilk test. The statistical 
differences in survival were calculated by the log-rank test. Matching was done using 
the GREEDY algorithm [250]. A multivariate analysis was not performed. There are 
multiple variables that may affect allograft outcome described in the literature (for example 
ABDR mismatch, dialysis time, crossmatch status, level of antibody, anti-class I or II, age, 
diabetes) and these were collected in this study. In this study there were 52 failed allografts 
at five years, and on this basis a multivariate analysis could only be limited in scope is 
potential susceptible to instability caused by variable collinearity. 
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4.3 Results 
4.3.1 Patients and Matched Control Subjects 
Of the 102 +XMKTx patients, the mean age was 46.3 ±12 years, 69.6% were women and 
96.1% were Caucasian (Table 4.1).  Comparing this group to 204 –XMKTx matched 
controls, differences existed in variables known to be associated with being sensitized 
to HLA including: a longer duration of dialysis pre-transplant (Median[Q1-Q3] 23.1 
[10.8-53.1] vs. 9.0 [5.1-24.4] months, p<0.0001); a lower rate of pre-emptive 
transplantation (18.6% vs. 51.0%, p<0.0001); a higher rate of patients who had a prior 
kidney transplant (39.2% vs. 22.1%, p=0.002); and a more HLA ABDR mismatches over 
2(82.4% vs. 66.7%, p=0.005, Pearson Chi squared). 
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Table 4.1. Comparison of +XMKTx and –XMKTx populations according to 
demographics and immunology  
 Non-sensitized 
HLA- 
Sensitized 
Class I 
only 
Combined Class 
II/I 
p value  N=204 N=102 N=36 N=66 
Age (years) 46.9 ± 10.2 46.3 ± 12 47.6 ± 11.7 45.6 ± 12.2 0.69 * 
Gender (Female) %(n) 69.6% (142) 69.6% (71) 83.3% (30) 62.1% (41) 1.0* 
Ethnicity (Caucasian) 
%(n) 
90.7% (185) 96.1% (98) 100% (36) 93.9% (62) 0.82* 
Retransplant %(n) 22.1% (45) 39.2% (40) 27.8% (10) 45.5% (30) 0.002 * 
ABDR mismatch 
Median(Q1-Q3) 
3 (2-4) 3 (3-5) 3 (2.25-4.75) 3 (3-4) 0.005 * 
Pre-emptive %(n) 51% (104) 18.6% (19) 16.7% (6) 19.7% (13) <0.001 * 
Dialysis time (months)  
Median [Q1-Q3] 
9.0 (5.1-24.4) 23.1 (10.8-53.1) 22.9 (15.1-90.3) 24.1 (9.6-24.4) <0.001 * 
Living donor %(n) 100% (204) 100% (102) 100% (36) 100% (66) 1.0 * 
Living Related Donor 
%(n) 
38.7% (79) 44.1% (45) 36.1% (13) 48.5% (32) 0.37 * 
      
Primary Disease %(n)      
Diabetes 26.5% (54) 10.8% (11) 13.9% (5) 9.1% (6) 0.002 * 
Polycystic 13.7% (28) 9.8% (10) 11.1% (4) 9.1% (6) 0.33 * 
      
CDC negative %(n)  59.8% (61) 44.4% (16) 68.2% (45) 
0.02 † 
CDC positive %(n)  40.2% (41) 55.6% (20) 31.8% (21) 
AHGCDC (Dilution)  4 (2-8) 4 (2-14) 4 (2-8) 0.76 † 
TFXM Channel Shift  187 ± 124.4 267.6 ± 86.8 150.6 ± 122.3 0.001 † 
BFXM Channel Shift  329.7 ± 92.5 310.2 ± 80.1 338.5 ± 97.2 0.239 † 
Class I only % (n)  35.3% (36) 100% (36) - n/a 
Class II only % (n)  19.6% (20) - 30.3% (20) n/a 
Class I and II % (n)  45.1% (46) - 69.7% (46) n/a 
Baseline Class I MFI 
Median(Q1-Q3) 
 
7378  
(2342-12363) 
10251  
(1452-16986) 
5248 
 (323-18317) 
0.002 † 
Baseline Class II MFI 
Median(Q1-Q3) 
 
2735  
(0-10616) 
n/a 
7269  
(1076-23293) 
<0.001† 
      
Follow up (days) 2929 ± 741 2488 ± 911 2514 ± 900 2474 ± 923 <0.001 * 
Donor gender 
(Female) 
56.4% (115) 59.8% (61) 66.7% (24) 56.1% (37) 0.33 * 
Donor age (years) 42.6 ± 12 41.0 ± 11.9 39.7 ± 11.3 41.7 ± 12.1 0.26 * 
Data is expressed as mean and standard deviation, unless specified. * The results are 
comparisons between the total HLA-sensitized and non-sensitized matched controls, not the 
Class of antibody groups. † p value is comparison between sensitized (+XMKTx) with antibody 
against donor Class I only or donor Class II/I  (Class II only or Class I and II).  
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The date of analysis was at least 5 years post transplantation (+XMKTx mean = 2488 ± 
911days vs. -XMKTx mean 2929 ± 741days). At baseline, 40% (n=41) of the +XMKTx 
had a crossmatch that was CDC+ (median dilution 1:4, range 1:1-1:64).  In the +XMKTx 
group, 36 had antibody against donor Class I only, 20 had antibody against donor Class 
II alone and 46 had antibodies against both donor Class I and II.   The level of antibody 
against Class I specificities was similar in the Class I only group and in Class I and II 
combined group with similar mean highest MFI against donor Class I specificities (MFI= 
10251 (6282-13223) vs. 7578 (3888-12480), p=0.17) and a similar proportion of CDC+ 
recipients (55.6% vs. 45.7%, p=0.37). The median highest MFI against Class I was 
higher in the CDC+ patients compared to the FXM+ group (12000 (2658-18317) vs. 
3404 (0-15851), p<0.0001), however, there was considerable overlap of MFI between 
these CDC+ and FXM+ patients.  The level of DSA against Class II specificities was similar 
in the Class II only and both Class I and II groups (5230 [1140-23293] vs. 6658 [672-
18265], p=1.0). These two groups were combined for further analysis (called Class II/I). 
4.3.2 Five-Year Patient and Graft Survival 
Patient survival at 5 years was lower in +XMKTx compared to –XMKTx (86.3% vs. 
92.5% p=0.01, Figure 4.1A). Death-censored graft survival at 5 years was lower in the 
+XMKTx than -XMKTx (70.7% vs. 88.0%, p<0.01, Figure 4.1B). +XMKTx patients 
therefore had significantly higher risk of a composite endpoint of patient death, allograft 
failure or transplant glomerulopathy (Odds Ratio 4.3, 95% CI 2.5-7.4, Logistic 
Regression). 
At 1 year, CDC+ transplants had lower death-censored graft survival than the CDC-
/FXM+ recipients  (82.4% vs. 96.7%, p=0.02), but the difference was not statistically 
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different at 5 years (64.9% vs. 72.7%, p=0.26, Figure 4.1C) demonstrating a similar rate 
of graft loss in CDC- grafts between 1 and 5 years.  
The anti-HLA specificity of antibody detected at baseline had an important impact on 5-
year death-censored graft survival.  Graft survival was higher in recipients with 
antibody against donor Class I only compared with those with Class II antibody (either 
alone or with Class I) (85.3 vs. 62.6%, p=0.05, Figure 4.1D) and was similar to that of the 
–XMKTx (85.3 vs. 88.0%, p=0.64).  In the Class I antibody only group, 60% (3/5) of graft 
losses occurred in the first year and the subsequent rate of graft loss averaged only 
1.6% per year in the 5 year study period. This is comparable with the rate of graft loss 
in the –XMKTx group (2.9% per year). In the Class I only group, patients who had a CDC- 
crossmatch had graft survival similar to that of –XMKTx recipients (93.3% vs. 88.0%, 
p=0.51). In contrast, antibody against donor Class II was associated with a higher rate of 
graft loss in the 5 year follow up (7.0% per year in the Class II/I combined group).  
 The higher 5-year graft survival of Class I alone vs Class II/I recipients did not appear to 
be due to differences in antibody levels, in as much as it is possible to assess antibody 
levels on the basis of binding to the Luminex beads (Figure 4.2). Also, there was no 
statistical difference in graft survival between CDC+ and CDC- patients with Class II 
antibodies (54.3% vs. 66.2%, p=0.23).  
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Figure 4.1 Five-year outcomes after Positive Crossmatch Live Donor Kidney Transplant 
(+XMKTx.)  
 Actual 5 year outcomes are shown for +XMKTx including patient survival (Panel A); overall 
death-censored graft survival (Panel B); graft survival by baseline crossmatch assay type 
(+XMKTx recipients who were CDC+ vs CDC-, Panel C); and graft survival by donor-specific HLA 
specificity (+XMKTx recipients with antibody against donor Class I only, Class II only and both 
Class I and II, Panel D).  
Patient numbers at each time point for survival are tabulated in each graph. 
A.   5-year Patient Survival 
 
B. 5-Year Overall Graft Survival  
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C.  Graft Survival by Crossmatch Assay (CDC+ vs CDC-/FXM+) 
 
D.  Graft Survival by Donor-Specific HLA Antibody Specificity 
 
 
 
 
 
 
 
 
183 
 
E.  Graft Survival by Donor-Specific HLA Antibody Specificity and early AMR 
episode 
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In general, baseline antibody levels by solid phase were similar in grafts that survived 
compared with grafts that failed (Figure 4.2).  The exception was in the presence of anti-
Class II antibody, lower levels (median fluorescence intensity of <3000) had better 
survival compared to those with higher levels (5-year DCGS 86.7% vs. 54.6%, p=0.05). 
There was no significant difference in 5-year outcomes comparing DSA against HLA-DR 
or HLA-DQ. Causes of graft loss in Class I only and Class II/I groups were similar, with 
60% related to transplant glomerulopathy overall (Class I 60.0% (3/5) vs Class II/I 
60.9% (14/23), p=0.97).  
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Figure 4.2. Anti-Donor Antibody Levels and Outcome by Specificity for Donor  HLA.  
Antibody levels against donor Class I HLA were similar in the Class I only group and the Class 
II/I group (Panel A).  For Class I, antibody levels were similar in surviving and failed allografts.  
Antibodies against donor Class II were absent in Class I group (Panel B).  The mean antibody 
levels were higher in Class II/I CDC-/FXM+  grafts that failed compared to those that survived 
(median 11747 [2098-23293] vs. 4420 [1140-16729], p=0.018, Wilcoxon rank-sum test) 
denoted in the graph by *. Scatterplots of anti-donor antibody levels as determined by solid 
phase assay and expressed as mean fluorescence intensity demonstrate distribution across 
surviving and failed grafts at 5 years.  
 
The different antibody groups are represented by different colours. Green circles are Class I 
only; orange circles are Class II only and Red circles are Class I + II. Data are expressed with 
median and interquartile ranges.  
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4.3.3 Antibody-Mediated Rejection 
The incidence of antibody-mediated rejection (AMR) was 37.2% (n=38) in the +XMKTx 
group and 2.5% (n=5) in the –XMKTx group.  Early AMR was less common in the Class II 
only group (15%) compared to either the Class I only (38.9%, p=0.06) or recipients with 
both Class I and II (45.7%, p=0.02). +XMKTx patients with an episode of AMR had lower 
graft survival compared to those without early AMR (53.2% vs. 81.2%, p<0.01) (Figure 
4.1E). 
4.3.4 Renal Function and Proteinuria at 5 Years 
Renal function in the +XMKTx at 5 years spanned a wide spectrum and was not 
significantly different from –XMKTx (Figure 4.3A+B) [+XMKTx mean estimated 
glomerular filtration rate (eGFR) = 44.4±19.6 ml/min, vs. -XMKTx mean eGFR = 
48.5±17.9, p=0.22)].  At 5 years, the percentage of surviving grafts with good function 
(GFR >40 ml/min) also was similar in +XMKTx vs. –XMKTx. (52.4% vs. 64.6%, p=0.09).    
 Proteinuria (24-hour urinary protein excretion), has been associated with 
chronic antibody-mediated injury [251].  At 5 years, the median 24-hour urine protein 
excretion was higher in the +XMKTx vs. –XMKTx patients (277 (range 23-10826) vs. 
91.5 (range 14-7784), p<0.01 Wilcoxon rank-sum test; Figure 4.3C + D).  In the +XMKTx, 
44.4% (n=20/44) of patients had 24-hour urinary protein excretion greater than 
500mg/24hrs compared to only 13.8% (n=18/130, p<0.01) in –XMKTx at 5 years. 
Proteinuria was significantly associated with the presence of transplant glomerulopathy 
at both 1-year (‘CG=0’ 108[range 26-7788] vs. ‘CG>0’ 496 [range 75-9997],p<0.01 ) and 
5-year(‘CG=0’ 72 [range 23-522]  vs. ‘CG>0’ 694 [range 49-10826] ,p<0.01). The level of 
proteinuria at 1-year was significantly higher in patients with no CG at 1 year biopsy 
A 
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who went on to develop CG by the 5 year biopsy (‘5-year CG=0’ 76 [range 26-229] vs. ‘5-
year CG >0’ 134 [range 26-2405], p<0.01) by light microscopy. 
 
 
Figure 4.3. Renal Function and Proteinuria after +XMKTx.  
Estimated glomerular filtration rate (eGFR) by MDRD at 1 (Panel A) and 5 years (Panel B) after 
transplantation with mean eGFR shown by green line.  Twenty-four hour urine protein 
excretion (mg/day) at 1 (Panel C) and 5 years (Panel D) after transplantation with box and 
whisker plot. Comparisons of data made using Student’s t-test for eGFR and Wilcoxon rank-sum 
test for proteinuria. 
A. Renal function at 1 year   B.  Renal function at 5 years 
 
C. Proteinuria 1 year    D.  Proteinuria at 5 years  
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4.3.5 Allograft Histology at 1 and 5 Years 
Similar to functional data, allograft histology provides insight into the extent of injury in 
functioning allografts. At 1 year after transplantation, surveillance biopsies were 
obtained in 75.1% (142/189) of the –XMKTX; 77.4% (24/31) of the Class I only group; 
and 80.4% (45/56) of the Class II/I group. The entire dataset is presented in Table 4.2. 
At 1 year, chronic glomerulopathy (cg, score >0), a histologic finding associated with 
chronic antibody mediated injury, was more common in +XMKTX compared to –XMKTX 
(27.5% vs 3.5%, p<0.0001, Table 4.2). CG was more common in the Class II/I group 
compared to Class I only (37.8% vs. 8.4%, (p=0.009) at 1 year, and was only seen in 
Class II/I patients with DSA MFI>3000(n=50) at the time of transplantation. By 5 years, 
the prevalence of CG within the Class II/I group was not predicted by baseline MFI 
(MFI<3000 - 50% vs. 62.5%, p=0.34).  In all biopsies, acute glomerulitis at 1 year was 
common in +XMKTx occurring in 44.4% of Class II/I patients, significantly higher than 
20.9% of Class I patients (p=0.05) and 7.7% of –XMKTX patients. In contrast to acute 
glomerulitis, acute peritubular capillaritis (ptc) was not significantly different between 
Class I or Class II/I patients at 1 year (53.3% vs. 75%, p=0.14) but at 5 years this was 
significantly different (45.5% vs. 91.3%, p=0.003, Table 4.3). There was no difference in 
peritubular capillaritis between Class II/I patients with DSA MFI>3000 and those <3000 
at 1 year (73.9% vs. 77.8%, p=0.82).  Interstitial fibrosis (ci) was similar in all groups at 
1 year (range 52.1 to 68.9%). By 5 years, the prevalence of cg had increased to 58.3% in 
the Class II/I group, 50.0% in the Class I group and was only 7.7% in the –XMKTX. In the 
+XMKTx cohort, the presence of CG at 1 year was associated with graft loss in 30.4% 
(n=7) of Class II/I patients at 5 years and 20% (n=1) Class I patient. In contrast, in the 
absence of CG at 1 year graft survival was >80% by 5 years in the +XMKTx cohort. 
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Table 4.2. All biopsy histological Banff scores from each cohort at 1 year biopsies  
 12 month TOTAL 12 month TOTAL 12 month TOTAL 12 month TOTAL 
 -XMKTx +XMKTx Class I Class II/I 
None g 92.3% (n = 131) g 63.8% (n = 44) g 79.2% (n = 19) g 55.6% (n = 25) 
Mild  N=142 5.6% (n = 8)  N=69 20.3% (n = 14)  N=24 16.7% (n = 4)  N=45 22.2% (n = 10) 
Mod-Sev   2.1% (n = 3)   15.9% (n = 11)   4.2% (n = 1)   22.2% (n = 10) 
None i 82.4% (n = 117) i 82.6% (n = 57) i 83.3% (n = 20) i 82.2% (n = 37) 
Mild  N=142 11.3% (n = 16)  N=69 10.1% (n = 7)  N=24 8.3% (n = 2)  N=45 11.1% (n = 5) 
Mod-Sev   6.3% (n = 9)   7.2% (n = 5)   8.3% (n = 2)   6.7% (n = 3) 
None t 76.1% (n = 108) t 62.3% (n = 43) t 75.0% (n = 18) t 55.6% (n = 25) 
Mild  N=142 16.2% (n = 23)  N=69 30.4% (n = 21)  N=24 16.7% (n = 4)  N=45 37.8% (n = 17) 
Mod-Sev   7.7% (n = 11)   7.2% (n = 5)   8.3% (n = 2)   6.7% (n = 3) 
None v 100.0% (n = 142) v 100.0% (n = 69) v 100.0% (n = 24) v 100.0% (n = 45) 
Mild  N=142 0.0% (n = 0)  N=69 0.0% (n = 0)  N=24 0.0% (n = 0)  N=45 0.0% (n = 0) 
Mod-Sev   0.0% (n = 0)   0.0% (n = 0)   0.0% (n = 0)   0.0% (n = 0) 
None ah 83.2% (n = 109) ah 76.6% (n = 49) ah 81.8% (n = 18) ah 73.8% (n = 31) 
Mild  N=131 13.7% (n = 18)  N=64 21.9% (n = 14)  N=22 18.2% (n = 4)  N=42 23.8% (n = 10) 
Mod-Sev   3.1% (n = 4)   1.6% (n = 1)   0.0% (n = 0)   2.4% (n = 1) 
None cg 96.5% (n = 137) cg 72.5% (n = 50) cg 91.7% (n = 22) cg 62.2% (n = 28) 
Mild  N=142 2.1% (n = 3)  N=69 15.9% (n = 11)  N=24 4.2% (n = 1)  N=45 22.2% (n = 10) 
Mod-Sev   1.4% (n = 2)   11.6% (n = 8)   4.2% (n = 1)   15.6% (n = 7) 
None ci 47.9% (n = 68) ci 36.2% (n = 25) ci 45.8% (n = 11) ci 31.1% (n = 14) 
Mild  N=142 38.0% (n = 54)  N=69 47.8% (n = 33)  N=24 45.8% (n = 11)  N=45 48.9% (n = 22) 
Mod-Sev   14.1% (n = 20)   15.9% (n = 11)   8.3% (n = 2)   20.0% (n = 9) 
None ct 33.8% (n = 48) ct 26.1% (n = 18) ct 37.5% (n = 9) ct 20.0% (n = 9) 
Mild  N=142 52.1% (n = 74)  N=69 56.5% (n = 39)  N=24 54.2% (n = 13)  N=45 57.8% (n = 26) 
Mod-Sev   14.1% (n = 20)   17.4% (n = 12)   8.3% (n = 2)   22.2% (n = 10) 
None cv 59.2% (n = 84) cv 62.3% (n = 43) cv 62.5% (n = 15) cv 62.2% (n = 28) 
Mild  N=142 36.6% (n = 52)  N=69 33.3% (n = 23)  N=24 33.3% (n = 8)  N=45 33.3% (n = 15) 
Mod-Sev   4.2% (n = 6)   4.3% (n = 3)   4.2% (n = 1)   4.4% (n = 2) 
None mm 84.2% (n = 16) mm 63.6% (n = 7) mm 100.0% (n = 1) mm 60.0% (n = 6) 
Mild  N=19 10.5% (n = 2)  N=11 27.3% (n = 3)  N=1 0.0% (n = 0)  N=10 30.0% (n = 3) 
Mod-Sev   5.3% (n = 1)   9.1% (n = 1)   0.0% (n = 0)   10.0% (n = 1) 
None C4d 90.0% (n = 9) C4d 85.0% (n = 51) C4d 100.0% (n = 23) C4d 75.7% (n = 28) 
Mild  N=10 10.0% (n = 1)  N=60 3.3% (n = 2)  N=23 0.0% (n = 0)  N=37 5.4% (n = 2) 
Mod-Sev   0.0% (n = 0)   11.7% (n = 7)   0.0% (n = 0)   18.9% (n = 7) 
None ptc   ptc 31.9% (n =15) ptc 46.7% (n = 7) ptc 25.0% (n = 8) 
Mild #    N=47 17.0% (n =8)  N=15 13.3% (n = 2)  N=32 18.8% (n = 6) 
Mod-Sev       51.1% (n = 24)   40.0% (n = 6)   56.3% (n = 18) 
All histological scores are according to the Banff 2005 and then Banff 2007 classification for grading 
kidney transplant allograft biopsies [142, 148]. Biopsy data that is not cumulative to total number of 
biopsy means that the biopsy material was not available for analysis. #The biopsies of –XMKTx were not 
re-examined to address ‘ptc’ in this cohort.   
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Table 4.3. All biopsy histological Banff scores from each cohort at 5 year biopsies 
 
 
60 month TOTAL 60 month TOTAL 60 month TOTAL 60 month TOTAL 
 -XMKTx +XMKTx Class I Class II/I 
None g 85.6% (n = 89) g 33.3% (n = 12) g 33.3% (n = 4) g 33.3% (n = 8) 
Mild  N=104 10.6% (n = 11)  N=36 25.0% (n = 9)  N=12 16.7% (n = 2)  N=24 29.2% (n = 7) 
Mod-Sev   3.8% (n = 4)   41.7% (n = 15)   50.0% (n = 6)   37.5% (n = 9) 
None i 86.5% (n = 90) i 72.2% (n = 26) i 58.3% (n = 7) i 79.2% (n = 19) 
Mild  N=104 11.5% (n = 12)  N=36 22.2% (n = 8)  N=12 33.3% (n = 4)  N=24 16.7% (n = 4) 
Mod-Sev   1.9% (n = 2)   5.6% (n = 2)   8.3% (n = 1)   4.2% (n = 1) 
None t 96.2% (n = 100) t 83.3% (n = 30) t 75.0% (n = 9) t 87.5% (n = 21) 
Mild  N=104 3.8% (n = 4)  N=36 13.9% (n = 5)  N=12 25.0% (n = 3)  N=24 8.3% (n = 2) 
Mod-Sev   0.0% (n = 0)   2.8% (n = 1)  0.0% (n = 0)  4.2% (n = 1) 
None v 100.0% (n = 104) v 100.0% (n = 35) v 100.0% (n = 12) v 100.0% (n = 23) 
Mild  N=104 0.0% (n = 0)  N=35 0.0% (n = 0)  N=12 0.0% (n = 0)  N=23 0.0% (n = 0) 
Mod-Sev   0.0% (n = 0)   0.0% (n = 0)   0.0% (n = 0)   0.0% (n = 0) 
None ah 34.3% (n = 35) ah 13.9% (n = 5) ah 25.0% (n = 3) ah 8.3% (n = 2) 
Mild  N=102 41.2% (n = 42)  N=36 44.4% (n = 16)  N=12 50.0% (n = 6)  N=24 41.7% (n = 10) 
Mod-Sev   24.5% (n = 25)   41.7% (n = 15)   25.0% (n = 3)   50.0% (n = 12) 
None cg 92.3% (n = 96) cg 44.4% (n = 16) cg 50.0% (n = 6) cg 41.7% (n = 10) 
Mild  N=104 1.0% (n = 1)  N=36 13.9% (n = 5)  N=12 16.7% (n = 2)  N=24 12.5% (n = 3) 
Mod-Sev   6.7% (n = 7)   41.7% (n = 15)   33.3% (n = 4)   45.8% (n = 11) 
None ci 37.9% (n = 39) ci 8.3% (n = 3) ci 16.7% (n = 2) ci 4.2% (n = 1) 
Mild  N=103 46.6% (n = 48)  N=36 61.1% (n = 22)  N=12 58.3% (n = 7)  N=24 62.5% (n = 15) 
Mod-Sev   15.5% (n = 16)   30.6% (n = 11)   25.0% (n = 3)   33.3% (n = 8) 
None ct 34.0% (n = 35) ct 8.3% (n = 3) ct 16.7% (n = 2) ct 4.2% (n = 1) 
Mild  N=103 50.5% (n = 52)  N=36 61.1% (n = 22)  N=12 58.3% (n = 7)  N=24 62.5% (n = 15) 
Mod-Sev   15.5% (n = 16)   30.6% (n = 11)   25.0% (n = 3)   33.3% (n = 8) 
None cv 41.3% (n = 43) cv 20.0% (n = 7) cv 25.0% (n = 3) cv 17.4% (n = 4) 
Mild  N=104 37.5% (n = 39)  N=35 45.7% (n = 16)  N=12 41.7% (n = 5)  N=23 47.8% (n = 11) 
Mod-Sev   21.2% (n = 22)   34.3% (n = 12)   33.3% (n = 4)   34.8% (n = 8) 
None mm 71.7% (n = 33) mm 52.6% (n = 10) mm 66.7% (n = 4) mm 46.2% (n = 6) 
Mild  N=46 26.1% (n = 12)  N=19 26.3% (n = 5)  N=6 16.7% (n = 1)  N=13 30.8% (n = 4) 
Mod-Sev   2.2% (n = 1)   21.1% (n = 4)   16.7% (n = 1)   23.1% (n = 3) 
None C4d 92.3% (n = 36) C4d 78.8% (n = 26) C4d 83.3% (n = 10) C4d 76.2% (n = 16) 
Mild  N=39 0.0% (n = 0)  N=33 6.1% (n = 2)  N=12 16.7% (n = 2)  N=21 0.0% (n = 0) 
Mod-Sev   7.7% (n = 3)   15.2% (n = 5)   0.0% (n = 0)   23.8% (n = 5) 
None ptc # 89.6% (n = 60) ptc 23.5% (n = 8) ptc 54.5% (n = 6) ptc 8.7% (n = 2) 
Mild  N=67 4.5% (n = 3)  N=34 26.5% (n = 9)  N=11 27.3% (n = 3)  N=23 26.1% (n = 6) 
Mod-Sev   6.0% (n = 4)   50.0% (n = 17)   18.2% (n = 2)   65.2% (n = 15) 
 
All histological scores are according to the Banff 2007 classification for grading kidney transplant 
allograft biopsies [142]. # The biopsies of –XMKTx were not re-examined to address ‘ptc’ in this cohort. 
Biopsy data that is not cumulative to total number of biopsy means that the biopsy material was not 
available for analysis.   
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Table 4.4. Summary of Histologic Lesions Commonly Associated with anti-HLA 
Antibody  
The overall incidence of histologic changes commonly-associated with anti-HLA antibody found 
on paired surveillance biopsies obtained at 1 and 5 years after transplantation are shown.   
 
Class I 1 year peritubular capillaritis shows only 9 biopsies in the paired analysis, as the 1 year 
biopsy for 1 patient was unavailable for review for interpreting peritubular capillaritis 
  
 Chronic 
glomerulopathy 
Acute glomerulitis Peritubular 
capillaritis 
 1 yr 5 yr 1 yr 5 yr 1 yr 5 yr 
-XMKTx 4.2% 
(4/95) 
7.4% 
(7/95) 
7.4% 
(7/95) 
14.7% 
(14/95) 
Not done Not done 
+XMKTx 21.2% 
(7/33) 
54.5% 
(18/33) 
30.3% 
(10/33) 
63.6% 
(21/33) 
63.3% 
(19/30) 
76.5% 
(24/32) 
Class I 10% 
(1/10) 
50% 
(5/10) 
20%  
(2/10) 
50% 
(6/10) 
55.5%   
(5/9) 
40% 
(4/10) 
Class II/I 26.1% 
(6/23) 
56.5% 
(13/23) 
34.7% 
(8/23) 
65.2% 
(15/23) 
66.6% 
(14/21) 
90.9% 
(20/22) 
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4.3.6 Paired Allograft Histology at 1 and 5 Years 
The data from the subset of patients who were biopsied at both 1 and 5 years (paired 
biopsies) might also yield data regarding the progression of antibody-mediated injury. 
Of the grafts that survived 5 years, paired surveillance biopsies at both 1 and 5 years 
were available for analysis in 56% (n=95) of the –XMKTx and 52% (n=33) +XMKTx.  At 
1 year, the prevalence of chronic glomerulopathy was 21.2% in +XMKTx and only 4.2% 
in –XMKTx (Table 4.3). This increased to 54.5% and 7.4% respectively by 5 years. At 5 
years, chronic glomerulopathy was equally common in grafts in the Class I only group 
and in the Class II/I group. Importantly, slightly more than half of all +XMKTx patients 
(15/26) with no cg at 1 year also had no cg at 5 years (50% (5/10) of patients in the 
Class I group and 43.5% (10/23) of patients in the Class II/I group).  Figure 4.4 shows 
the actual Banff scores in paired biopsies obtained at 1 and 5 years in +XMKTx.  These 
data show that in addition to an increase in the prevalence of glomerulopathy between 
1 and 5 years, the severity also increased in these patients with CG (Figure4.4A).  
However, at 5 years, 50% of the Class I only group and 43.5% of the Class II/I group had 
no evidence of chronic glomerulopathy.  
The prevalence and severity of inflammatory changes associated with antibody-
mediated injury (glomerulitis and peritubular capillaritis) increased from 1 to 5 years in 
+XMKTx (Figure 4.4B and Figure 4.4C).  Interstitial fibrosis and tubular atrophy also 
was commonly seen, but was mild in many cases (Figure 4.4D and Figure 4.4E). See 
Tables 4.2 and 4.4 for all biopsy data. 
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Figure 4.4.Detailed Histologic Score at 1 and 5 years in Paired Biopsies in 
+XMKTx.  
Actual Banff scores at 1 and 5 years in paired biopsies in +XMKTx showing chronic 
glomerulopathy (Panel A); glomerulitis (Panel B), peritubular capillaritis (Panel C), interstitial 
fibrosis (Panel D) and tubular atrophy (Panel E).    
A.  Chronic glomerulopathy 
 
B.  Glomerulitis 
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C.  Peritubular capillaritis 
 
D.  Chronic interstitial fibrosis 
 
E.  Tubular atrophy 
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4.3.7 Outcomes of +XMKTx Excluded.  
In addition to the 102+XMKTx studied above, we excluded 52 +XMKTx including: 8 lost 
to follow-up prior to 5 years; 12 CDC+ patients who did not achieve a negative CDC- 
crossmatch by the day of transplantation (5-year DCGS was 41.7% and all surviving 
grafts developed CG); 16 (1 CDC+, 15 FXM+) had no DSA detected by solid phase assay 
(the 5 year DCGS was 93.8% and none of the grafts developed CG); 5 had an MFI <1000 
(the 5 year DCGS was 100%) and 11 had no pre-transplant sera stored for DSA testing 
(5 year DCGS was 62.3%). 
4.4 Discussion 
In this study, the actual 5-year outcomes of +XMKTx were retrospectively analysed.  
These results show 5-year patient survival of 83.5% were similar to those of HLA-
incompatible kidney transplant recipients recently reported by the Johns Hopkins 
group [24]. The overall 5-year graft survival of 70.7% was similar to that of FXM+ living 
donors at the University of Maryland (70%  in 19 patients followed to 5 years) and in 
deceased donors with donor-specific antibodies at Hôpital Saint-Louis de Paris (70% in 
30 patients followed 5 years) [185, 252].  
 The current study supports prior studies showing that CDC+ allografts with high 
levels of anti-Class I antibody have a high rate of early graft loss [94].  However, our 
study suggests that the anti-HLA specificity may have an even greater impact on long-
term graft survival.  Most of the graft losses in the Class I only group occurred in the first 
year and the rate of graft loss between 1 and 5 years was similar to –XMKTx.  In 
contrast, Class II DSA appears associated with a low rate of early AMR (15% in those 
with Class II only), yet a high rate of chronic injury with more than 40% of allografts 
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failing within the first 5 years after transplantation. Patients with antibody against both 
donor Class I and II (almost half of the +XMKTx cohort) had similar poor long-term 
outcomes as patients with Class II only. The rate of allograft loss is associated with the 
presence of CG at an earlier stage in the Class II/I group, compare with that of the Class I 
only group. The whole group histology at 1 year demonstrates 37.8% in Class II/I group, 
compared to only 8.3% in the Class I only cohort (p<0.01).  Overall, if 1 year CG is 
present it is highly associated with graft failure at 5 years (42.1% vs 12%, p<0.01). The 
development of proteinuria in allografts at 1 year without histology evidence by light 
microscopy of CG was a good predictor of the development of CG at 5 years. 
 The cohort in this study was from the early “era” of the positive crossmatch 
transplant program at Mayo Clinic, USA. More recent data has shown a trend toward 
fewer graft losses in the first year after transplantation.  This is likely due to many 
different protocol changes including improved DSA monitoring.  However, the actual 
graft survival data presented here reflects the true incidence of chronic injury that 
occurs over time in +XMKTx—especially in patients with anti-Class II DSA. 
The functional and histologic data provide important additional insight into the 
outcomes of +XMKTx. Chronic glomerulopathy was common at 1 year and increased 
over time in patients with anti-donor HLA antibody. Similar to the findings of Haas et al 
and Loupy et al, chronic inflammation (peritubular capillaritis and glomerulitis) also 
was extremely common at 1 and 5 years after +XMKTx  [161, 253, 254].  An encouraging 
finding from the histology data was that approximately half of the biopsies at 5 years 
showed no evidence of transplant glomerulopathy suggesting that some grafts may 
avoid chronic antibody-mediated injury.  Conversely, a worrisome finding is the 
increasing prevalence of inflammation and glomerulopathy from 1 to 5 years in the 
Class I only group suggesting that despite having survived 5 years, these grafts may still 
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be destined to fail from chronic injury. Since more grafts with Class II DSA were lost in 
the first 5 years after transplantation, the negative impact of Class II DSA on graft 
histology is potentially underestimated by the paired histologic data presented. 
 A limitation of this study is that post-transplant anti-donor antibody data were 
not available for sufficient number of patients to be analyzed in this study.  Longitudinal 
studies correlating antibody levels and specificity with outcomes after +XMKTx are 
needed. In addition, the histologic data at 5 years should be interpreted with some 
caution because only 52% of eligible patients underwent paired surveillance biopsies. 
 Sensitization to HLA is a major problem affecting approximately 30% of wait-
listed kidney transplant candidates. The results of this study have important 
implications in both informed consent for patients and for the development of protocols 
for the management of renal transplant candidates with anti-HLA antibodies. The data 
suggest that protocols designed to enhance the transplantation rate and outcomes of 
sensitized patients should consider the presence of antibody against donor Class II HLA 
in their algorithms and the sole reliance on a negative CDC crossmatch is insufficient. 
When available, both paired donation and acceptable mismatch programs are important 
and viable options for some sensitized patients. Most, if not all, sensitized candidates 
should be entered into a paired donor program for at least a short period of time. 
However, despite these efforts, many sensitized candidates will never be matched with 
a donor against whom they have no antibody [19].   Thus, a +XMKTx may be the only 
realistic option for transplantation. While many of the grafts in +XMKTx may fail within 
5 years necessitating another kidney transplant, others will show no signs of chronic 
injury.  Given the expected good outcome, +XMKTx patients with antibody against 
donor Class I only that are CDC- might be considered relatively low risk and thus 
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transplanted without a prolonged wait in the paired or acceptable mismatch programs. 
The same consideration also applies to +XMKTx patients with antibodies against Class II 
with MFI < 3000 who also comprise a lower-risk group within the +XMKTx population.  
Finally, the study highlights the fact that chronic injury affects the majority of +XMKTx 
in the first five years leading to a very high rate of graft loss. Thus, these data clearly 
suggest that the prevention and treatment of chronic antibody-mediated injury should 
be a major focus of future research. 
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Chapter 5  Differences in Chronic Intragraft Inflammation between 
Positive Crossmatch and ABO Incompatible Kidney Transplants 
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This chapter has been published in Transplantation[255]. 
5.1 Introduction  
While anti-donor antibody is present in both ABOiKTx and +XMKTx, their long-term 
outcomes appear to be quite different.  Anti-HLA antibody, especially against donor 
Class II, is associated with a high rate of chronic injury which presents histologically as 
chronic transplant glomerulopathy (cg) and commonly progresses to graft loss [256].  
In contrast, ABOiKTx rarely develop cg and appear to have long-term graft survival 
similar to that of transplants without anti-donor antibody [93, 125, 189-191].  The 
causes of these divergent outcomes are unclear, however, several mechanisms have 
been suggested including the development of resistance to antibody mediated injury in 
ABOiKTx termed accommodation [177].   
In +XMKTx, recent studies have suggested that subclinical cellular infiltration by 
macrophages, neutrophils and lymphocytes in peritubular capillaries and glomeruli has 
a high correlation with chronic injury [147, 253].  Comparative data in ABOiKTx are 
lacking. 
The aim of the current study was compare the 5 year outcomes of ABOiKTx and 
+XMKTx with a specific emphasis on impact of histologic findings of surveillance 
biopsies on late outcomes.   
.   
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5.2 Methods  
This study was approved by the Institutional Review Board at the Mayo Foundation and 
Clinic, Rochester, Minnesota.  All live donor kidney transplant recipients that took place 
between May 1999 and December 2006 were reviewed and separated into 3 categories 
according to baseline anti-donor antibody status including: 1) Blood group 
incompatible (ABOi) recipients with negative crossmatch; 2)Positive crossmatch 
(+XMKTx) recipients—i.e. those with donor-specific alloantibody (DSA) at high enough 
levels to achieve a positive crossmatch (either T and/or B cell flow cytometric 
crossmatch as described in chapter 4) against their living donor at baseline; and 3) 
Conventional kidney transplants that were both ABO blood group compatible and had a 
negative crossmatch at the time of transplant (conventional KTx). Recipients who were 
both ABOi and +XMKTx were excluded (n=4). 
During this time period, an ABO incompatible kidney transplant was offered to all 
candidates whose only living donor was blood group incompatible.  The cutoff for 
accepting recipients in this setting was an anti-blood group titer of ≤ 1:512.  A positive 
crossmatch kidney transplant was offered to any sensitized patient who had a positive 
crossmatch against their living donor.  The cutoff for accepting recipients in this setting 
was the ability to achieve a negative T cell AHG crossmatch on the day of 
transplantation.  
5.2.1 Populations 
Within these cohorts, patients were included for further analysis if they had a 
surveillance biopsy performed at 1 year following day of transplant (median days (Q1-
Q3) 371 [361-393]). Of the seventy three ABOiKTx performed, 65 patients survived 1 
year and there were 56.9% (37/65) had protocol biopsies performed at 1 year. One 
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hundred and two +XMKTx were reviewed which had been performed during the same 
time period and 75.0% (69/92) had a 1-year protocol biopsies performed.  Finally, as a 
control cohort, 652 ABO compatible, -XMKTx living donor kidney recipients 
transplanted during the same time period were included of which 67.4% (416/617) 
patients had protocol biopsies performed at 1year. These populations are shown in 
Figure 5.1. 
 
Figure 5.1. Population of transplant recipients in each antibody category included 
in this study who were available to be studied at 1 year allograft  survival.  
 
 
5.2.2 Antibody Measurement 
Baseline (i.e. prior to any therapy) anti-HLA antibody levels were determined at the 
time of transplantation using a combination of cytotoxicity assays (T cell anti-human 
globulin CDC crossmatch) and T cell and B cell flow cytometric crossmatch (TFXM and 
BFXM) as previously described [69, 70, 257].  The solid-phase, single antigen bead assay 
1 year biopsy data 
37 patients 
1 year graft survival 
65 patients  
ABOiKTx 
73 patients  
1 year biopsy data 
69 patients 
1 year graft survival 
88 patients  
+XMKTx 
102 patients  
1 year biopsy data 
416 patients 
1 year graft survival 
598 patients  
Conventional KTx 
652 patients  
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was not available during the entire study period, so for some patients, the 
determination of the presence of donor-specific alloantibody (DSA) was determined 
retrospectively using LABscreen (One Lambda, Canoga Park, CA).   
 Anti-blood group antibody was determined using isohemagglutination using 
AHG [191].  Single antigen bead testing was not carried out on the –XMKTx or ABOiKTx 
recipients at time of transplant.  
5.2.3 Immunosuppression and Desensitization 
All patients received induction immunosuppression with rabbit polyclonal anti-
lymphocyte antibodies (Thymoglobulin™, Sangstadt, Menlo Park, CA, USA; 1.5mg/kg per 
day 4–10 doses), tacrolimus (Prograf™, Fujisawa, Deerfield, IL, USA), mycophenolate 
mofetil (750–1000 mg twice daily) (Cellcept™, Roche, Nutley, NJ, USA) and prednisone 
(tapering doses reaching 5 mg daily by month 3). The dose of tacrolimus was adjusted 
to achieve trough levels of 10–12 ng/mL (High-performance Liquid Chromatography/ 
Tandem Mass Spectrometry technique) during the first 4 months after transplantation 
and 6–8 ng/mL thereafter. 
In addition to the conventional immunosuppression described above, recipients of 
ABOiKTx underwent pre-transplant conditioning and post-transplant management 
using a protocol reported previously [191]. The pre-conditioning consisted of plasma 
exchange (PE) followed by low-dose intravenous immunoglobulin (IVIG, 100 mg/kg 
after each PE (Gamimune 10%:Bayer Pharmaceutical, Elkhart, IN, USA or Venoglobulin-
S-10%, Alpha Therapeutic Corporation, Los Angeles, CA, USA)) with a goal of achieving 
an anti-donor blood group antibody titer ≤1:8 on day of transplant. 
Recipients of +XMKTx with a positive T-cell AHG-CDC at baseline underwent pre-
transplant conditioning using a protocol described previously which is similar to that 
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described for ABOiKTx recipients [144, 186]. The goal of PE/IVIG in these patients was 
to achieve a negative T-cell AHG-CDC crossmatch on the day of transplantation. 
Individuals  with a negative CDC but positive FXM received IVIG (Venoglobulin-S 10%, 
Alpha Therapeutic Corporation or Gamimune N, 10%, Bayer Biological, Elkhart, IN) at 2 
g/kg immediately prior to transplantation, and did not undergo PE. This cohort has 
been previously well described [144, 257].  
5.2.4 Biopsy and Clinical Outcomes 
Patients underwent surveillance biopsies at 1 and 5 years after transplantation. A 
percutaneous ultrasound guided 18 gauge biopsy gun (Bard, Murray Hill, NJ) was used.  
Biopsies were interpreted using Banff 1995 criteria. Peritubular capillaritis (PTC) 
scores were reviewed by a single renal pathologist blinded to the clinical information 
using recent Banff 2007 criteria for both the +XMKTx and the ABOiKTx cohorts [142, 
148].   
Biopsy data were classified according to each category of the Banff criteria where a 
score of 0 was classified “none” ; a score of 1 as “mild” and a score greater than 1 as 
“moderate to severe”.  Graft failure was defined as the need for maintenance dialysis 
therapy or the need for retransplantation.  Glomerular filtration rate (eGFR, 
ml/min/m2) was estimated using the 4 variable Modification of Diet in Renal Disease 
(MDRD) equation [258].  
5.2.5 Statistical Analysis 
Analyses were performed using JMPv9. (SAS, Cary, NC, USA) using the Kruskal–Wallis/ 
Wilcoxon rank-sum test, Pearson and Student’s t-tests according to the nature and 
distribution of the data compared. Shapiro-Wilk test was used to assess normal 
distribution of these data. Differences in patient and graft survival were calculated by 
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the log-rank test.  Unless otherwise indicated, data are expressed as proportions or as 
mean ± standard deviation or median and range. Univariate and multivariate analysis 
was performed using a logistical regression model. Data for analysis of these patient 
cohorts was censored at 1st January 2012.  
5.3 Results  
5.3.1. Study Population 
The study population included 73 ABOiKTx, 102 +XMKTx and 652 Conventional KTX 
(i.e. ABO compatible/-XMKTx) living donor kidney recipients.  All patients were at least 
5 years after the day of transplantation surgery.  The demographics of the three groups 
are compared in Table 5.1. Compared to +XMKTx, ABOiKTx had increased recipient age 
(50.6 ± 14.5 vs. 46.3 ± 12.0, p=0.029); fewer females (35.6% vs. 69.6%, p<0.001); older 
donor age (45.1 ± 11.2 vs. 40.0 ± 13.0, p=0.048); more pre-emptive transplants (60.3% 
vs. 18.6%, p<0.001) and fewer re-transplants (17.8% vs. 39.2%, p=0.003).  Patients in 
the ABOiKTx and +XMKTx groups were on dialysis longer prior to transplant 
(Respective median(Q1-Q3) time 18(11-52) months vs. 23(11-52) months, p=0.231) 
compared to Conventional KTx (Median (Q1-Q3) 9(4-20) months; ABOiKTx p=0.004 
and +XMKTx p<0.001, respectively).  
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Table 5.1. Demographics and immunological profile in the 3 cohorts of transplant 
recipients in this study 
 
Conventional 
KTx 
+XMKTx ABOiKTx 
      
  652 102 73 
 Con vs. 
ABOi 
 Con vs. 
+XM 
ABOi 
vs. 
+XM 
Age (years) Mean±StDev 51.1 ± 14 46.3 ± 12 50.6 ± 14.5 0.862 <0.001 0.029 
Gender(Female) %(n) 43.7% (285) 69.6% (71) 35.6% (26) 0.271 <0.001 <0.001 
Ethnicity=Caucasian %(n) 92.9% (606) 96.1% (98) 93.2% (68) 0.948 0.237 0.387 
Retransplant %(n) 14.7% (96) 39.2% (40) 17.8% (13) 0.423 <0.001 <0.001 
ABDR mismatch  
Median (Q1-Q3) 
3 (2-4) 3 (3-5) 3 (2-5) 0.381 <0.001 0.141 
Pre-emptive %(n) 48.2% (314) 18.6% (19) 60.3% (44) 0.050 <0.001 <0.001 
Dialysis time (months) 
Median (Q1-Q3) 
9.1  (4.0-19.9) 23.1  (11.1-52.2) 18 (9.8-35.8) 0.004 <0.001 0.231  
Living donor %(n) 100% (652) 100% (102) 100% (73) n/a n/a n/a 
              
AHGCDC Dilution        
Median (Q1-Q3)   
4  (1-64) 
        
CDC negative %(n)   59.8% (61)         
CDC positive %(n)   40.2% (41)         
TFXM Channel Shift 
Mean±StDev   
187 ± 124 
        
BFXM Channel Shift 
Mean±StDev   
330 ± 93 
        
Anti-Class I antibody only 
%(n)   
35.3% (36) 
        
Anti-Class II antibody only 
%(n)   
19.6% (20) 
        
Both anti-Class I & anti-class 
II antibody %(n)   
45.1% (46) 
        
Baseline Class I MFI     
Median (Q1-Q3)   
7378 
(2342-12363)         
Baseline Class II MFI    
Median (Q1-Q3)   
2735  
(0-10616)         
              
Recipient Blood group O %(n) 39.1% (255) 46.1% (47) 65.8% (48) <0.001 0.182 0.010 
Donor Blood group A %(n) 27.6% (180) 28.4% (29) 57.5% (42) <0.001 0.863 <0.001 
        
Follow up (days)  
Mean±StDev 
2891 ±968 2488 ± 911 2795 ± 1043 0.034 <0.001 0.228  
Donor age (years) 
Mean±StDev 
43.5 ± 11.6 41 ± 11.9 45.1 ± 11.2 0.221 0.048 0.043 
* comparison made between each group using Student’s t-test for parametric data; 
Wilcoxon rank-sum test for non-parametric continuous data and between each group 
using Pearson chi-squared analysis for categorical data.  
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5.3.2. Antibody Data 
The ABOiKTx cohort consisted of mainly blood group “O" recipients (48/73, 66.6%) of 
which 32 (68.7%) received a blood group “A” donor, 10 of which were A2 donors.  At 
baseline, the median anti-blood group antibody titer in ABOiKTx was 1:64 (range 1:1 -
1:512).  In the +XMKTx group, 40.2% (n=41) had a positive CDC crossmatch at baseline 
and 59.8% (n=61) had a negative CDC crossmatch, but a positive flow cytometric 
crossmatch with a channel shift >200.  The mean B flow cytometric channel shift was 
330 ± 93 and the mean T flow cytometric channel shift was 187 ± 124. In the +XMKTx 
group, 35.3% (n=36) had antibody against donor Class I HLA only, 19.6% (n=20) had 
antibody against donor Class II HLA only and 45.1% (n=46) had antibody against both 
donor Class I and Class II HLA.  The different outcomes of these +XMKTx based on target 
HLA class specificity have been reported previously [144, 186].  
5.3.3. Patient and Graft survival 
Patient survival at 5 years was not significantly different between the 3 groups:  
ABOiKTx (88.9%), +XMKTx (86.3%); and Conventional KTx (87.9%); (ABOiKTx vs. 
+XMKTx, p=0.165) (Figure 5.2a).  Actual 5 year death-censored graft survival (DCGS) 
was higher in ABOiKTx compared to the +XMKTx (79.5% and 70.7%, p= 0.03), but both 
were lower than Conventional KTx (86.7%) (Figure 5.2b). 
Importantly, in grafts surviving at least 1 year, the subsequent death censored graft 
survival (DCGS) between 1 and 5 years after transplantation was similar in the ABOiKTx  
and Conventional KTx (89.2% vs. 92.9%, p=0.155), and higher than +XMKTx (89.2% vs. 
77.6%, p=0.03; Figure 5.2c).   A calculation of these data is that the rate of graft loss in 
ABOiKTx between 1 and 5 years was 1.7%/year in Conventional KTx,  2.6%/year in 
ABOiKTx and 5.8%/year in the +XMKTx.  
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Figure 5.2 Five year outcomes for Patient and Graft Survival 
Conventional KTx are solid lines (    ); +XMKTx are dotted lines (···) and ABOiKTx are 
dashed lines (---).  Patient survival (Figure 5.2A) is comparable between groups while 
actual 5-year death-censored graft survival rates in antibody incompatible kidney 
transplants are inferior to conventional KTx (Figure 5.2B). While overall survival in 
ABOiKTx is similar at 5 years to +XMKTx, ABOiKTx allografts that survive to 1 year have 
significantly better outcome than +XMKTx (Figure 5.2C). 
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At baseline, data for transplant recipients was assessed using logistic regression to 
identify risk factors for 5 year allograft failure using the following variables: Pre-
emptive transplantation, Age at Transplantation, Age of Donor, ABDR mismatch, Re-
transplantation, Diabetes, Female Gender; Caucasian Ethnicity. The significant 
univariate factors are shown in Table 5.2A. The factors with p<0.1 were then used in a 
logistic regression analysis and results are shown in Table 5.2B. Increased Age at 
Transplant, Increased Age of Donor and Increased Length of time on dialysis were 
related to 5 year allograft failure.   
5.3.4. Renal Allograft Function 
Estimated GFR spanned a wide spectrum in all 3 groups at both 1 and 5 years after 
transplantation.  The mean eGFR was similar in all 3 groups at 1 year (Figure 5.3A) 
including Conventional KTx (49.4±15.5ml/min); ABOiKTx (51.4±13.4 ml/min, p=0.30 
vs. Conventional KTx) and +XMKTx (49.3ml/min, p=0.15 vs. ABOiKTx).  In patients 
whose allograft survived 5 years, using a paired comparison analysis, the mean eGFR 
between 1 and 5 years in the ABOi group remained stable (52.8+12.8ml/min to 
51.7+15.0ml/min, p=0.47) with similar function to the Conventional KTx (50.1±15.1 
ml/min to 48.1±16.9 ml/min, p=0.78).  In contrast, the mean eGFR declined in the 
+XMKTx group (51.4±16.7 ml/min to 44.4±19.6 ml/min, p=0.01).  In addition, at 1 and 5 
years, the proportion of patients with an eGFR <40 ml/min was higher in the +XMKTx 
group compared to the ABOiKTx group (1 year 32.8% vs. 17.0%, p=0.04 and 5 year 
48.8% vs. 19.2%%, p<0.01).  At 5 years (Figure 5.3B), in surviving transplants the mean 
eGFR was significantly lower in the +XMKTx group compared to ABOiKTx (44.8 ± 19.6 
ml/min vs. 51.7 ± 15.0 ml/min, p=0.04) although the difference with Conventional KTx 
(48.5 ± 16.5ml/min, p=0.09) did not reach statistical significance. Thus, at 5 years, the 
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+XMKTx group had experienced a higher number of graft losses and the eGFR was 
lower in the grafts still functioning.  
Table 5.2. Table of Variables included in the Analysis for 5 year graft failure.  
Table 5.2A. Univariate Analysis 
 
  B S.E. Wald df Sig. OR 
95% C.I.for OR 
Lower Upper 
Age At Transplant 
(per year of age) 
-0.03 0.01 13.37 1.00 <0.001 0.97 0.96 0.99 
Donor Age 
(per year of age) 
0.03 0.01 13.91 1.00 <0.001 1.03 1.02 1.05 
Pre-emptive -0.69 0.21 10.44 1.00 0.001 0.50 0.33 0.76 
Dialysis Time (per 
month of dialysis) 
0.01 0.00 8.90 1.00 0.003 1.01 1.00 1.02 
ABDR mismatch 
(per mismatch unit) 
0.18 0.07 7.80 1.00 0.005 1.20 1.06 1.37 
Re-transplanted vs. 
1
st
 transplant 
 
0.55 0.24 5.45 1.00 0.020 1.73 1.09 2.74 
 
Table 5.2B.Multivariate Analysis 
 
  B S.E. Wald df Sig. OR 
95% C.I.for OR 
Lower Upper 
Age At Transplant 
(per year of age) 
-0.02 0.01 4.86 1.00 0.027 0.98 0.96 1.00 
Donor Age 
(per year of age) 
0.04 0.01 10.83 1.00 0.001 1.04 1.02 1.07 
Pre-emptive 0.01 0.00 7.67 1.00 0.006 1.01 1.00 1.02 
Dialysis Time (per 
month of dialysis) 
-18.88 28151.01 0.00 1.00 0.999 0.00 0.00   
ABDR mismatch 
(per mismatch unit) 
0.17 0.09 3.52 1.00 0.060 1.19 0.99 1.43 
Re-transplanted vs. 
1
st
 transplant 
 
0.58 0.32 3.30 1.00 0.069 1.79 0.96 3.34 
Constant -3.32 0.76 19.18 1.00 0.000 0.04   
 
B= coefficient of the constant; S.E. = standard error around B; df=degrees of freedom; 
OR= Odds Ratio of Allograft Failure at 5 years., CI= Confidence Interval. Analysis 
performed using logistic regression. Variables were included in multivariate analysis if 
p<0.1 in univariate analysis  
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5.3.5. Acute Rejection Rates 
Given that anti-HLA immune responses are thought to be T cell dependent, it is 
possible that differences in the incidence and severity of cellular rejection in the 
sensitized patients might contribute to the differences in the late outcomes. To address 
this, I examined in detail all biopsies (n=2544) in the 3 groups prior to their 1 year 
surveillance biopsy: these were undertaken per protocol or for indication for graft 
dysfunction (Table 5.3). There was no significant difference between all 3 groups for 
cellular rejection (+XMKTx vs. –XMKTx 5.8% [n=6/102] vs. 14.2% [n=93/652], p=0.45; 
ABOiKTx vs. –XMKTx 9.6% [n=7/73] vs. 14.2% [n=93], p=0.40 and +XMKTx vs. 
ABOiKTx 5.9% [n=6] vs. 9.6% [n=7], p=0.92).  
The severity of the cellular rejection in the three groups appeared to be similar and "v" 
lesions were similar in biopsies at 4 months in the 3 groups (Conventional KTx 1%, 
+XMKTx 1% and ABOiKTx 0%). Thus, pure cellular rejection as defined by the current 
Banff classification does not explain the differences in outcome. While there were 
higher rates of AMR in both +XMKTx (33.3%, n=34) and ABOiKTx (31.5%, n=23) than 
Conventional KTx group (1.5%, n=10, p<0.001 for both groups), mixed cellular and 
humoral rejections might explain the differences in allograft outcomes.  In all groups, 
the incidence of mixed cellular and humoral rejection was rare—even in the +XMKTx 
with AMR .The prevalence of interstitial infiltration (‘i’) and/or tubulitis (‘t’) with AMR 
was similar in Conventional KTx (20.0%) and +XMKTx (17.6%) and lower in the 
ABOiKTx group although did not reach statistical significance (4.3%, p=0.15 and p=0.13 
respectively).Thus, the phenotype of mixed rejection does not equate with poor 
allograft survival. 
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Figure 5.3. Renal Allograft Function (eGFR) at 1 and 5 years in Surviving Kidney 
Transplants.  
Allograft function is not significantly different at 1 year (A), however at 5 years the 
+XMKTx had inferior eGFR compared to both Conventional KTx and ABOiKTx (B). Mean 
eGFR (MDRD) is shown by the green line. Analysis made by Student’s t-test.  
 
  
A B 
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Table 5.3. Incidence of acute rejection episodes for patients in each cohort  
Biopsy scores according to Banff criteria in the first year following transplant classified 
for rejection, type of rejection and cellular component of AMR. The highest Banff score 
was used for each patient in the first year for rejection episodes if multiple biopsies 
were performed. This demonstrates a higher number of patients in the antibody 
incompatible groups with biopsies with rejection (+XMKTx 39.2% and ABOiKTx 42.9% 
compared to Conventional KTx 15.7%). There were similar rates of cellular rejection 
rates in each cohort. 
 
Conventional KTx +XMKTx ABOi 
Patient number 652 102 73 
Number of patients biopsied % (n) 94.9% (619) 100% (102) 95.9% (70) 
Number of Biopsies  1651 553 340 
Biopsies/patient (Median [Q1-Q3]) 3[2-3] 5[4-6] 5[4-6] 
 Percentage of patients with rejection on biopsy (n) 15.7% (103)* 39.2% (40)* 41.1% (30)* 
Total Cellular Rejection % (n) 14.2% (93)* 5.9% (6)* 9.6% (7)* 
Total Antibody Mediated Rejection % (n) 1.5% (10)* 33.3% (34)* 31.5% (23)* 
 Highest Banff score of rejection % (n) 
   Total Cellular Rejection of rejection biopsies 90% (93)† 15% (6)† 23.3% (7)† 
AR0 35.9% (37)† 2.5% (1) † 6.7% (2) † 
AR1 39.8% (41) † 10% (4) † 16.7% (5) † 
AR2 14.6% (15) † 2.5 (1) † 0 † 
Antibody Mediated Rejection of rejection biopsies 9.7% (10) † 85% (34) † 76.7% (23) † 
of AMR, interstitial inflammation % (n) 10% (1) † 2.9% (1) † 4.3% (1) † 
of AMR, tubulitis % (n) 0 † 11.8% (4) † 0 † 
of AMR, tubulitis and interstitial inflammation 10% (1) † 2.9%(1) † 0 † 
AR0 = subclinical rejection; AR1 = Banff 1 rejection AR2 = Banff 2 rejection  
*= of all patients in each group;  †= of all patients with biopsies in each group.  
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5.3.6. Protocol Surveillance Biopsies 
A goal in the transplant programme was to perform protocol surveillance biopsies on all 
functioning grafts at 1 and 5 years after transplantation, but lack of consent, the need 
for chronic anticoagulation, and other medical reasons decreased the biopsy rate.  Thus, 
in the +XMKTx group, 78.4% (69/88) had biopsies at 1 year and 63.5% (40/63) at 5 
years. In the ABOiKTx group, 56.9% (37/65) had biopsies at 1 year and 55.5% (25/45) 
at 5 years.  In the Conventional KTx group, 69.6% (416/598) had biopsies at 1 year and 
60.1% (280/466) at 5 years.  
A summary of the histological differences in the surveillance biopsies of the surviving 
allografts are shown in Table 5.4. At 1 year (Table 5.4A),  +XMKTx demonstrated higher 
rates of microcirculatory inflammation as evidenced  by glomerulitis (g) and peritubular 
capillaritis (ptc) at 3 months have been associated with early chronic injury in +XMKTx 
[163]. In both ABOiKTx and Conventional KTx, the prevalence of microcirculation injury 
was low and generally similar. In the Conventional KTx there was 20% vs. 73.7% in 
+XMKTx, (p=0.045) and in the ABOiKTx  27.8% vs. 73.7% in +XMKTx, (p<0.001).  At 1 
year, the prevalence of glomerulitis was 36.2% in +XMKTx compared to only in 2.7% 
ABOiKTx and 6.0% in Conventional KTx (p<0.001 for both compared to +XMKTx).  
Similarly at 5 years, there was significantly higher rates of antibody-mediated injury in 
the +XMKTx, than the other 2 groups (Table 5.4B). 
A lack of inflammation on renal biopsy was associated with improved graft 
survival in all groups.  Using a cumulative microcirculation score (addition of 
glomerulitis and peritubular capillaritis), the transplants were stratified into no 
inflammatory infiltrate (score 0); mild infiltration (cumulative score 1-3) and heavy 
infiltrations (cumulative score >3) [152]. There were lower microcirculation scores in 
ABOiKTx group than +XMKTx group (p<0.001) shown in Table 5.5.   
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Table 5.4. Differences in the surveillance biopsies scores of the surviving 
allografts at 1 year and then 5 years respectively 
Table 5.4A – Summary of Surveillance Biopsies at 1 year. Increased microcirculatory 
inflammation in antibody incompatible compared to Conventional KTx, but significantly 
greater in +XMKTx. C4d was not done routinely in the early transplant programme, thus 
under-represented at 1 year biopsies. 
  
Conventional KTx 
(n=416) 
+XMKTx 
(n=69) 
ABOiKTx 
(n=37) 
Con/ 
ABOi* 
Con/ 
+ XM* 
+XM/ 
ABOi* 
  
G 
None 94.0% (n=391) 63.8% (n=44) 97.3% (n=36) 
0.403 <0.001 <0.001 
Positive 6.0%  (n=25) 36.2% (n=25) 2.7% (n=1) 
Cg 
None 96.9% (n = 403) 71.0% (n = 49) 88.9% (n = 32)   
0.018 
  
  
<0.001 
  
  
0.026 
  Positive 3.1% (n=13) 29.0% (n=20) 11.1% (n=4) 
C4d 
None 94.7% (n = 18) 84.1% (n = 53) 16.7% (n = 1)   
<0.001 
  
  
0.21 
  
  
<0.001 
  Positive 5.3% (n=1) 15.9% (n=10) 83.3%  (n=5) 
ptc # 
None 80.0% (n = 4) 27.7% (n = 18) 72.2% (n = 26)   
0.918 
  
  
0.045 
  
  
<0.001 
  Positive 20.0% (n=1) 73.3% (n=47) 27.8% (n=10) 
 
* comparison made between groups using Pearson chi-squared analysis 
Data not cumulative to total number of biopsy was not available for analysis  
# The biopsies of Conventional KTx were not re-examined to address ‘ptc’ in this cohort.   
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Table 5.4B - 5 year Histology - Increased microcirculatory inflammation and chronic 
injury in +XMKTx. No significant differences in ABOiKTx to Conventional KTx at 5years, 
except the activation of complement with increased C4d deposition in allografts. 
  
Conventional KTx 
(n=280) 
+XMKTx 
(n=40) 
ABOiKTx 
(n=25) 
Con/ 
ABOi* 
Con/ 
+ XM* 
+XM/ 
ABOi* 
  
g 
None 90.4% (n = 253) 30.0% (n = 12) 92.0% (n = 23) 
0.762 <0.001 0.001 
Positive 9.6% (n=27) 70% (n=28) 8% (n=2) 
i 
None 88.9% (n = 249) 74.4% (n = 29) 76.0% (n = 19) 
0.055 0.01 0.884 
Positive 11.1% (n=31) 25.6% (n=10) 24.0% (n=6) 
ah 
None 37.3% (n = 103) 15.0% (n = 6) 40.0% (n = 10) 
0.539 0.001 0.005 
Positive 62.7% (n=173) 85.0% (n=34) 60.0% (n=15) 
cg None 92.4% (n = 257) 42.5% (n = 17) 88.0% (n = 22) 
0.457 <0.001 <0.001 
 Positive 
7.6% (n=21) 57.5% (n=23) 12.0% (n=3) 
ci None 38.0% (n = 106) 12.5% (n = 5) 52.0% (n = 13) 
0.123 0.002 <0.001 
 Positive 
62.0% (n=173) 87.5% (n=35) 48.0% (n=12) 
ct None 28.1% (n = 78) 10.0% (n = 4) 40.0% (n = 10) 
0.125 0.013 0.003 
 Positive 
71.9% (n=200) 90.0% (n=36) 60.0% (n=15) 
cv None 38.0% (n = 106) 20.5% (n = 8) 32.0% (n = 8) 
0.676 0.017 0.129 
 Positive 
62.0% (n=173) 79.5% (n=31) 68.0% (n=17) 
C4d None 94.3% (n = 83) 81.1% (n = 30) 22.2% (n = 4) 
<0.001 0.02 <0.001 
 Positive 
5.6% (n=5) 18.9% (n=7) 77.8% (n=14) 
ptc # None 91.1% (n = 123) 33.3% (n = 10) 92.3% (n = 12) 
0.863 <0.001 0.001 
 Positive 
8.9% (n=12) 66.7% (n=20) 7.7% (n=1) 
 
* comparison made between groups using Pearson chi-squared analysis  
Biopsy data that is not cumulative to total number of biopsy means that the biopsy 
material was not available for analysis 
# The biopsies of Conventional KTx were not re-examined to address ‘ptc’ in this cohort.   
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Table 5.5. Microcirculation scores of different transplant groups in biopsies at 1 
and 5 years post transplantation.  
MIC scoring was done in the available biopsies at each time period where both 
glomerulitis and peritubular capillaritis were recorded.  Severity of microcirculation 
injury was not scored in the Conventional KTx group and is therefore not shown. 
 
  
  
XM POS ABOi 
+XM/ 
ABOi* 
1yr MIC 
score 
0 26.2% (n=17) 
70.6% 
(n=24) 
<0.001 1 
46.2% 
(n=30) 
29.4% 
(n=10) 
2 27.7% (n=18) 0 
5yr MIC 
score 
0 13.3% (n=4) 92.3% (n=12) 
<0.001 1 56.7% (n=17) 0 
2 30.0% (n=9) 7.7% (n=1) 
 
Biopsy data that is not cumulative to total number of biopsy means that the biopsy 
material was not available for analysis 
* comparison made between groups using Wilcoxon rank-sum test treating Banff score 
as continuous data  
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At 1 year chronic glomerulopathy (cg) was much more common in +XMKTx, occurring 
in 29.0% (n=20) of biopsies compared to only 11.0% (n=4) of ABOiKTx (p=0.026) and 
3.1% (n=13) of Conventional KTx (p<0.001 for both compared to +XMKTx).  The 
severity of the ‘cg’ was much higher in the +XMKTx group, in which 14.5% (n=10) had 
moderate to severe ‘cg’, whereas no ABOiKTx had this degree of severity (Table 5.6A).   
At 1 year, chronic glomerulopathy was more common in ABOiKTx (11.1%) compared to 
Conventional KTx (3.1%, p=0.018). 
These differences in inflammation and chronic injury persisted and increased on 5 year 
biopsies (Table 5.6B).  The prevalence of peritubular capillaritis was 66.7% in +XMKTx 
compared to only 7.7% in ABOiKTx and 8.9% in Conventional KTx (p<0.001 for both 
compared to +XMKTx).  Similarly, at 5 years the prevalence  of glomerulitis was 70.0% 
in +XMKTx compared  to only in 8.0% ABOiKTx and 9.6% in Conventional KTx (p<0.001  
for both compared to +XMKTx).  Chronic glomerulopathy was much more common in 
+XMKTx at 1 year occurring in 57.5% of biopsies compared to only 12.0% of ABOiKTx 
and 7.6% of Conventional KTx (p<0.001  for both compared to +XMKTx).  In contrast to 
the 1 year data, the prevalence of chronic glomerulopathy was similar in ABOiKTx and 
Conventional KTx. Peritubular capillaritis on 1 year protocol biopsy correlated with 
chronic glomerulopathy on the 5 year biopsy in both the ABOiKTx (p=0.009) and 
+XMKTx (p=0.003).   
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Table 5.6. Overall histological Banff scores for biopsies at 1year and 5years  
Overall histological Banff scores for all 1 year biopsies. 
 
Table 5.6A 
1 year  
biopsies 
Conventional KTx 
(n=416) 
+XMKTx 
(n=69) 
ABOiKTx 
(n=37) 
Con/ 
ABOi* 
Con/ 
+ XM* 
+XM/ 
ABOi* 
  
  None 94.0% (n = 391)  49.3% (n = 34)  97.3% (n = 36)        
g Mild 4.6% (n = 19)  27.5% (n = 19)  2.7% (n = 1)  0.403 <0.001 <0.001 
  Mod-Sev 1.4% (n = 6)  23.2% (n = 16)  0.0% (n = 0)        
  None 84.6% (n = 352)  84.1% (n = 58)  91.9% (n = 34)        
i Mild 8.7% (n = 36)  8.7% (n = 6)  2.7% (n = 1)  0.274 0.902 0.3 
  Mod-Sev 6.7% (n = 28)  7.2% (n = 5)  5.4% (n = 2)        
  None 79.6% (n = 331)  62.3% (n = 43)  83.8% (n = 31)        
t Mild 12.5% (n = 52)  30.4% (n = 21)  10.8% (n = 4)  0.537 0.004 0.032 
  Mod-Sev 7.9% (n = 33)  7.2% (n = 5)  5.4% (n = 2)        
  None 99.8% (n = 415)  100.0% (n = 69)  100.0% (n = 37)        
v Mild 0.2% (n = 1)  0.0% (n = 0)  0.0% (n = 0)  0.772 0.688 1 
  Mod-Sev 0.0% (n = 0)  0.0% (n = 0)  0.0% (n = 0)        
  None 81.0% (n = 319)  75.8% (n = 50)  83.8% (n = 31)        
ah Mild 16.2% (n = 64)  22.7% (n = 15)  13.5% (n = 5)  0.689 0.355 0.372 
  Mod-Sev 2.8% (n = 11)  1.5% (n = 1)  2.7% (n = 1)        
  None 96.9% (n = 403)  71.0% (n = 49)  88.9% (n = 32)        
cg Mild 1.7% (n = 7)  14.5% (n = 10)  11.1% (n = 4)  0.018 <0.001 0.026 
  Mod-Sev 1.4% (n = 6)  14.5% (n = 10)  0.0% (n = 0)        
  None 45.9% (n = 191)  36.2% (n = 25)  52.8% (n = 19)        
ci Mild 39.2% (n = 163)  49.3% (n = 34)  30.6% (n = 11)  0.591 0.148 0.182 
  Mod-Sev 14.9% (n = 62)  14.5% (n = 10)  16.7% (n = 6)        
  None 30.5% (n = 127)  26.1% (n = 18)  38.9% (n = 14)        
ct Mild 55.0% (n = 229)  56.5% (n = 39)  44.4% (n = 16)  0.374 0.267 0.164 
  Mod-Sev 14.4% (n = 60)  17.4% (n = 12)  16.7% (n = 6)        
  None 57.7% (n = 239)  62.3% (n = 43)  60.0% (n = 21)        
cv Mild 35.3% (n = 146)  33.3% (n = 23)  34.3% (n = 12)  0.784 0.428 0.793 
  Mod-Sev 7.0% (n = 29)  4.3% (n = 3)  5.7% (n = 2)        
  None 94.7% (n = 18)  84.1% (n = 53)  16.7% (n = 1)        
C4d Mild 5.3% (n = 1)  1.6% (n = 1)  0.0% (n = 0)  <0.001 0.21 <0.001 
  Mod-Sev 0.0% (n = 0)  14.3% (n = 9)  83.3% (n = 5)        
  None 80.0% (n = 4)  27.7% (n = 18)  72.2% (n = 26)        
ptc # Mild 0.0% (n = 0)  16.9% (n = 11)  22.2% (n = 8)  0.918 0.045 <0.001 
  Mod-Sev 20.0% (n = 1)  55.4% (n = 36)  5.6% (n = 2)        
* comparison made between groups using Wilcoxon rank-sum test treating Banff score as continuous 
data. Biopsy data that is not cumulative to total number of biopsy means that the biopsy material was not 
available for analysis. . #The biopsies of Conventional KTx were not re-examined to address ‘ptc’ .  
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. Overall histological Banff scores for all 5 year biopsies. 
 
Table 5.6B 
5 year  
biopsies 
Conventional KTx 
(n=280) 
+XMKTx 
(n=40) 
ABOiKTx 
(n=25) 
Con/ 
ABOi* 
Con/ 
+ XM* 
+XM/ 
ABOi* 
  
  None 90.4% (n = 253)  30.0% (n = 12)  92.0% (n = 23)        
g Mild 6.8% (n = 19)  25.0% (n = 10)  8.0% (n = 2)  0.762 <0.001 0.001 
  Mod-Sev 2.9% (n = 8)  45.0% (n = 18)  0.0% (n = 0)        
  None 88.9% (n = 249)  74.4% (n = 29)  76.0% (n = 19)        
i Mild 9.3% (n = 26)  20.5% (n = 8)  20.0% (n = 5)  0.055 0.01 0.884 
  Mod-Sev 1.8% (n = 5)  5.1% (n = 2)  4.0% (n = 1)        
  None 94.3% (n = 264)  87.5% (n = 35)  92.0% (n = 23)        
t Mild 5.4% (n = 15)  10.0% (n = 4)  8.0% (n = 2)  0.649 0.101 0.564 
  Mod-Sev 0.4% (n = 1)  2.5% (n = 1)  0.0% (n = 0)        
  None 100.0% (n = 280)  100.0% (n = 39)  100.0% (n = 25)        
v Mild 0.0% (n = 0)  0.0% (n = 0)  0.0% (n = 0)  1 1 1 
  Mod-Sev 0.0% (n = 0)  0.0% (n = 0)  0.0% (n = 0)        
  None 37.3% (n = 103)  15.0% (n = 6)  40.0% (n = 10)        
ah Mild 39.1% (n = 108)  40.0% (n = 16)  44.0% (n = 11)  0.539 0.001 0.005 
  Mod-Sev 23.6% (n = 65)  45.0% (n = 18)  16.0% (n = 4)        
  None 92.4% (n = 257)  42.5% (n = 17)  88.0% (n = 22)        
cg Mild 2.2% (n = 6)  10.0% (n = 4)  8.0% (n = 2)  0.457 <0.001 <0.001 
  Mod-Sev 5.4% (n = 15)  47.5% (n = 19)  4.0% (n = 1)        
  None 38.0% (n = 106)  12.5% (n = 5)  52.0% (n = 13)        
ci Mild 44.4% (n = 124)  60.0% (n = 24)  40.0% (n = 10)  0.123 0.002 <0.001 
  Mod-Sev 17.6% (n = 49)  27.5% (n = 11)  8.0% (n = 2)        
  None 28.1% (n = 78)  10.0% (n = 4)  40.0% (n = 10)        
ct Mild 54.3% (n = 151)  62.5% (n = 25)  52.0% (n = 13)  0.125 0.013 0.003 
  Mod-Sev 17.6% (n = 49)  27.5% (n = 11)  8.0% (n = 2)        
  None 38.0% (n = 106)  20.5% (n = 8)  32.0% (n = 8)        
cv Mild 42.3% (n = 118)  48.7% (n = 19)  64.0% (n = 16)  0.676 0.017 0.129 
  Mod-Sev 19.7% (n = 55)  30.8% (n = 12)  4.0% (n = 1)        
  None 94.3% (n = 83)  81.1% (n = 30)  22.2% (n = 4)        
C4d Mild 1.1% (n = 1)  5.4% (n = 2)  0.0% (n = 0)  <0.001 0.02 <0.001 
  Mod-Sev 4.5% (n = 4)  13.5% (n = 5)  77.8% (n = 14)        
  None 91.1% (n = 123)  33.3% (n = 10)  92.3% (n = 12)        
ptc # Mild 5.2% (n = 7)  30.0% (n = 9)  7.7% (n = 1)  0.863 <0.001 0.001 
  Mod-Sev 3.7% (n = 5)  36.7% (n = 11)  0.0% (n = 0)        
* comparison made between groups using Wilcoxon rank-sum test treating Banff score as continuous 
data. Biopsy data that is not cumulative to total number of biopsy means that the biopsy material was not 
available for analysis. . #The biopsies of Conventional KTx were not re-examined to address ‘ptc’ . 
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At 1 year, almost all of the other Banff scores were similar among the 3 groups, 
including acute indices (interstitial inflammation, i; vascular inflammation, v;) and 
chronic indices: interstitial fibrosis (ci); tubular atrophy (ct) and arteriolar hyalinosis 
(ah).  The one exception was an increased prevalence of acute tubulitis (t) in the 
+XMKTx at 1 year (37.6%) compared to the ABOiKTx (16.2%, p=0.032) and 
conventional KTx (19%, p=0.004).  In contrast to the 1 year findings, at 5 years, the 
+XMKTx generally showed more interstitial inflammation, but no differences in 
tubulitis.  Chronic indices in the +XMKTx at 5 years were higher than those in ABOiKTx 
and Conventional KTx further suggesting the presence of chronic injury.  For example, 
interstitial fibrosis (ci) was present in 87.5% of +XMKTx compared to 48% in ABOiKTx 
(p=0.001) and 62% of Conventional KTx (p=0.002).  In addition, 27.5% of +XMKTx had 
moderate-to-severe interstitial fibrosis compared to 8.0% ABOiKTx (p<0.001) and 
17.6% Conventional KTx (p=0.002). 
Special mention should be made of the C4d staining of protocol biopsies.  This 
immunofluorescent stain was not performed routinely on all biopsies during this entire 
time period—especially in conventional KTx.  For +XMKTx and ABOiKTx, C4d testing 
became the standard of care toward the end of the study and thus was performed more 
commonly on 5 year biopsies.  Interestingly, the prevalence of C4d deposition was much 
more common in ABOiKTx even at 5 years (77.8%) than in +XMKTx (18.9%, p<0.0001) 
despite a higher prevalence of chronic inflammation and glomerulopathy in the +XMKTx 
group.  
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5.3.7 Correlation between Antibody titre and histology 
There was no association between starting titre and microcirculatory injury histology 
on 1-year or 5-year biopsies, when categorized into >1:16, >1:64 or >1:128 categories.  
Distribution of starting titers and titers at 1 year can be seen in Figure 5.4.   
5.3.8 Correlation between Histology and Outcomes 
In all 3 groups, the presence of chronic glomerulopathy at 1 year was correlated with 
graft failure (OR 9.6, 4.2-21.3) and peritubular capillaritis was also associated with graft 
failure (OR 3.2, 1.03-12.0).  Figure 5.5 A and B depict the difference in rate of graft loss 
with and without chronic glomerulopathy on the 1-year surveillance biopsy.  Even in 
the absence of chronic glomerulopathy at 1 year, the +XMKTx patients have significantly 
higher rate of graft loss over time. 
The presence of chronic glomerulopathy at 1 and 5 years in the +XMKTx group was 
associated with reduced eGFR at both time points (1 yr CG 40.0±9.7ml/min vs.1yr No 
CG 51.7±18.4ml/min p=0.001 and 5yr CG 38.8±14.9ml/min vs. 5yr No CG 
57.2±15.5ml/min p<0.001)–whereas ABOiKTx did not experience a decline in allograft 
function when chronic glomerulopathy was present at 5 years.  The presence of chronic 
damage in 1 year biopsies was associated with significantly reduced function in the 
Conventional KTx group, but did not affect the other 2 groups (Table 5.7A).  The 
presence of peritubular capillaritis at 1 year was not associated with a change in eGFR 
between 1 or 5 years in either ABOiKTx or +XMKTx cohort and did not predict an eGFR 
<40ml/min.  
While there was significantly more chronic injury (5 yr ci/cv/ah) in the +XMKTx cohort 
compared the other cohorts, this was not associated with worse function in the 
allograft, as it was in the Conventional KTx group (Table 5.7B), although care needs to 
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be taken in interpretation given the already higher rates of graft loss in the +XMKTx 
cohort. This could therefore be confounded by a degree of survivor bias. 
Early AMR was significantly associated with the development of cg at 1 year in the 
ABOiKTx cohort (p=0.001), but not in the +XMKTx cohort (p=0.74).  There was no 
association with AMR and peritubular capillaritis in either group. 
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Figure 5.4. Comparison of anti-ABO titers at baseline and 1 year post 
transplantation.  
There is a reduction in titers between baseline and 1 year post transplantation in the 
ABOiKTx patients in both immediate (IM) and antihuman globulin (AHG) techniques for 
anti-A/B titer measurement. The graph demonstrates titers expressed in number of 
dilutions. Median values of titer were 1:4 (AHG) or 1:8 (AHG) at 1 year, compared to 
1:16 (IM) or 1:64 (AHG) at baseline. 
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Table 5.7. Association between biopsy findings and eGFR at 1 and 5 years.  
Table 5.7A - 1 year eGFR with 1 year surveillance biopsy results for each cohort. 
 1 year  ah No  
ah 
 P 
value 
 cg No  cg  P 
value 
 ci No  ci  P 
value 
 ct No  ct  P 
value 
 cv No  cv  P 
value 
Conventional 
(n=416) 
47.8 ±  
14.7 
49.7 ±  
13.8 
0.303 44.2 ±  
14.9 
49.6 
±  
13.8 
0.218 47.2 ±  
14.6 
52.1 ±  
12.4 
<0.001 48.4 ±  
14.6 
51.7 ±  
11.8 
0.014 48.3 
±  
15.7 
50.3 
±  
12.2 
0.168 
+XMKTx 
(n=69) 
48.6 ±  
18.6 
47.3 ±  
16.2 
0.809 39.8 ±  
9.5 
51.7 ±  
18.4 
0.001 47.9 ±  
20.3 
49.0 
±  9.5 
0.759 48.3 ±  
19.1 
48.3 
±  
10.4 
0.995 49.4 
±  
16.9 
47.7 ±  
17.5 
0.691 
ABOiKTx 
(n=37) 
52.5 ±  
14.4 
48.7 
±  
13.0 
0.565 40.8 ±  
6.7 
50.3 
±  
13.6 
0.055 48.5 
±  
14.0 
49.8 
±  
12.9 
0.763 47.8 ±  
12.5 
51.4 ±  
14.6 
0.461 51.7 ±  
14.2 
48.2 
±  
12.6 
0.465 
 
Table 5.7B - 5 year eGFR with 1 year surveillance biopsy results for each cohort. 
 5 year  ah No  ah  P 
value 
 cg No  cg  P 
value 
 ci No  ci  P 
value 
 ct No  ct  P 
value 
 cv No  cv  P 
value 
Conventional 
(n=250) 
48.4 
±  
16.7 
51.9 ±  
13.9 
0.076 36.9 ±  
11.0 
50.4 ±  
15.7 
0.001 45.2 ±  
13.6 
56.7 ±  
16.6 
<0.00
1 
47.1 ±  
15.5 
51.2 ±  
17.2 
0.036 47.8 
±  
15.9 
52.4 
±  
15.3 
0.025 
+XMKTx 
(n=40) 
45.6 
±  
17.3 
50.7 ±  
17.9 
0.578 37.4 ±  
12.6 
57.9 ±  
15.6 
0.001 45.1 ±  
17.8 
52.9 ±  
13.2 
0.292 43.0 ±  
18.6 
46.1 ±  
20.1 
0.658 47.0 
±  
18.9 
45.4 
±  
12.2 
0.786 
ABOiKTx 
(n=25) 
51.5 
±  
14.9 
51.8 ±  
8.8 
0.96 56.0 ±  
23.3 
51.0 ±  
11.4 
0.747 48.8 ±  
13.0 
54.5 ±  
12.4 
0.278 52.9 ±  
11.1 
46.6 
±  
13.4 
0.191 50.7 
±  
10.7 
53.9 
±  
17.5 
0.67 
 
ah- arteriolar hyaline thickening; cg-allograft glomerulopathy; ci-interstitial fibrosis; ct-
tubular atrophy; cv-vascular fibrous intimal thickening 
eGFR calculated using MDRD equation – expressed as Mean ± StDev and compared 
using Student’s t-test 
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Figure 5.5. Longer term DCGS for transplant recipients with and without ‘CG’ on 1 
year biopsy.  
Figure 5.5A. No Chronic glomerulopathy 
Kaplan-Meier Graft survival for patients who had 1 year biopsies without chronic 
glomerulopathy (cg) on 1 year surveillance biopsy demonstrated +XMKTx had 
significantly worse allograft survival than other 2 groups (p=0.003. log-rank test). 
Solid line = Conventional KTx; Dotted line = ABOiKTx; Mixed line = +XMKTx. 
 
Figure 5.5B. Chronic glomerulopathy on the 1 year biopsy  
In the presence of cg on 1 year biopsy, there is no difference in allograft survival 
between groups (p=0.470 log-rank test).  
  
A 
B 
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5.4. Discussion 
The current study validates previous studies and extends our understanding of the 
outcome of kidney transplants in patients with anti-donor antibody.  While some 
studies have demonstrated inferior outcome in +XMKTx compared to Conventional KTx 
and other studies have demonstrated equivalent outcome in ABOiKTx compared to 
Conventional KTx [72, 144, 259], no study has compared the outcomes of these 3 
cohorts together in the same centre.  The current study shows that the 5-year graft 
survival and renal function of ABOiKTx and Conventional KTx were superior to those of 
+XMKTx.  In addition, the rate of graft loss between 1 and 5 years after 
transplantation—a measure of chronic injury—was similar and low in Conventional 
transplants (1.7%/year) and ABOiKTx (2.6%), but was significantly higher in +XMKTx 
(5.8%/ year).   
In addition to the increased rate of graft loss in +XMKTx, data from this study suggest 
that surviving grafts also demonstrate more chronic injury compared to ABOiKTx and 
Conventional KTx.  These data show however that ABOiKTx have a higher rate of early 
graft loss in the first year compared to Conventional KTx, but chronic injury is low 
despite the presence of antibody and complement activation as judged by C4d staining. 
+XMKTx showed lower mean eGFR and a higher percentage of patients with an 
eGFR<40 ml/min.  +XMKTx had a higher prevalence of glomerulitis and peritubular 
capillaritis, which correlated with the presence and/or later development of chronic 
glomerulopathy.  
Taken together, these data support the paradigm that chronic injury in +XMKTx follows 
a progression involving early evidence of peritubular capillaritis and glomerulitis 
followed by the development of chronic glomerulopathy months to years later which 
finally may result in declining renal function progressing to graft loss [163].  
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This study also presents new data showing that other forms of chronic injury such as 
fibrosis, tubular atrophy and arteriolar hyalinosis also increase in +XMKTx by 5 years 
after transplantation. Previous data have suggested an association with DSA and intimal 
thickening vasculopathy, which may explain some of these changes [260]. 
Finally, this study reemphasizes the lack of association between C4d deposition and 
chronic injury late after kidney transplantation.  C4d deposition in the peritubular 
capillaries was extremely common in ABOiKTx at 5 years (77.8%), yet chronic injury 
was absent.  In contrast, C4d deposition was much less common in +XMKTx at 5 years 
(18.9%) but evidence of inflammation and chronic injury was more common.   
 The light microscopic data presented in this study are similar to findings from gene 
expression studies performed on these cohorts of patients.  In these studies, +XMKTx 
recipients demonstrated increased expression of inflammatory markers including cell-
specific markers such as CD68, CD3 and CD20 [182]. These changes were present even 
in grafts that showed little signs of cellular infiltration at the light microscopic level.  In 
contrast, ABOiKTx recipients did not show increased expression of inflammatory genes 
when compared to conventional kidney transplants [261].   
These studies shed new light on the pathobiology of chronic renal allograft injury in 
recipients with anti-donor antibody at the time of transplantation.  For example, the fact 
that chronic inflammation occurs commonly in the absence of C4d deposition and that 
C4d deposition does not necessarily lead to inflammation both suggest that this 
inflammation is not critically dependent on complement activation in the allograft.  The 
fact that a recent study showing that peritubular capillaritis develops in +XMKTx 
recipients receiving terminal complement blockade with eculizumab further supports 
this hypothesis [136].  
 
 
229 
 
An active protective process termed “accommodation” has been hypothesized to 
prevent antibody-mediated injury despite complement deposition in ABOi renal 
allografts.  Indeed, the lack of inflammation could be yet another manifestation of 
“accommodation” in which the graft protects itself from injury [177].  Anti-apoptotic 
genes (HO-1, Bcl-2, Bcl-xl and Bax) are upregulated in certain experimental models of 
accommodation [262, 263], but in previous studies increased expression of these genes 
classically associated with accommodation were not identified in some of the same 
grafts studied here [261].   
Anti-blood group antibodies are predominantly IgG2 and others have suggested that 
differences in antibody isotype class may explain differences in rejection and non-
rejection after ABOiKTx [66, 214].  These studies have involved very few patients and 
focused on early graft loss.  However, it is possible that antibody class differences could 
impact on chronic injury rates.  In the current study, a detailed analysis of antibody 
class types was not performed. 
The differences in inflammation between +XMKTx and ABOiKTx may be more fully 
explained by a different mechanism.  The immune response against carbohydrate 
antigens such as blood groups involves primarily antibodies and does not lead to 
activation of antigen presenting cells and T cells.  In contrast, the response to protein 
antigens such as HLA proteins commonly involves both a cellular and humoral immune 
response.  Thus, allosensitized recipients likely possess not only anti-HLA antibodies, 
but also a variety of alloreactive cell types including memory T cells and activated 
dendritic cells.  When viewed from this perspective, antibody against donor HLA is only 
one aspect of the immune response that may or may not be important for the 
development of peritubular capillaritis and glomerulitis.  The fact that this inflammation 
appears relatively independent of complement activation in the graft is consistent with 
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the possibility that this process may be only partially dependent on the presence of anti-
donor antibody.   The persistent presence of the allograft could allow for continued 
activation of these and other immune cells.  This might explain why the prevalence of 
peritubular capillaritis and glomerulitis increases over time even when antibody levels 
in the serum decrease and C4d staining is absent [248].  This hypothesis not only may 
help to explain the differences in cellular infiltration and chronic injury observed in the 
current study, but also suggests that strategies to prevent and/or treat these processes 
should address the cells involved and not the antibody.  
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Chapter 6  Early Antibody Mediated Rejection Despite Inhibition of 
Terminal Complement 
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This chapter has been published in Transplant International [264]. 
6.1 Introduction 
The Mayo Clinic Kidney transplant group recently demonstrated that terminal 
complement blockade with eculizumab, a humanized monoclonal antibody with high 
affinity for C5, decreased early acute antibody mediated rejection (eAMR) in positive 
crossmatch kidney transplantation (+XMKTx).  The incidence of clinically-significant 
eAMR in patients treated post-transplant with eculizumab was 7.7% (2/26) compared 
to 41.2% (21/51, p=0.003) in a historical control group treated with a plasma exchange 
(PE) based protocol that was similar in both groups [136]. 
 The goal of the current study was to investigate the possible causes of eAMR in 
the first month after +XMKTx in patients treated with eculizumab.  Eculizumab had 
blocked haemolytic assays of complement activity with therapeutic levels in all 26 
eculizumab treated patients in the first month after transplantation. Thirteen patients 
developed high levels of IgG DSA and even C4d+ biopsies which would have likely been 
associated with eAMR without terminal complement blockade, yet protocol surveillance 
biopsies in the majority of these patients did not show evidence of eAMR.  Importantly, 
IgM DSA was detected in 4 patients after transplantation including both cases of clinical 
eAMR, the only case of subclinical eAMR and one case without eAMR who developed 
chronic injury in the first year after transplantation.   These data suggest a possible role 
of anti-donor IgM alloantibody in the pathogenesis of eAMR in patients treated with 
terminal complement blockade.    
 
 
 
233 
 
6.2 Methods 
6.2.1 Patient population  
These studies were carried out using protocols approved by the Institutional Review 
Board of the Mayo Foundation and Clinic. Twenty-six consecutive +XMKTx patients 
were studied between 2008 and 2010 who received C5-inhibition (Eculizumab) as part 
of a PE-based desensitization protocol [136].  Study patients had samples taken at 
baseline, on the day of transplant and on post-operative days (POD) 7, 14 and 28.  The 
primary endpoint of the original study and of this report was the incidence of biopsy-
proven, clinically-significant, eAMR in the first 28 days after transplantation. 
6.2.2 Desensitization Protocol  
As described by Stegall et al, recipients with baseline positive B-cell flow cytometric 
crossmatch (BFXM) channel shift greater than 200 and less than 450 were included in 
the eculizumab protocol [136].  IgG DSA specificity was identified using LABscreen (One 
Lambda, Canoga Park, CA) on a Luminex platform with levels expressed as the mean 
fluorescence intensity (MFI).  The protocol included pre-transplant PE if the BFXM was 
greater than 300 in order to reduce the pre-transplant BFXM to less than 300; low dose 
intravenous immune globulin (IVIG, 100 mg/kg) therapy was administered with PE; 
antithymocyte globulin and triple therapy of tacrolimus, mycophenolate mofetil and 
prednisolone [136]. PE consisted 1.0 plasma volume exchanges performed using the 
COBE Spectra version 7.0 software (CaridianBCT, Lakewood CO, USA) with acid citrate 
dextrose solution A (ACD-A) as the anticoagulant. Replacement fluid was 5% albumin 
(27). Eculizumab was given on day of transplant and day 1 (1200 mg and 600 mg 
respectively) and weekly for the first 4 weeks and continued until the BFXM was less 
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than 200. No protocol post-operative PE was performed after the first 2 patients; 
however, 2 patients did receive PE as treatment of eAMR. 
6.2.3 IgM DSA Assay 
Anti-HLA IgM was identified retrospectively using serum samples which were collected 
prior to desensitization with plasma exchange; prior to transplant (Day 0); and on POD 
7; 14 and 28 in patients treated with eculizumab. This was done using a modification of 
the commercially available single antigen bead IgG detection assay (LABscreen, One 
Lambda, Canoga Park, CA, USA). In brief,  20μL  serum and 3μL single antigen beads of 
each class specificity were incubated for 30minutes in the dark, washed, incubated with 
the 100μL secondary PE-conjugated anti-human IgM antibody diluted at 1:100 with 
luminex wash buffer(Goat Anti-Human IgM (μ) R-PE, Invitrogen Corporation, Camarillo, 
CA 93012) for 30minutes in the dark, washed and then re-suspended before reading. 
IgG results were obtained at the same time points for these samples using the clinically 
approved manufacturer’s protocol. The positive control anti-HLA IgM control serum 
was a kind gift of Karen Nelson, Puget Sound Blood Center. The positive control for the 
IgM assay produced an MFI of >8000 each assay. An MFI >1000 was considered positive 
as in the IgG assay. 
In order to deduce IgM specific binding, dithiothreitol (DTT, Sigma, St Louis, MO) 
was used to treat samples to cleave the disulphide bonds (ratio 1:1 sample volume to 
0.01 M DTT, incubated at 37 ºC for 15minutes). Assessment of IgG and IgM was carried 
out according to the technique described above for the undiluted and post-dithiothreitol 
and post-dilution samples for both isotypes. 
Sera was tested initially on twelve patients at all time points where complete 
sera samples were available, but extended to 6 further patients at time of biopsy on day 
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7 and day 14 who had higher levels of IgG DSA. IgG3 HLA antibodies were tested in all 
patients by Terasaki Foundation using LABscreen kits and a secondary anti-human IgG3 
PE-conjugated antibody (IgG3 clone HP6050, Southern Biotech, Birmingham, AL) [265]. 
6.2.4 Efficacy of C5 inhibition  
The efficacy of eculizumab therapy was assessed using two in-vitro assays including:  1)  
serum drug levels using a validated enzyme-linked immunosorbent assay that detects 
both free and C5-bound eculizumab (PK levels) and; 2) activity as determined by the 
ability of the eculizumab-treated patient’s serum to lyse chicken erythrocytes in a 
validated total human serum–complement hemolytic assay (PD levels) [266, 267]. 
These methods are described below. 
6.2.4.1 Drug levels (PK) ELISA binding assay 
For detection of recombinant Fab binding to human C5, F96 PolySorp microtiter plates 
(Nunc, Naperville, IL, U.S.A.) were coated overnight at 4°C with 0.1 mg/well human C5 
(Quidel, San Diego, CA, U.S.A.) at a concentration of 2 mg/ml in 0.1 M Na,CO3, pH 9.6. The 
plates were then washed three times with 100 µl/well wash buffer (PBS containing with 
0.5% (v/v) Tween 20) and blocked with 100 µl/well blocking buffer (PBS supplemented 
with 1% (w/v) bovine serum albumin, fraction V and 0.5% (v/v) Tween 20) at 37°C for 
1 hr. The plates were again washed three times with wash buffer and incubated with 50 
µl/well blocking buffer, containing 30 ng/ml murine 5G1.1 mAb, plus the indicated 
concentrations of inhibitor, at 37°C for 2 hr. The plates were  again washed three times 
with wash buffer, and incubated with 50 µl/well blocking buffer, containing peroxidase 
conjugated goat anti-mouse IgG Fc antibody, at a 2000- fold dilution (Sigma, St. Louis, 
MO, U.S.A.), at 37°C for 1 hr. After three final washes, the plate was developed with 50 
µl/well substrate buffer (0.05 M phosphate-citrate buffer, pH 5.0, containing 0.3mg/ml 
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sodium perborate and 0.4 mg/ml σ-phenylenediamine dihydrochloride). Reactions 
were stopped by the addition of 50 µl/well 1 M sulfuric acid and quantified using a Bio-
Rad model 3550 plate reader set at 490 nm. 
6.2.4.2 Haemolytic assay 
Haemolytic assays to determine the complement activity in samples were performed as 
described above on frozen serum samples that were rapidly thawed at 37°C 
immediately before the assay. Human serum was diluted to 20% vol/vol with gelatin 
veronal-buffered saline buffer (GVB 2+: 0.1% gelatin, 141 mM NaCl, 0.5 mM MgCl2, 0.15 
mM CaCl2, 1.8 mM sodium barbital [Sigma Chemical Co., St. Louis, MO]) buffer and 
added (50 µl/well) to the rows of the same 96-well plate such that the final 
concentration of human serum in each well was 10%. The plate was then incubated at 
room temperature for 30 min while chicken erythrocytes (Lampire Biological 
Laboratories, Piperville, PA) were washed five times with 1 ml of GVB 2+ buffer and re-
suspended to a final concentration of 5 x 107/ml in GVB 2+ buffer. 4 ml of the chicken 
erythrocytes were sensitized by the addition of an anti-chicken red blood cell polyclonal 
antibody (0.1% vol/vol, Intercell Technologies, Hopewell, NJ), and the cells were 
incubated at 4°C for 15 min with frequent vortexing. The cells were then washed twice 
with 1 ml of GVB 2+ buffer and re-suspended to a final vol of 2.4 ml in GVB 2+ buffer. 
30µl aliquots of chicken erythrocytes (2.5 x 106 cells) were added to the plate human 
serum samples and mixed well. Then these were incubated at 37°C for 30 min. Each 
plate contained two additional wells of 30 µl of identically prepared chicken 
erythrocytes, one incubated with GVB 2+ buffer alone (negative control) as a control for 
spontaneous haemolysis and the other containing 0.1% nonyl 
phenoxypolyethoxylethanol (NP- 40 [Sigma]) serving as a control for 100% lysis. The 
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plate was then centrifuged at 1,000 g for 2 min and 85 µl of the supernatant transferred 
to a new 96-well plate. Haemoglobin release was determined at OD 415 nm using a 
microplate reader (Bio-Rad Laboratories, Richmond, CA), and the percent haemolysis 
was determined using the following formula:   
Percent haemolysis = 100x (OD sample - OD negative control)/(OD 100% lysis - OD 
negative control) 
6.2.5 C1q binding of IgG DSA 
The Bio-C1q assay is a modification of the commercially available method and was 
performed as described in [268]. It detects both IgM and IgG. Briefly, 10 µl of serum, 
absorbed with beads (Spherotech, Lake Forest, IL), was spiked with 10 µl (0.1 mg/ml) 
purified human C1q (Sigma) biotinylated in house (Bio-C1q) and incubated with 2.5 µl 
of LabScreen Single Antigen Bead (SAB) for 30 min at room temperature (rt) followed 
by 10 µl of phycoerythrin-conjugated streptavidin. After an additional 20 min rt 
incubation, the beads were washed X2 with wash buffer and analysed on a Luminex 
instrument. Data were analyzed by HLA Fusion software. All reagents and software 
except absorption beads and Bio-C1q were obtained from One Lambda, Inc.. 
6.2.6 Criteria for AMR and Histologic Assessment 
Renal allograft biopsies were obtained percutaneously using ultrasound guidance, and 
submitted for routine light microscopy, immunofluorescence for C4d, and electron 
microscopy.  All biopsies were reviewed by a pathologist and AMR was diagnosed using 
standard Banff criteria in combination with graft dysfunction (increase in serum 
creatinine ≥0.3 mg/dL over nadir) [142].  
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6.2.7 Statistical Analysis 
Data were analyzed using JMP 9 (SAS, Cary, NC). Continuous normally distributed data 
were expressed as mean ± standard deviation, non-parametric data by median and 
range, and nominal data by counts and percentages The data were compared using a 
Student’s t-test for normally distributed data, otherwise non-parametric tests were 
applied (Wilcoxon rank-sum test,). Normality of distribution of variables was tested 
using Shapiro-Wilk test. A p value of <0.05 was considered significant. 
 
6.3 Results 
These patients demographics have been described previously in published data by 
Stegall et al [136]. Table 6.1 displays the demographics of the 26 patients in this study 
cohort. All 26 +XMKTx recipients received eculizumab for at least 1 month post-
transplant—the duration of the primary endpoint of the original study.   
 Two patients developed acute clinical eAMR in the first month and one had 
subclinical eAMR on a 1 week protocol biopsy.  None of the other patients showed 
evidence of eAMR on biopsy (all patients underwent at least 1 protocol biopsy during 
the first month).  Three patients developed graft dysfunction and their biopsy did not 
demonstrate eAMR.  Renal function in these patients improved without specific DSA-
reduction therapy.  No episodes of eAMR were diagnosed in months 1 to 12.  All patients 
had functioning grafts at 1 year after transplantation  
6.3.1 Antibody-Mediated Rejection Episodes 
Two patients who met criteria for eAMR (Table 6.2) had graft dysfunction with the 
classic triad of AMR (one on post-operative day (POD) 7 and another on POD 14) that 
included: 1) a biopsy consistent with antibody-mediated damage on light microscopy 
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(Banff 97 Level II or III AMR); 2) C4d+ staining of the peritubular capillaries and 3) 
circulating DSA by both B flow cytometric crossmatch and total IgG DSA.   
The first patient that developed eAMR had a surveillance biopsy on day 4 which was 
C4d negative and showed only mild acute tubular injury without inflammation or other 
features of AMR.  On day 7, the serum creatinine rose from 2.1 mg/dl to 2.7 mg/dl in 24 
hours and the biopsy demonstrated glomerular thrombi, endothelial swelling, 
mesangiolysis and glomerular neutrophil margination with acute tubular injury and the 
peritubular capillaries showed diffuse dim staining for C4d.  Electron microscopy 
showed endothelial swelling with loss of fenestration and peritubular capillary 
endothelial cell swelling. Treatment consisted of PE (daily for 12 days), ongoing 
eculizumab (600 mg after each PE session) and low dose IVIG.  The serum creatinine 
decreased to 1.9 mg/dl by day 21.  This patient, at one year and two years of follow up, 
had creatinine values of 1.7 mg/dl and 2.0 mg/dl respectively (eGFR MDRD 34ml/min 
and 28ml/min). 
The second patient with eAMR had a surveillance biopsy done on day 7 which did not 
show any evidence of tissue injury or inflammation by light microscopy, although there 
was diffuse C4d deposition in the peritubular capillaries.  Electron microscopy did show 
segmental endothelial cell swelling of glomerular and peritubular capillaries.  On POD 
11, the serum creatinine rose to 1.3 mg/dl and on day 14 a biopsy was obtained that 
demonstrated glomerular microthrombi, interstitial hemorrhage; glomerulitis and 
peritubular capillaritis in addition to diffuse C4d deposition in the peritubular 
capillaries.  Electron microscopy showed diffuse swelling of endothelial cells in 
glomerular and peritubular capillaries (Figure 6.1). Treatment consisted of PE (9 days), 
low dose IVIG and continued eculizumab (600 mg after each PE). The 1 year and 2 year 
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serum creatinine measurements were 1.5 mg/dl and 1.6 mg/dl (eGFR 38ml/min and 35 
ml/min), respectively.   
A third patient met criteria for “subclinical AMR” who had high levels of DSA (BFXM 
>360), C4d+ staining and a biopsy consistent with antibody-mediated injury 
(peritubular capillaritis and glomerulitis on POD 7), but did not develop graft 
dysfunction during the first 28 days after transplantation, and did not receive additional 
therapy. 
Table 6.1. The Baseline Characteristics of the Eculizumab Study Cohort 
 
Eculizumab Cohort 
  N=26 
Age (years) Mean±StDev 47.8 ± 12.3 
Gender (Female) n(%) 21(80.8%) 
Ethnicity=Caucasian n(%) 26(100%) 
Retransplant n(%)) 13 (50%) 
ABDR mismatch Mean±StDev 3.7 ± 1.3 
Pre-emptive n(%) 4 (15.4%) 
Dialysis time (months) Median (Q1-Q3) 21.0 (15-32) 
Living donor n(%) 26(100%) 
    
BFXM Channel Shift Mean±StDev 333 ± 112 
BFXM >360 Channel Shift n(%) 10 (38.5%)  
Anti-Class I antibody only n(%) 9 (34.6%) 
Anti-Class II antibody only n(%) 3 (11.5%) 
Both anti-Class I & anti-class II antibody 
n(%) 
14 (53.8%) 
Baseline Class I MFI Mean±StDev 
 
7175 ± 4808. 
Baseline Class II MFI Mean±StDev 
  
8899 ± 3521 
Patients with Pre-transplant apheresis  19 ( 73.1%) 
Pre-Transplant Apheresis. Mean±StDev 6.7 ± 3.3 
 
Data expressed as Mean ± St Dev for normally distributed data, tested using Shapiro–
Wilk test, otherwise expressed as median (Q1-Q3)  
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Table 6.2 Post-Transplant Clinical Characteristics of patients with eAMR and those 
without eAMR       
 N Graft 
Dysfunction1 
DSA2 C4d 
Deposition 
Histologic 
Injury 
AMR  2 2 IgG and IgM Yes Yes3 
      
Subclinical AMR 1 No IgG and IgM Yes Yes6 
      
No AMR 23     
Normal Histology 
Low DSA4 
15 2 IgG 11/15 None 
Normal Histology 
High DSA5 
8 1 IgG 7/8 None 
 
1Increase in serum creatinine ≥0.3 mg/dl (27micromol/L) over baseline during the first 
month. 2DSA is a positive BFXM and/or DSA by solid phase assay that is either IgG or 
IgM. 3Glomerular microthrombi, mesangiolysis and/or peritubular capillaritis. 4Low 
DSA means highest post-transplant BFXM <360. 5High DSA means highest post-
transplant BFXM >360. 6Capillaritis only 
Figure 6.1. Histology of eAMR in patient with eculizumab. 
Histological evidence of early AMR in Eculizumab-treated patients with IgM DSA. By 
light microscopy, a glomerulus shows a thrombus (arrow) and acute tubular injury 
(arrowhead)(left panel). By electron microscopy, glomerular endothelial cells are 
enlarged (arrow) and show loss of fenestrations and microvillous change.  
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6.3.2 Eculizumab Levels 
  Serum eculizumab drug levels were therapeutic (>25µg/ml) in all patients and the 
hemolytic assay was blocked (<20% haemolysis), indicating effective complement 
blockade. There was no significant difference in either drug level or hemolytic lysis 
score between the 3 patients with rejection and the 23 patients without rejection (see 
Figure 6.2). 
6.3.3 DSA Levels and AMR 
It has previously been shown that high DSA levels after +XMKTx correlate highly with 
the development of acute AMR in patients not treated with eculizumab [136].  In the 
current eculizumab study, DSA levels were allowed to increase without PE. Eculizumab 
treatment did not appear to prevent the development of high levels of DSA in that in the 
first month 38.5% (10/26) of eculizumab treated patients develop a BFXM channel shift 
>360—a level associated with AMR in 100% of historical controls from Stegall et al (see 
Figure 6.3)[136].  Two of the three cases of AMR (one clinical and one subclinical) had a 
BFXM >360 and in the other the highest BFXM was 303.  This patient’s highest IgG DSA 
was against Cw7 which can be poorly expressed on lymphocytes.  Thus, 8 patients 
treated with eculizumab who did not develop rejection would have been predicted to 
have AMR based on historical data.  In addition, all 10 of the biopsies were C4d+ (with 
high levels of DSA - IgG DSA SAB, median 10453, Q1 3480-Q3 11710; BFXM median 445, 
Q1 409-Q3 544) consistent with antibody-dependent complement activation of the 
allograft.   
A more detailed analysis of DSA levels by Ig type is presented in Figure 6.4.  This shows 
that high levels of DSA were present at some time point in the first month after 
transplantation in both rejecting and non-rejecting patients.  Specifically, high levels of 
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total IgG (as commonly measured in the LABscreen SAB assay), IgG3 and C1q+ binding 
were detected in both groups and none were associated with the development of eAMR 
(Comparison were not significant with p=0.279; p=0.799 and p=0.711 respectively). 
 
Figure 6.2. Eculizumab drug levels and complement blockade assay results in the 
cohort 
Hemolytic assays showed almost complete blockade (left panel) and eculizumab levels 
were therapeutic (right panel) in all patients including at the time of AMR in the two 
patients who developed AMR (open circles) and non-rejections (closed diamonds). 
Actual levels expressed as median (Q1-Q3). 
Table A  
Serum Haemolytic Assay (% haemolysis) 
Week 0 Week 1 Week 2 Week 4 
Rejection 
Median 
(Q1-Q3) 
95 
(93-97) 
9 
(0-18) 
1 
(0-2) 
28 
(1-56) 
No 
Rejection 
Median 
(Q1-Q3) 
82.5 
(31-130) 
2.5 
(1.3-5.8) 
1 
(0-3) 
1 
(0-2) 
 
Table B  
Eculizumab Levels (µg/ml) 
Week 0 Week 1 Week 2 Week 4 
Rejection 
Median  
(Q1-Q3) 
0  
(0-0) 
110.1 
(92.8-127.3) 
166.4 
(147.8-185) 
154.8 
(43.2-266.4) 
No 
Rejection 
Median  
(Q1-Q3) 
0  
(0-0) 
111.5 
(83.0-182.3) 
131.7 
(92.5-182.6) 
162.5 
(107-193.5) 
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Figure 6.3. Eculizumab does not prevent the development of high levels of 
alloantibody after transplantation  
Figure 6.3A.  BFXM Channel Shift of patients following treatment with Eculizumab with 
a high DSA level (BFX>360) in the first month after transplant. Rejecter in Red Dashed 
line(- - - -); Continuous lines are non-rejecters(___); Black Dotted line is the subclinical 
rejection patient(…….). 
 
Figure 6.3B.  BFXM following transplant with BFXM<360. 
Patient with rejection had indistinguishable levels from rest of cohort. Rejecter in 
dashed line(- - - -); Continuous lines are non- rejecters(___). 
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In contrast, IgM DSA was detected in only 4 patients after transplantation including:  the 
two patients with eAMR (maximum MFI levels of 1721 against HLA-B8 and 8816 
against HLA-DR7), the patient with subclinical eAMR (maximum MFI = 1997 against 
HLA-DQ8) and a patient who had normal biopsies throughout (maximum MFI = 2320 
against HLA-DR53). Comparison between rejecters and non-rejecters demonstrated a 
significantly higher IgM DSA MFI (median 1997 [1344-8816] vs. 0[0-2320], p=0.006 
Wilcoxon rank-sum test).  Interestingly, this 4th patient also had persistently high DSA 
that necessitated continued treatment with eculizumab for 1 year according to study 
protocol.  This patient developed transplant glomerulopathy on a 7 month biopsy and 
his allograft failed at 15 months after transplantation.   
Patient #1 had increased levels of IgM DSA (anti-B8 and anti-Cw7) at day 7 correlating 
with eAMR. Plasma exchange started on Day 7 rapidly reversed the eAMR episode and 
led to reduced IgM DSA.  IgG DSA continued to rise despite the resolution of AMR both 
clinically and on follow-up biopsy. Patient #2 showed an increase in IgM DSA at day 7 
correlating with early peritubular capillaritis and then subsequent developed clinical 
AMR on day 14.  Again, the eAMR episode was easily treated with plasma exchange and 
IgM quickly was reduced while IgG DSA continued to rise. These data are shown in 
Figures 6.5A and 6.5B. Figure 6.5C shows a DSA pattern typical of a patient with 
persistently high IgG DSA (MFI>8,000) without IgM DSA who did not develop eAMR. 
There was no significant difference in IgG3 DSA levels over the first 1 month after 
transplant in rejecters and non-rejecters (Figure 6.5D).  
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Figure 6.4. Comparison of levels of anti-donor antibody during the first month 
post transplantation. 
This demonstrates significantly higher levels in rejecters for IgM DSA (A), but no 
difference in IgG DSA (B); C1q DSA (C) or IgG3 DSA (D). Patients with Rejection are with 
full diamonds, the one patient with no rejection, but accelerated transplant 
glomerulopathy is in open diamond, the non-rejecters are in closed circles. 
 
Non-parametric data compared using Wilcoxon rank-sum test. 
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Figure 6.5. Anti-HLA antibody patterns in patients who developed early AMR and 
one without AMR. 
Figure 6.5A.  AMR Patient #1 DSA Levels 
Increased levels of IgM DSA (anti-B8 and anti-Cw7) at day 7 correlating with early AMR 
(solid arrow).  Plasma exchange started on Day 7 rapidly reversed the AMR episode and 
led to reduced IgM DSA but IgG DSA continued to rise.  
 
Figure 6.5B.  AMR Patient #2 DSA Levels. 
Increase in IgM DSA at day 7 correlating with early peritubular capillaritis (dashed 
arrow) and then subsequent early AMR (solid arrow) in patient 2.  Again, the AMR 
episode was easily treated with plasma exchange and IgM quickly was reduced while 
IgG DSA continued to rise. 
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Figure 6.5C.  High levels of IgG DSA without IgM DSA in a patient who did not 
develop AMR.  Typical DSA pattern in a patient with persistently high IgG DSA and C4d 
deposition on surveillance biopsy who did not develop AMR and did not have IgM DSA.   
 
 
 
 
 
 
 
 
Figure 6.5D.  Levels of IgG3 in patients with AMR and without AMR do not 
differentiate.  The level of IgG3 DSA subclass does not determine early AMR (red lines) 
against no early AMR (grayscale lines) plotted for each patient within the first month 
post transplant. 
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6.4 Discussion 
Terminal complement inhibition significantly reduces the rate of acute clinical AMR in 
+XMKTx patients with high levels of DSA and evidence of complement deposition in the 
allograft, which suggests that most cases of  AMR are C5-dependent [136]. However, 
despite C5 inhibition being therapeutic and functionally adequate, 2 +XMKTx recipients 
who received eculizumab developed clear-cut, clinically-significant AMR and another 
developed subclinical AMR.  All 3 of these patients had IgM DSA detected and only 1 of 
23 patients without AMR had IgM DSA. That the 2 episodes of eAMR were reversed 
easily with PE which more effectively removed IgM without reducing IgG levels further 
supports the concept that IgM DSA might be a possible causative agent in early AMR 
independent of C5.  Importantly, high levels of total IgG DSA and complement-binding 
DSA (IgG3 subclass and C1q+) were commonly present in recipients who did not have 
eAMR further supporting the concept that complement binding IgG was not the 
mediator of eAMR in eculizumab-treated patients.  
These data do not suggest that IgM is the only possible mechanism of AMR in 
eculizumab-treated patients.  Further studies of larger numbers of patients might reveal 
other possible mechanisms. For example, it is possible that high levels of DSA might be 
sufficient to cause forme fruste AMR in some patients via either direct endothelial cell 
activation or via infiltration of cells via FcγR binding to IgG bound to the allograft. Yet 
the data from the current study did not suggest either of these mechanisms were a 
common cause of early clinical AMR.   
IgM will not be the major cause of most AMR in +XMKTx recipients not treated with 
eculizumab, where in the absence of terminal complement blockade, it is likely that IgG 
DSA is the major cause and its blockade is the major reason for the reduced incidence of 
AMR in eculizumab treated patients.  However, IgM DSA may be capable of causing 
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eAMR in specific situations.  Techniques to identify IgM in serum have varied over time 
and the resulting conclusions from these studies have ranged from the irrelevance of 
IgM to a protective mechanism to being associated with poor outcomes [269-273].  
More recently, IgM DSA binding complement was associated with AMR without IgG DSA 
in cardiac transplantation [157]. One of the factors that may have contributed to this 
confusion is that different methods have been used to identify IgM and few have been 
able to identify HLA specificities clearly [55, 60, 129, 274, 275]. 
IgM commonly has been associated with early B cell responses, but IgM DSA production 
can be long-lived similar to that of IgG production and can be produced in a memory B 
cell response [276, 277]. In the current study, 15.4% (4/26) had IgM DSA and all had 
the same specificity as the IgG DSA.  The coexistence of IgM and IgG with the same HLA 
specificity has been previously reported  [278].    
 One patient in this study had increased IgM after transplantation, but did not 
develop eAMR.  The reason for the lack of AMR in this patient is unclear, but underlies 
the fact that not all IgM may be capable of causing eAMR.   While this patient went on to 
develop chronic AMR by 1 year, the current study cannot clearly address the role of IgM 
in chronic injury because C5-independent processes may contribute to chronic injury. It 
has been previously shown that a BFXM channel shift > 360 post-transplant was 
associated with AMR with a sensitivity of 100% and a specificity of 95.4% in +XMKTx 
who develop AMR [70].  Since, approximately 1/3 of all transplanted patients in the 
eculizumab-treated patients in the current study had these levels, and it would have 
been expected that they develop AMR with high DSA, yet only 1/26 did.  The other case 
had a relatively low BFXM, but high IgG DSA by single antigen beads against an unusual 
HLA-Cw7 which is known to be variably expressed on lymphocytes. The IgG3 DSA was 
not detectable for this allele on solid phase assay, but had high levels of C1q binding. 
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Interestingly, in this case, the increase in IgM DSA preceded the development of IgG 
DSA, and the episode of AMR occurred when the IgM DSA was rising.  
It is possible that DSA can injure the allograft via complement-independent 
mechanisms.  For example, anti-HLA antibody can directly activate endothelial cells in 
vitro without complement and NK cells may attach to membrane-bound IgG via their 
Fcγ receptor.  However, these mechanisms do not explain why some patients with high 
levels of IgG DSA developed AMR and others did not [279].   
IgM might cause AMR via several mechanisms.  For example, IgM has a higher affinity 
for C3 (not blocked by eculizumab) and this may significantly increase the local effect of 
C3 and its breakdown products [280]. The increased number of C3 binding sites on IgM 
compared to IgG leads to increased inflammation and tissue damage sufficient to cause 
histologic changes of AMR and graft dysfunction and altered monocyte infiltration [281, 
282]. C3a, an anaphylatoxin, increases inter-endothelial cell dilatation and this increase 
gives rise to the pro-thrombotic process. The exposure of inter-endothelial gap 
junctions leads to increased intravascular coagulation on endothelial surfaces due to the 
increased expression of tissue factor and plasminogen activator inhibitor type I via 
complement activation [283].  C3a also leads to neutrophil adhesion, chemotaxis and 
cellular allograft infiltrate [284]. Local tissue injury leads to increased C3 production, 
further increasing the local inflammation and cellular infiltrate [285]. C3b produced 
binds to endothelium and attracts leukocytes which express complement receptors 
[286]. C3b also amplifies the alternate complement pathway, as C3b bound to tissue is 
not inhibited by regulatory proteins [287]. The increase in C3b activates C3 convertase, 
as C3b becomes an active protein, thus increasing the presence of C3a in the allograft 
[288]. Furthermore, IgM- mannose binding lectin (MBL) complexes can initiate cell 
injury. Without the presence of C1q, it has been demonstrated that binding of MBL can 
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initiate cell injury and lead to increased C3 deposition.  This would increase the cell 
injury through the C3 pathway described above, in addition to the classical pathway 
[289].  
These preliminary data suggest that there is a possible role of IgM DSA in the 
pathogenesis of AMR in patients treated with terminal complement blockade.  These 
data also suggest a testable hypothesis in that monitoring IgM DSA and preemptive PE 
might further reduce AMR in eculizumab-treated patients.   
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Chapter 7  Conclusion 
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Antibody incompatible kidney transplantation allows transplantation in a select 
group of patients to improve clinical outcomes compared to remaining on dialysis. 
Whilst the outcomes are inferior to antibody compatible live donor transplantation, 
there is a role for antibody incompatible transplantation; however, the risks and 
benefits need to be explained to patients. This thesis provides more information to 
guide clinical decisions. 
7.1 Summary of main research findings and limitations 
The assessment of anti-ABO specific antibodies can be measured with good 
reproducibility by a single user in agglutination and a defined protocol using 
haemagglutination. This allowed comparison between centres for ABO titres and 
demonstrated a wide range of local titre results in centres which was associated with 
more antibody removal therapy. There was a similar distribution of ABO titres in the 
major centres when compared using the central assay. Comparative studies would be 
possible in these cohorts; however, the treatment needs to be guided by a standardised 
assay, so that treatment variations are based on clinical parameters and not assay 
variability. 
The development of a synthetic assay on microspheres has yielded a sensitive, 
but not specific assay; however, the same trisaccharide structures on the SPR platform 
demonstrate binding specificity. The use of different oligosaccharides was limited to the 
availability of oligosaccharide provided by Dextra Ltd. There were intellectual property 
restrictions on obtaining tetrasaccharides with the 8-carbon linker to be able to 
compare different binding characteristics between the tri- and tetrasaccharides. Further 
work would develop the SPR assay to differentiate binding characteristics of similar 
ABO titres, and the impact on clinical events, including antibody removal and rejection. 
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In the ABOUT-K study, the rate of early antibody-mediated rejection was low and a 
larger cohort is needed to be able to correlate assays with clinical events. 
The clinical outcome data in the ABOUT-K study demonstrated that ABOiKTx can 
be performed safely and effectively with equivalent outcomes to ABO compatible live 
kidney donation transplantation. There was a greater incidence of acute rejection in this 
cohort than is widely reported; however this did not affect allograft survival. The rate of 
viraemia and associated transplant viral nephropathy is in keeping with published data, 
but needs further investigation to determine whether the therapy given or the nature of 
ABO incompatibility increases the risk of viral nephropathies, particularly BK 
nephropathy. The prospective assessment of data and local anti-ABO specific antibodies 
was limited by local adherence to protocol and compliance with study protocol from 
local transplant centres. The ABOUT-K study cohort was a descriptive cohort, and an 
equivalent control cohort from the same centres for ABOcKTx would provide a good 
comparative group for data analysis. 
A major risk factor for allograft loss in positive crossmatch (HLAiKTx) 
transplantation was the presence of anti-Class II antibody at time of transplantation and 
the onset of early antibody-mediated damage on histology before there was a change in 
allograft function. Patients with anti-Class I DSA had equivalent 5-year allograft survival 
compared to the –XMKTx control cohort, and thus could be an acceptable DSA in live 
donor exchange, while avoiding Class II DSA.   The Mayo Clinic antibody incompatible 
data may not be transferable to other centres, as patients were referred from different 
centres across the USA which would not transplant these patients due to high 
immunological risk. This creates a selection bias of highly sensitized patients. The 
analysis of this clinical cohort from the Mayo Clinic describes a cohort of patients with 
heterogeneous treatment regimens during which the experience guided further 
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development in techniques for +XMKTx. The retrospective nature of the analysis of 
serum for DSA informs assessment, however the continual development of the single 
antigen bead assay leads to difficulties in application of these data to current 
populations. The development of the assay has led to increases in the number of 
specificities to HLA antigens (for example Cw and DP) able to be identified over time 
and thus may reveal different antibody data on more recent single antigen bead kits. 
Furthermore, the recent assays also assess C1q binding for each DSA for which the 
current dataset had not been measured. The presence of C4d staining as part of the 
diagnosis for antibody-mediated rejection is not associated with the same cellular 
infiltration in ABOiKTx compared to +XMKTx recipients. The cellular infiltration is 
neither associated with the activation of the classical complement cascade nor the 
degree of early rejection in these cohorts. The use of eculizumab in patients in Chapter 6 
was given under pharmaceutical sponsorship of this study. There would be significant 
financial implications for using this drug in a larger cohort of patients and thus use of 
this as a routine protocol therapy is unlikely to be implemented. The clinical 
effectiveness of reducing early AMR is apparent, but it does demonstrate that despite 
preventing acute changes, the chronic infiltrate associated with DSA still occurs. 
Glomerulitis and capillaritis occur earlier with IgM DSA present; by removing IgM with 
plasma exchange it may be possible to test this hypothesis for reducing early tissue 
injury after transplantation.  
 In conclusion, this thesis demonstrates that despite antibody incompatible 
kidney transplantation carrying a higher risk than ABO compatible live donor kidney 
transplantation, there are sub-populations of patients that will benefit from antibody 
incompatible transplants, whilst other higher risk patients may benefit from alternative 
pathways to transplantation.  
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Appendix 
8.1 Solutions and Buffers 
8.1.1 Luminex 
Preparation of PBS 
Preparation of PBS solution 
PBS 150mM  NaCl (MW 1.71g) 
 25mM Phosphate (MW 0.78g) 
Adjusted to pH 7.4  5M NaOH  
De-ionised water  Total Volume 200ml 
Preparation of Luminex Wash Buffer (LWB): 
PBS (As prepared above) 95ml 
Fetal Calf Serum (4.9%), (F6178 Sigma. UK) 4.9ml 
Sodium Azide (0.1%), (438456, Sigma. UK) 0.1ml 
 
Non-denaturaturing Lysis buffer 
Stock Need Use  
1M TRIS-HCL pH 8 
 
20mM 20ml  
5M NaCl 137mM 27.4ml  
100% Glycerol 10% 100ml  
100% NP-40 1% 10ml +838.6ml Distilled Water 
0.5M EDTA 2nM 4ml  
Store for up to 6months at 4°C 
 
  
 
 
288 
 
PVA and PVP formation 
For suppression of non-specific binding, after Waterboer et al [224]. 
PVA 0.5% Polyvinylalcohol  (P8136, Sigma 
Aldrich) 
0.5g 1000ml PBS 
 
PVP 0.8% Polyvinylpyrrolidone  (PVP-360 
Sigma Aldrich) 
 
0.8g 1000ml PBS 
 
PVX 1: 1 ratio of PVA and PVP  50ml PVA 50ml PVP 
 
For each solution, agitated until no residual components are seen. 
Marvel Preparation 
Marvel prepared at 5% w/v in Distilled Water.  
Serial dilutions of 5%; 2.5% and 1.25% were made in distilled water. 
8.1.2 Flow Cytometry 
Flow Cytometry Diluent prepared as per Luminex Wash Buffer  
PBS (As prepared above) 95ml 
Fetal Calf Serum (4.9%) 
(F6178 Sigma. UK) 
4.9ml 
Sodium Azide (0.1%) 
(438456, Sigma. UK) 
0.1ml 
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8.1.3 Surface Plasmon Resonance  
SPR Running Buffer  
This was prepared using the following chemicals. After mixing, the solution was de-
aerated using a suction filter before running on the SPR machine. 
Constituent Volume Final Concentration in 1L 
2M NaCl 75ml 0.15M 
0.5mM HEPES 20ml 0.01mM 
0.5M EDTA 6.3ml  3.15mM 
Tween 20 5ml 0.5% 
 
In order to conjugate trisaccharides to the SPR chip, the trisaccharides were dissolved 
in 1M Boric acid (Sigma, UK) was made using 15g in 250ml of PBS and adjusting the pH 
to pH 8.5 using 1M NaOH    
8.2 Reagents 
Sigma 
P8136-250g   Poly(vinyl alcohol) 
PVP360-500g  Polyvinylpyrrolidone 
E6383   N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride 
56485-250mg  N-Hydroxysulfosuccinimide sodium 
S7148   Type AB, frozen liquid (Sigma) 
F1641-2ML  Goat Anti-Human IgG (γ-chain specific), F(ab′)2 fragment–FITC antibody 
P5413 Poly Ethylene Glycol (PEG) 
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Southern Biotech 
1140-09  Rat anti-mouse IgM R-phycoerythrin (R-PE) conjugate 
9042-09  Mouse Anti-Human IgG R-phycoerythrin (R-PE) conjugate 
9022-09  Mouse Anti-Human IgM R-phycoerythrin (R-PE) conjugate 
9080-02 Mouse anti-human IgG2 FITC 
9210-09 Mouse anti-human IgG3 R-PE 
9190-01 Mouse anti-human IgG4 purified 
DAKO 
X0902 Rabbit Serum  
Millipore 
NI – BIOSCOT® Core Anti-A (clone Birma-1) FFMU 
NJ – BIOSCOT® Core Anti-B (clone LB-2) FFMU 
Chemiblock™ - SUPERCHEMIBLOCK HETEROPHILE BLOCKING AGENT (10.5mg/ml) 
Luminex 
L100-S011-01   SeroMAP™ Microspheres 
BIORAD 
171-506021   Bio-Plex COOH Bead # 21, 1 ml 
176-5011   ProteOn GLC Sensor Chip 
176-5012   ProteOn GLM Sensor Chip 
170-5013   GLH Sensor Chip ProteOn System 
176-6010   ProteOn Sample Vials 
176-2410   ProteOn Amine Coupling Kit 
176-2810   ProteOn Chip Normalization Sol 
100405   Anti-A1 Lectin 
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AbD Serotec 
LNK073PERCP  LYNX RAPID PerCP ANTIBODY CONJUGATION KIT 
MACS 
130-093-113  Anti-human IgA – APC 
130-093-189  Anti-human IgG1 - APC 
Dextra Laboratories 
Blood Group A Series  
L305 Blood Group A trisaccharide  
GalNAcα1-3Gal           2           |     Fuc α 1 
C20H35NO15 FW 529.50 CAS: 49777-13-1  
 
L306 Blood Group A trisaccharide amine derivative  
GalNAcα1-3Galβ-1-O(CH2)7CONH(CH2)2NH2           2            |       Fucα1 
 
 
Blood Group B Series 
G323 Blood Group B Trisaccharide  
Galα1-3Gal       2       |   Fucα1 
C18H32O15 FW 488.44 CAS: 49777-14-2  
 
G324 Blood Group B trisaccharide amine derivative  
Galα1-3Galβ-1-O(CH2)7CONH(CH2)2NH2        2        |    Fucα1 
C28H52N2O16 FW 687.73 
 
Blood Group H (O) Series 
L205 Blood Group H Disaccharide  
Fucα1-2Gal - C12H22O10 FW 326.30 CAS: 16741-18-7 
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Abstract: In order to characterise antibody binding characteristics it is necessary to determine
reaction constants from quantitative measurements of the process. Surface plasmon resonance
(SPR) provides convenient real-time measurement of the reaction that enables subsequent
estimation of the reaction constants. Two models are considered that represent the binding
reaction in the presence of transport eﬀects. One of these models, the eﬀective rate constant
approximation, can be derived from the other applying a quasi-steady state assumption. Unique-
ness of the reaction constants with respect to SPR measurements is considered via a structural
identiﬁability analysis. It is shown that the eﬀective rate constant model is unidentiﬁable, unless
the analyte concentration is known, while the full model is structurally globally identiﬁable
provided association and dissociation phases are considered. Both models provide comparable
estimates for the unknown rate constants for a commercial anti-A monoclonal IgM experiment.
Keywords: Biomedical systems, structural identiﬁability, parameter estimation, surface
plasmon resonance, surface-volume reactions, binding aﬃnity
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Renal transplant candidates with high levels of donor-
specific anti-HLA antibodies have low transplantation
rates and high mortality rates on dialysis. Using de-
sensitization protocols, good short-term outcomes are
possible in “positive crossmatch kidney transplants
(+XMKTx)”, but long-term outcome data are lacking.
The aim of the current study was to determine actual
5-year graft outcomes of +XMKTx. We compared graft
survival and the functional and histologic status of 102
+XMKTx to 204 −XMKTx matched for age and sex.
Actual 5-year death-censored graft survival was lower
in the +XMKTx group (70.7% vs. 88.0%, p < 0.01) and
chronic injury (glomerulopathy) was present in 54.5%
of surviving grafts. Graft survival was higher in recip-
ients with antibody against donor class I only com-
pared with antibody against class II (either alone or in
combination with class I) (85.3% vs. 62.6%, p = 0.05)
and was similar to −XMKTx (85.3 vs. 88.0%, p = 0.64).
Renal function and proteinuria ranged across a wide
spectrum in all groups reflecting the different histolog-
ical findings at 5 years. We conclude that when com-
pared to −XMKTx, +XMKTx have inferior outcomes at
5 years, however, almost half of the surviving grafts
do not have glomerulopathy and avoiding antibodies
against donor class II may improve outcomes.
Key words: Antibody-mediated rejection, donor-
specific antibodies, HLA-sensitized patients, Long-
term outcomes, positive crossmatch kidney transplant
Abbreviations: AMR, antibody-mediated rejection;
BFXM, B cell flow cytometric crossmatch; CDC,
complement-dependent cytotoxicity; eGFR, estimated
glomerular filtration rate; +XMKTx, positive cross-
match kidney transplants; −XMKTx, negative cross-
match kidney transplants; TFXM, T cell flow cytomet-
ric crossmatch.
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Differences in Chronic Intragraft Inflammation
Between Positive Crossmatch and ABO-Incompatible
Kidney Transplantation
Andrew Bentall,1,2 Loren P. Herrera,1,3 Lynn D. Cornell,3 Manuel A. Moreno Gonzales,1 Patrick G. Dean,1
Walter D. Park,1 Manish J. Gandhi,4 Jeffrey L. Winters,4 and Mark D. Stegall1,5
Background. ABO-incompatible kidney transplantations (ABOiKTxs) seem to have better long-term outcomes than
positive crossmatch kidney transplantations (+XMKTxs).
Methods. This study aimed to assess the differences in chronic injury on histologic findings on 1- and 5-year sur-
veillance biopsies and the clinical outcomes in living-donor kidney transplantations performed between May 1999
and November 2006 including 102 +XMKTxs, 73 ABOiKTxs, and 652 conventional KTxs.
Results. Although 5-year patient survival was similar between groups, graft loss between 1 and 5 years was similar in
ABOiKTx (2.6% per year) and conventional KTx (1.7% per yr), and both were lower than that of +XMKTx (5.8% per
year). At 5 years, renal function was similar in ABOiKTx and conventional KTx, and both were higher than that of +
XMKTx, which had higher rates of inflammation and chronic glomerulopathy on both 1- and 5-year biopsies. Despite
having evidence of less chronic injury, ABOiKTx showed a higher rate of intragraft complement activation (C4d
deposition) at 5 years compared with +XMKTx (77.8% vs. 18.9%, PG0.001).
Conclusion. These data suggest that +XMKTxs have high rates of chronic inflammation at 1 and 5 years after
transplantation, which may explain the higher rates of graft loss and lower renal function compared with other factors
such as antiYdonor antibody or intragraft complement deposition.
Keywords: ABO incompatible, HLA antibodies, Positive crossmatch, Chronic histologic injury, Kidney transplant.
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Summary
Terminal complement blockade has been shown to decrease the incidence of early
acute antibody-mediated rejection (eAMR) in the first month after positive cross-
match kidney transplant recipients, yet some patients still develop eAMR. The
current study investigated possible mechanisms of eAMR despite eculizumab
treatment. Of the 26 patients treated with eculizumab, two developed clinical
eAMR and another patient developed histologic signs of eAMR without graft dys-
function (‘subclinical eAMR’). Twenty-three did not have histologic injury on
early surveillance biopsies. All 26 patients had therapeutic levels of eculizumab
and showed complete blockade of complement in hemolytic assays. High levels of
donor-specific alloantibody (DSA) including total IgG, IgG3, and C1q+ DSA were
present in patients with and without eAMR, and none correlated well with eAMR.
In contrast, IgM DSA was present in only four patients after transplantation: the
two patients with clinical eAMR, one patient with subclinical AMR, and one
patient without eAMR (P = 0.006 correlation with eAMR). Both clinical eAMR
episodes were easily treated with plasma exchange which removed IgM more
completely and rapidly than IgG, resulting in normalization of function and his-
tology. These data suggest a possible role of antidonor IgM DSA in the pathogen-
esis of eAMR in patients treated with terminal complement blockade
(ClinicalTrials.gov Identifier: NCT00670774).
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